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ABSTRACT
The Cytochrome P450s (CYP) in families 1-3 are integral to the metabolism of
xenobiotics such as pharmaceuticals, pesticides and plasticizers as well as endobiotics such
as hormones, bile salts and fatty acids. Recently, hepatic CYP activity was associated with
fatty liver and potentially obesity. The CYPs in the 3A and 2B families are critical in
xenobiotic detoxification and are regulated by transcription factors that control toxic
responses in addition to energy homeostasis. Therefore, we assessed the significance of
CYP3A and CYP2B in obesity and hepatic energy metabolism using Cyp3a or Cyp2b
knockout mouse models. Cyp3a-null and Cyp2b-null mice were challenged with a high
fat diet (HFD) for 8-10 weeks to test whether these mice were more susceptible to obesity
and fatty liver disease. We determined changes in body weight, organ weight, white
adipose tissue mass, hepatic lipids, glucose metabolism and sensitivity, hormone changes
in these mice after 8-10 weeks of HFD treatments. We hypothesized that the lack of Cyp2b
/ Cyp3a will increase the susceptibility of the -null mice to diet-induced obesity. Our results
indicate that Cyp2b’s are crucial in protection of HFD-induced obesity. Cyp2b-null male
but not Cyp2b-null female mice gained more body weight coupled with increased white
adipose tissue mass compared to their wild-type counterparts following a HFD. The
response in Cyp3a-null mice were not as strong; however, gender-based differences were
observed in both models. Cyp3a-null female mice were moderately protected from HFDinduced obesity. We also observed significant increase in liver triglycerides in the Cyp3anull and Cyp2b-null mice. In conclusion, loss of Cyp2b exacerbates obesity, while loss of
Cyp3a mitigates the development of HFD-induced obesity.
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CHAPTER ONE
INTRODUCTION
The purpose of this study was to determine the significance of Cytochrome P450’s
(CYP) 2B and 3A in obesity and the potential for inhibition of CYPs to perturb energy and
more specifically lipid homeostasis. Recent studies using hepatic cytochrome P450
oxidoreductase-null mice shows that the lack of all CYP activity in the liver leads to
accumulation of unsaturated fats and these unsaturated fats activate constitutive androstane
receptor (CAR) and induce the expression of Cyp2b10 to eliminate the fats (Finn et al.,
2009). An earlier study from our laboratory shows that the repression of Cyp2b genes
increased body weight gain, increased adipose tissue weight and accumulation of
unsaturated fats in old male Cyp2b-null RNAi mediated knockdown mice (Damiri et al.,
2012). To demonstrate the significance of CYP2B in lipid metabolism, we developed triple
knockout mice missing hepatic Cyp2b enzymes-Cyp2b9, Cyp2b10 and Cyp2b13 using
CRISPR/Cas 9 with targeted small guide RNAs. Also, we also investigated the significance
of CYP3A in lipid metabolism using a seven-Cyp3a gene knockout mice model. Because
CYP3A members are highly expressed in the liver making up 30-40% of hepatic CYP
expression and metabolize more than 50% of pharmaceuticals available in the market, we
hypothesized that this predominant hepatic CYP member would be crucial in hepatic lipid
metabolism and lack of this CYP member will increase susceptibility to diet-induced
obesity.

1

1.1 Obesity and Obesogens
Obesity is one of the fastest growing metabolic disorders in the world, and
according to World Health Organization (WHO), global obesity prevalence has tripled
between 1975 and 2016. WHO 2016 obesity statistics reports that 39% of adults are
overweight and 13% of adults are obese (WHO, 2017). For example, the percent of obese
individuals is increasing in Latin America (i.e. Panama 31.5%, Chile 21.9%), Europe
(Greece 22.5%, Malta 20.7%), and the Middle East (United Arab Emirates 33.7%, Saudi
Arabia 35.6%, Egypt 30.3%) (WHO, 2018). In turn, the rates of dyslipidemia,
hypertension, diabetes, and other metabolic disorders have increased dramatically placing
a significant burden on our healthcare systems (LeBlanc et al., 2012b;Sharp, 2009). Nonalcoholic fatty liver disease is one of the comorbities associated with obesity, wherein there
is alcohol-independent, increase in accumulation of fat in the liver exceeding >5% of total
liver weight.
The primary causes of obesity are a dense calorie diet and lack of physical activity;
however, recent studies show that exposure to certain environmental chemicals called
obesogens can enhance the accumulation of fats, perturb lipid metabolism and lead to the
development of obesity (Grun et al., 2009a). Worse yet, this may be a couple with nonalcoholic fatty liver disease(Fabbrini et al., 2010).
Obesogens increase depuration of lipids into white adipose tissue. They increase
proliferation of new fat cells, increase fat content in the fat cells or by reprogramming the
multipotent stem cells to generate adipocytes over bone cells (Grun et al., 2009b). Food
additives such as sodium benzoate and curcumin reduce leptin levels and xenobiotics such
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as tributyltin and benzyl butyl phthalates induce adipocyte differentiation through
peroxisome proliferator-activated receptor gamma (PPARg) (Yin et al., 2016). These are
some known obesogens that associate with obesity.
Most obesogens are thought to interact with nuclear receptors, such as the
peroxisome proliferator-activated receptors (PPARs), which act as metabolic sensors
(Grun et al., 2009a;Hurst et al., 2003;Li et al., 2011). PPARg is a crucial nuclear receptor
in lipid homeostasis and energy metabolism (Sugii et al., 2009). PPARs bind fatty acids
and eicosanoids to regulate their distribution and use (Kliewer et al., 1997). One of the
standard treatment regimens for type II diabetes includes activation of PPARg using drugs
such as thiazolidinediones to increase insulin sensitivity by decreasing plasma triglyceride
levels; however, this leads to accumulation of lipids in white adipose tissue and weight
gain in the long term (Larsen et al., 2003). Tributyltin activates PPARg: RXR to promote
adipogenesis in murine 3T3-L1 cells and increases hepatic steatosis and epidydimal
adipose tissue mass in adult mice exposed to tributyltin at gestational of 12-18 days (Grun
et al., 2006). Similarly, male mice exposed to repeated low dosage (5µg/kg) of tributyltin
for 45 days had an increase in body weight, fat mass, insulin, and leptin levels compared
to control mice indicates that chronic tributyltin exposure could induce obesity (Zuo et al.,
2011).
Other nuclear receptors implicated in obesity include Farnesoid-X-receptor (FXR),
estrogen receptor (ER a), glucocorticoid receptor (GR), activation of the pregnane-Xreceptor (PXR), and inhibition of the constitutive androstane receptor (CAR) (Paul et al.,
2013;Takeshita et al., 2001). The OECD considers metabolic disorders one of three critical
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areas in toxicology in addition to testicular dysgenesis and the increased incidence of
autism spectral disorders(LeBlanc et al., 2012a).

Tributyltin

PPARg

RXR

Adipocyte differentiation

Insulin resistance

Increase adipose tissue

Glucose intolerance

Weight gain

Figure 1.1: Nuclear receptors that stimulate weight gain and associated
disorders. Activation of PPARg:RXR by tributyltin induces adipocyte
differentiation, increases adipose tissue weight and leads to body weight
gain. The increase in body weight causes insulin resistance and glucose
intolerance. Thus, leading to the development of obesity and potentially
diabetes (LeBlanc et al., 2012a).
1.2 CAR (Constitutive Androstane Receptor)
CAR belongs to nuclear receptor superfamily NR1l3. It is responsible for the
metabolism of foreign chemicals such as drugs, pesticides (Hernandez et al., 2009a) and
endogenous compounds such as bilirubin (Huang et al., 2003) and fatty acids (Finn et al.,
2009). CAR regulates the expression of cytochrome P450 (CYP) 2Bs and to a lesser extent
CYP3As that are crucial in phase I detoxification pathways, phase II enzymes such as
uridine 5’-diphospho glucuronosyltransferase (Sugatani et al., 2001) and sulfotransferase
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(Saini et al., 2004) and phase III transporters such as multidrug resistance proteins and
multidrug resistance associated proteins (Xiong et al., 2002).
Inactive CAR is present in the cytoplasm bound by cytoplasmic CAR retention protein,
heat shock protein (HSP90), P-23 and immunophilins (Kobayashi et al., 2003;Yoshinori et
al., 2003). It can be activated by direct binding of ligands such as 1,4 bis (2-(3,5dichloropyridyloxy)) benzene TCPOBOP (Tzameli et al., 2000). CAR can also be activated
indirectly by compounds such as phenobarbital that do not bind the receptor (Kawamoto
et al., 1999) but changes the phosphorylation status of Thr38 residue (Mutoh et al., 2009),
which results in conformational change and allows translocation of CAR into the nucleus.
In the nucleus, CAR heterodimerizes with its partner, retinoid-X-receptor and then binds
to direct repeats 4 or inverted repeats 6 in the phenobarbital response element upstream of
promoter region on the DNA to induce transcription of its target genes.

CAR
Cytoplasm

CCRP HSP90

Nucleus

RXR

CAR RXR
PBREM

PBREM

Figure 1.2: Mechanism of activation of CAR. CAR is retained in the
cytoplasm by cytoplasmic CAR retention proteins (CCRP) , HSP90 and
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immunophilins, while the presence of ligand represented as “x” activates
CAR by causing conformational change and allowing the movement of
CAR into the nucleus. CAR dimerizes in the nucleus with RXR to induce
transcription of its target genes.

CAR and its target gene Cyp2b10 levels were increased in db/db mice while zucker
rats, which have a mutation in leptin receptor gene, had decreased expression of CAR and
Cyp2b1 demonstrates CAR’s role in regulating energy homeostasis (Xiong et al., 2002;K
Yoshinari et al., 2006). CAR was activated during HFD treatment in order to get rid of the
accumulating hepatic fat especially during treatment with unsaturated fats rich sunflower
oil in HRN-null mice (Finn et al., 2009). Activation of CAR using mouse-specific CAR
agonist TCPOBOP shows decrease in hepatic glucose production, increase insulin
sensitivity and alleviate fatty liver in ob/ob mice but these changes were absent in CARnull ob/ob double mutant mice (Dong et al., 2009). CAR also increases the production of
anti-lipogenic protein, insig-1 (Roth et al., 2008) and also suppress FoxO1 to prevent it
from binding insulin response sequences on gluconeogenic genes (Kodama et al., 2004).
FoxO1 regulates the expression of gluconeogenic genes such as phosphoenol pyruvate
carboxykinase (PEPCK1) and glucose-6 phosphate (G6P) and is also known to coregulate
other nuclear receptors such as glucocorticoid receptor and thyroid receptors (Nakae et al.,
2001;Zhao et al., 2001). Insulin represses FoxO1 by phosphorylating it via PI3-Akt
pathway to preventing it from binding insulin response element present upstream of
PEPCK1 and G6P (Matsuzaki et al., 2003). Kodama et al group demonstrated that CAR
and PXR crosstalk with FoxO1 using yeast two hybrid screening and FoxO1 acts as
coactivator of CAR while activated CAR binds FoxO1 to repress gluconeogenic genes such
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as PEPCK1 (Kodama et al., 2004). Thus, CAR regulates energy metabolism related genes
and has a protective effect against the development of obesity and diabetes.

Coactivator

CAR

FoxO1

Insig-1

IRIS-1

Sterol regulatory
binding protein-1

Phosphoenol
pyruvate kinase-1
Glucokinase

CAR downregulates
gluconeogenic and lipogenic
genes. Thus, CAR is
associated with anti-obesity.

G

Figure 1.3: CAR is cross talks with transcription factors associated
with anti-obesity. FoxO1 acts as coactivator of CAR but active CAR
phosphorylates FoxO1, and downregulates its target gene expression
(Kodama et al., 2004). CAR activates insig-1 that downregulates sterol
regulatory elemental binding protein-1(Roth et al., 2008).
FoxA2 is a hepatocyte nuclear factor that regulates lipid metabolism and ketone
body formation(Wolfrum et al., 2004). FoxA2 is activated during fasting and starvation to
increase triglyceride breakdown, fatty acid oxidation genes such as Carnitine palmitoyl
transferase-1 a and decrease glycolysis genes such as glucokinase (Wang et al.,
2001;Wolfrum et al., 2004). FoxA2 is inhibited by insulin via PI3-AKT phosphorylation
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during fed state and is excluded from the nucleus in order to downregulate its target gene
expression (Wang et al., 2001). FoxA2 is involved in sexual dimorphic expression of
Cyp2b9 and it is regulated by HNF4a (Hashita et al., 2008;Wiwi et al., 2004). HNF4a is
an important nuclear receptor and regulates sexually dimorphic expression of key hepatic
genes such as cytochrome P450 and also regulates CAR expression (Wiwi et al., 2004).
Thus, FoxA2, HNF4a and CAR are important regulators of hepatic gene expression
(Hashita et al., 2008;Hernandez et al., 2009b;Wiwi et al., 2004).
In our study, we characterized the compensatory changes in CYP gene expression,
protein expression and cytochrome P450 enzyme activity changes in CAR-null mice. This
study will help us to determine changes in xenobiotic and drug metabolism in patients with
low CAR or CYP activity. In addition, CAR is important because it is the primary positive
regulator of Cyp2b10 in mice and CYP2B6 in humans.
1.3 Cytochrome P450s (Cyps)
Cytochrome P450s belong to a superfamily of heme-containing monooxygenases
and are crucial in phase I detoxification of exogenous compounds such as drugs and
environmental pollutants (Hernandez et al., 2009a;Perloff et al., 2000) and endogenous
compounds such as hormones (Waxman, 1988) and fatty acids (Bylund et al., 1998). There
are 57 human CYP genes and 108 murine CYP genes classified into 18 families (Nelson,
2011). CYPs of the families 1-3 are known to play an important role in xenobiotic
metabolism. But recent studies shows that the CYPs 1-3 are also important in the
metabolism of fatty acids such as arachidonic acid (Capdevila et al., 1990), linoleic acid
(Finn et al., 2009) and epoxyeicosatrienoic acid (Du et al., 2005).
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The lack of cytochrome P450 activity in a liver specific knockdown in HRN-null
mice increases fatty acid accumulation in the liver (Finn et al., 2009). Opposingly, a
Cyp2e1-null shows improved glucose tolerance and insulin sensitivity coupled with
increased energy expenditure and are protected from high fat diet-induced obesity (Zong
et al., 2012). In the former mouse model, HRN-null mice lack CYP activity in the liver
therefore treatment with high fat diet leads to accumulation of unsaturated fatty acids in
the liver due to lack of functional detoxification CYPs. These hepatic lipids then activate
CAR to induce Cyp2b10 expression to prevent lipid toxicity and restore lipid homeostasis
but lack of cytochrome P450 oxidoreductase prevents CYP’s ability to metabolize lipids.
In the latter mouse model, Cyp2e1 oxidizes foreign compounds such as alcohol and
endogenous compounds such as fatty acids. Cyp2e1 generates reactive oxygen species
while metabolizing its substrate in a NADH/NADH dependant pathway and also increases
mitochondrial oxidative stress markers such as glutathione-s-transferase A4 (Raza et al.,
2004). Increased production of these reactive oxygen species will induce inflammation and
insulin resistance by activating serine/threonine kinase pathways such as nuclear factor-kB
which in turn will phosphorylate insulin receptor and insulin receptor substrate 1(IRS-1).
Increase in serine phosphorylated IRS-1 decrease their tyrosine phosphorylation and also
reduce their ability to bind insulin receptor or downstream targets such as PI3-kinase; thus
oxidative stress and dysregulation in intracellular signaling lead to insulin resistance
(Evans et al., 2005). Therefore, Cyp2e1 knockout mice did not show insulin resistance but
had improved insulin sensitivity and glucose tolerance compared to their wild-type
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counterparts fed high fat-diet. These studies indicate that different CYPs may perform
completely different roles and outcomes when it comes to obesity and diabetes.
Cyp2b RNAi knockdown mouse model developed in our own laboratory show that
older male knockdown mice had increased white adipose tissue weight and body weight
compared to their wild-type counterparts. The knockdown mice also had difficulty clearing
out corn oil, which is rich in 85% unsaturated fats (Damiri et al., 2012).
Thus, cytochrome P450’s has a significant role in lipid homeostasis apart from mere
xenobiotic biotransformation and the development of metabolic disorders. In our study, we
have used two cytochrome P450-null mice to demonstrate their role in hepatic lipid
metabolism.
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•
Increase
in body weight
•
Glucose
intolerance and
insulin resistance
•
Changes
in hormone levels
such as adiponectin
and leptin

Chemical
inhibitors or

gene
knockout

High fat
diet (60%
fat)

Lack of
CYP2B
or
CYP3A

•
Accumulation
of unsaturated fatty acids
in the liver
•
Lack
of
Cyp2b/Cyp3a fatty acid
metabolites such as
EETs and HETEs that
are
important
intracellular signals for
inflammation
and
behavior
Mice lacking
CYP2B/3A are obese
and develop nonalcoholic fatty liver
disease

Fig. 1.4: Lack of Cyp2b/Cyp3a will increase susceptibility to high fat
diet-induced obesity. To demonstrate significance of CYP2B/CYP3A in
hepatic lipid metabolism, treatment with either chemical inhibitors such as
triclopidine and ketaconazole or targeted gene editing using Crispr/Cas9
will repress/knockout Cyp2b/Cyp3a in mice. These mice will be challenged
with high fat diet for 8-10 weeks to simulate western diet-induced obesity.
Mice lacking Cy2b/Cyp3a will have an increase in body weight, glucose
intolerance and insulin resistance because of accumulation of unsaturated
fatty acids and lack of intracellular signaling molecules such as EETs. Thus,
mice lacking Cyp2b/Cyp3a will develop diet-induced obesity and nonalcoholic fatty liver disease.
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1.4 CYP2B
Cytochrome P450 2B is one the least studied among the CYPs because it was
considered to be expressed <1% of total hepatic CYP expression; however, recent
development of sensitive probes and inhibitors have shown that it constitutes 2-10% of
total hepatic CYP (Wang et al., 2008) and metabolizes approximately 25% of the drugs
available in the market (Xie et al., 2001). CYP2B’s also metabolizes environmental
pollutants such as nonylphenol (Lee et al., 1998), N,N-diethyl-m-toluamide (DEET)
(Usmani et al., 2002), parathion (Foxenberg et al., 2007), and polychlorinated biphenyls
(Warner et al., 2009) and pharmaceuticals such as efavirenz (Ward et al., 2003), bupropion
(Faucette et al., 2000) and cyclophosphamide (Xie et al., 2003). CYP2B also metabolizes
endobiotics such as linoleic acid (Finn et al., 2009), testosterone (Mo et al., 2009) and
arachidonic acid (Capdevila et al., 1990;Keeney et al., 1998a). Cyp2b12 participates in
arachidonic acid metabolism by epoxygenation to generate 11,12- and 8,9epoxyeicosatrienoic acids (Keeney et al., 1998b), which acts as bioactive lipids and
participates in intracellular signaling in renal function and blood pressure regulation
(Zeldin, 2001). Cyp2b19 expressed on mouse epidermal keratinocytes metabolize
arachidonic to 11, 12-epoxyeicosatrienoic acid which is crucial for regulating epidermal
cornification (Du et al., 2005).
The CYP2B subfamily in humans is represented by only CYP2B6 while in mouse
there are 5 isoforms Cyp2b9, Cyp2b10, Cyp2b13, Cyp2b19 and Cyp2b23. Cyp2b23 is
expressed only in adolescent mice (after birth till day 20) (Peng et al., 2012) while Cyp2b19
is expressed in fetal mouse keratinocytes (Keeney et al., 1998a) and has low hepatic
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expression. The hepatic CYPs are Cyp2b9, Cyp2b10, and Cyp2b13 and they show sexual
dimorphism with Cyp2b9 and Cyp2b13 expressed more in the females than males
(Hernandez et al., 2006;Mota et al., 2010;Wiwi et al., 2004).
CAR regulates Cyp2b10 expression (Honkakoski et al., 1998) by forming a
heterodimer with RXR, binds to the phenobarbital response element present upstream of
the promoter region on the DNA and induces gene expression. CAR induces Cyp2b10
expression during nutrient or metabolic stress due to changes in cAMP levels (Ding et al.,
2006). FoxA2, which is female predominant in mice, induces female predominant,
Cyp2b9, and is modulated by female type growth hormone secretion (Hashita et al., 2008).
Recent studies using cytochrome P450 oxidoreductase-null mice shows increase in
Cyp2b expression; Cyp2b expression increased in correlation with increases in hepatic
triacylglycerol levels especially during treatment with sunflower oil that is high in omega6 polyunsaturated fatty acids. The induction of Cyp2b expression appears to be a response
to eliminate the excess hepatic lipids (Finn et al., 2009). Cyp2b RNAi knockdown male
mice generated in our laboratory showed increases in hepatic fatty acid accumulation
during treatment with corn oil and increase in body weight coupled with an increase in
white adipose tissue weight compared to their wild-type counterparts. The older
knockdown mice also did not show any difference in Cyp2b expression levels during corn
oil treatment when compared to wild-type mice despite the repression of Cyp2b genes in
this study (Damiri, 2011). A HFD rich in soybean oil administered to mice lead to an
increase in body weight, adiposity and increased deposition of fat in the liver coupled with
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hepatocyte ballooning. These mice show a significant increase in Cyp2b; similar to our
observations in earlier studies (Deol et al., 2015).
6-weeks old C57/BL6oja Hsd mice fed a high fat diet (40% fat) made up of fats
such as 70% sunflower oil and 18% coconut oil for 12-weeks shows significant increase in
body weight and white adipose tissue weight, increase in hepatic lipids and leptin levels
compared to their standard-diet fed counterparts. Pearson correlation study in these mice
revealed a strong correlation between Cyp2b9 expression level and weight gain, white
adipose tissue gain and leptin levels(Hoek-van den Hill et al., 2015). Recent microarray
analysis done to determine gene expression changes in brown adipose tissue on mice
treated with (35 kcal) high fat diet shows significant downregulation of Cyp2b10 within 2weeks of high fat diet treatment (McGregor et al., 2013). These studies show that CYP2B
is highly inducible by high fat diet.
Taken together, CYP2B metabolizes fatty acids, it is induced by dietary fatty acids
and its loss is associated with dysregulation of lipid homeostasis.

Therefore, we

hypothesize that lack of Cyp2b9, 10 and 13 in our knockout mice will increase their
susceptibility to high fat diet-induced obesity.
1.5 CYP3A
Cytochrome P450 3A is the most predominant CYP in the liver (constitutes 3040% of the CYPs in the liver) and metabolizes > 60% of the drugs available in the market
(Guengerich, 2002). CYP3A plays a crucial role in the biotransformation of drugs such as
valproic acid (Cerveny et al., 2007), midazolam (Perloff et al., 2000) and simvastatin
(Prueksaritanont et al., 2003) and environmental pollutants such as endosulfan (Casabar et
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al., 2006), chlorpyrifos (Tang et al., 2001) and phthalates (Cooper et al., 2008). CYP3A
also metabolizes endogenous compounds such as lithocholic acid (Staudinger et al., 2001),
arachidonic acid (Bylund et al., 1998) and steroid hormones (Waxman et al., 1983).
CYP3A4 metabolizes linoleic acid to 11-hydroxyoctadecanoic acid and arachidonic acid
is oxidized to generate 13- hydroxyecosatrienoic acid (HETE), 10-HETE and 7-HETE
(Bylund et al., 1998). The arachidonic acid epoxides do not have any known function in
the liver but inhibition assays suggest that Cyp3a-mediated metabolite is responsible for
relaxation of arterial endothelium (Ayajiki et al., 1999).
Anandamide is a derivative of arachidonic acid that is oxidized by CYP3A4 to
generate 5,6-,8,9-,11,12- and 14,15-epoxyeicosatrienoic acid ethanolamide (EET-EA) that
can activate cannabinoid receptors (CB1/2). Anandamide and CYP3A metabolites bind
CB1 that is responsible for nociception, cognition, memory and orexigenic effects in
peripheral and central nervous system (Pratt-Hyatt et al., 2010;Snider et al., 2010). Cyp3ametabolite activates cannabinoid receptor 2 (CB2) which is responsible for
immunosuppression and obesity (Zhang et al., 2016). Similarly, CYP3A metabolizes
linoleic acid into an oxidized metabolite which has been associated with nociception via
activation of a major class of nociceptors called Transient receptor potential vanilloid
1(TRPV1) cation channel in inflamed dental pulps(Ruparel et al., 2013).Thus, Cyp3aderived metabolites of unsaturated fatty acids are responsible for specific functions and
disruption of this function by chemical inhibitors or genetic impairments may affect fatty
acid metabolism, distribution and use (Wojnowski et al., 2006).
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CYP3A expression is regulated by pregnane-x-receptor (PXR) and CAR. PXR is a
promiscuous nuclear receptor and is activated by environmental pollutants such as
methoxychlor and bisphenol-A (Jacobs et al., 2005;Takeshita et al., 2001) and endogenous
compounds such as pregnanes, other steroids, and Triol (intermediate in cholesterol
metabolism) (Dussault et al., 2003;Kliewer et al., 1997). Recent studies show that
activation of mouse PXR increases obesity and metabolic disorders (Spruiell et al., 2014).
HRN-null mice lacking cytochrome P450 oxidoreductase shows complete loss of
all CYP activity in the liver, but subsequent treatment with sunflower oil causes increase
in Cyp2b10 and Cyp3a11 mRNAs in these mice. Thus, high levels of unsaturated fat induce
CYP activity as a protective mechanism from fatty acid toxicity (Finn et al., 2009). Fatty
acids induce CYP3A expression in HepG2 cells (Hu et al., 2014). Studies using high fat
diet-induced obese guinea pigs (Patoine et al., 2013) and mice (K Yoshinari et al., 2006)
show significant decrease in CYP3A. CYP3A expression is increased in both type1 and
type 2 diabetes mouse models (Patoine et al., 2014). Thus, the most predominant hepatic
CYP, CYP3A that metabolizes more than 60% of drugs, is induced by dietary fatty acids
and, metabolic diseases such as obesity and diabetes modulate CYP3A expression.
In our study, we used a Cyp3a-null mouse model to study the compensatory
changes in other CYP gene expression, protein expression and enzyme activity in mice
lacking seven Cyp3a genes Cyp3a11, Cyp3a16, Cyp3a25, Cyp3a41, Cyp3a44, Cyp3a57,
and Cyp3a59. We also challenged the Cyp3a-null mice with high fat diet for 8-weeks to
demonstrate the significance of CYP3A in hepatic lipid metabolism because of its high
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expression, role in fatty acid metabolism, and propensity for disrupted activity and
expression by anthropogenic chemicals.
1.6 Mouse model
Animal models have been used in obesity research to study the mechanisms and
pathways affected during the progression of disease. Rodents are suitable for obesity
studies because they are easy to handle, have a relatively short lifecycle, their genetic
similarities (and differences) to humans are well studied, and it is easy to perform
controlled experiments (Andrade et al., 2006). The development of leptin resistant mice
increased their use in obesity research (Zhang et al., 1994). We have used C57Bl/6 (B6)
background mice because its genome sequence is available, this is the most common strain
of mouse used in biomedical research, and B6 are susceptibility to diet-induced obesity.
Cytochrome P450 null mouse models have been used to study the metabolism and
distribution of drugs in toxicology research (Mota et al., 2011;Scheer et al., 2010;Van
Herwaarden et al., 2007). We have used three different mouse models in this study; CARnull, Cyp3a-null, and Cyp2b-null, of which Cyp3a-null and Cyp2b-null were used in our
obesity studies. All three models were used in Aim 1 so that we would have a basic
understanding of the compensatory changes that take place in the absence of CAR, CYP3A
and CYP2B. CAR is a crucial regulator of Cyp3a and Cyp2b expression. Further, we have
treated the Cyp3a-null and Cyp2b9/10/13-null mouse models with high fat diet to simulate
western diet based type 2 obesity development in human and demonstrate the significance
of CYP3A and CYP2B in lipid homeostasis and obesity development.
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In this study, we developed novel triple knockout mice missing the hepatic Cyp2b
members, Cyp2b9, Cyp2b10 and Cyp2b13 using CRISPR/Cas9 technology. We did not
knock out the other two Cyp2b19 and Cyp2b23 because they are located several genes
downstream. Neither Cyp2b19 nor Cyp2b23 are significantly expressed in the liver as
Cyp2b19 is expressed in keratinocytes while Cyp2b23 is expressed in adolescent mice and
have very low hepatic expression (Keeney et al., 1998a;Peng et al., 2012;Renaud et al.,
2011). Moreover, there are five development-associated genes that are located in between
Cyp2b9/10/13 cluster and Cyp2b19 and Cyp2b23 genes. We confirmed the loss of Cyp2b9,
10 and13 using PCR in our mouse colony and loss of functional Cyp2b protein expression
using western blot. This Cyp2b9/10/13-null mouse model can be used to investigate
CYP2B’s role in xenobiotic and endobiotic metabolism. It can also demonstrate if lack of
Cyp2b9, Cyp2b10 and Cyp2b13 will increase susceptibility to dyslipidemia, diet-induced
obesity and fatty liver disease.
CRISPR/Cas9 is an adaptive immune mechanism in viruses and archae (Mojica et
al., 2000). Clustered regularly interspaced short palindromic repeats (CRISPR) are a series
of short repeats while Cas 9 is an endonuclease protein that has together been used to
genetically engineer cells and model organisms using endogenous DNA repair mechanism.
Small guide RNA is designed for target genes, which is composed of 20-nucleotide
sequence complementary to target sequence at the 5’ end and double stranded structure at
3’ end to bind Cas 9. The 20-nucleotide sequence can be modified according to target as
long as it includes PAM (protospacer adjacent motif). When foreign DNA are integrated
into CRISPR loci that are transcribed and processed into short RNA sequences called
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(CRISPR RNA) cr RNA. Now crRNA will guide RNA for Cas9 matching DNA and PAM
sequences. Thus, crRNA directs cleavage of foreign DNA by Cas9 endonuclease after
complementary base pairing with similar sequences to increase specificity of the
deletion(Doudna et al., 2014).
1.7 Specific aims
Cyp3a constitutes 40% and Cyp2b constitutes 2-10% of total hepatic CYPs in the
human liver (Zanger et al., 2013), and these contribute to the metabolism of most of the
xenobiotics such as environmental pollutants (Hernandez et al., 2009a), drugs (Perloff et
al., 2000) and endobiotics such as bile acids (Huang et al., 2003), hormones (Waxman et
al., 1983) and fatty acids (Bylund et al., 1998). We hypothesize that lack of either CYP3A
or CYP2B will increase susceptibility to diet-induced obesity and fatty liver disease:
CYP3A and CYP2B contribute to metabolism of unsaturated fatty acids and most of the
western diet is composed of unsaturated fats. Recent studies have also indicated altered
expression levels of Cyp3a and Cyp2b during the development of metabolic disorders such
as obesity, diabetes and fatty liver disease (Blouin R A et al., 1993;Hoek-van den Hill et
al., 2014;Leung et al., 2016;Patoine et al., 2014). We will use mice lacking CYP2B or
CYP3A genes and treat them with a high fat diet to demonstrate the significance of CYP2B
and CYP3A in lipid homeostasis, obesity and fatty liver disease.
Aim 1: Determine compensatory changes in the detoxification CYPs in CAR-null,
Cyp3a-null and Cyp2b9/10/13-null mouse models
1. Determine whether changes in hepatic CYP gene expression occurs in CARnull, Cyp3a-null and Cyp2b9/10/13-null mouse models by qPCR.
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2. Determine whether these changes in CYP gene expression manifest themselves
at the protein and activity level. We will prepare RNA and microsomes from
these mouse models and measure CYP expression and activity by qPCR,
Western blotting, and testosterone hydroxylase assays.
Aim 2: Test whether Cyp3a-null are mice are susceptible to HFD-induced obesity
and non-alcoholic fatty liver disease (NAFLD)
1. We will provide wild type (WT) and Cyp3a-null mice a high-fat diet for 8weeks. Mouse weight, tissue weights, fasting serum glucose, and glucose
tolerance will be monitored in each mouse model.
2. We will determine changes in key lipid metabolism genes such as Carnitine
palmitoyl transferase 1a and Sterol regulatory binding protein 1 using qPCR.
We will also determine compensatory changes in detoxification CYP gene and
protein expression after the dietary treatment using qPCR and western blots.
3. We will also determine biochemical changes in hormone levels and hepatic
lipids using Enzyme Immuno Assay and mass spectrophotometry respectively.
4. Behavioral studies will be done to determine susceptibility of Cyp3a-null mice
to anxiety and fear.
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Aim 3: Test whether Cyp2b9/10/13-null are mice are susceptible to HFD-induced
obesity and non-alcoholic fatty liver disease (NAFLD)
1. We will provide wild type (WT) and Cyp2b9/10/13-null mice a high-fat diet for
10-weeks. Mouse weight, tissue weights, fasting serum glucose, and glucose
tolerance will be monitored in each mouse model.
2. We determine changes in key lipid metabolism genes such as Carnitine
palmitoyl transferase 1a and Sterol regulatory binding protein 1 using qPCR.
We will also determine compensatory changes in detoxification CYP gene and
protein expression after the dietary treatment using qPCR and western blots.
3. We will also determine biochemical changes in hormone levels and serum lipids
using Enzyme Immuno Assay and mass spectrophotometry respectively.
4. Behavioral studies will be done to determine susceptibility of Cyp2b9/10/13null mice to anxiety and fear.
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CHAPTER TWO
COMPENSATORY CHANGES IN CYP EXPRESSION IN THREE DIFFERENT
TOXICOLOGY MOUSE MODELS: CAR-NULL, CYP3A-NULL, AND
CYP2B9/10/13-NULL MICE
This Chapter has been published in PLoS one journal.
2.1 Abstract
Targeted mutant models are common in mechanistic toxicology experiments
investigating the absorption, metabolism, distribution, or elimination (ADME) of
chemicals from individuals. Key models include those for xenosensing transcription
factors and cytochrome P450s (CYP). Here we investigated changes in transcript levels,
protein expression, and steroid hydroxylation of several xenobiotic detoxifying CYPs in
constitutive androstane receptor (CAR)-null and two CYP-null mouse models that have
subfamily members regulated by CAR; the Cyp3a-null and a newly described
Cyp2b9/10/13-null mouse model. Compensatory changes in CYP expression that occur in
these models may also occur in polymorphic humans, or may complicate interpretation of
ADME studies performed using these models. The loss of CAR causes significant changes
in several CYPs probably due to loss of CAR-mediated constitutive regulation of these
CYPs. Expression and activity changes include significant repression of Cyp2a and Cyp2b
members with corresponding drops in 6α- and 16β-testosterone hydroxylase activity.
Further, the ratio of 6α-/15α-hydroxylase activity, a biomarker of sexual dimorphism in
the liver, indicates masculinization of female CAR-null mice, suggesting a role for CAR
in the regulation of sexually dimorphic liver CYP profiles. The loss of Cyp3a causes fewer
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changes than CAR. Nevertheless, there are compensatory changes including genderspecific increases in Cyp2a and Cyp2b. Cyp2a and Cyp2b were down-regulated in CARnull mice, suggesting activation of CAR and potentially PXR following loss of the Cyp3a
members. However, the loss of Cyp2b causes few changes in hepatic CYP transcript levels
and almost no significant compensatory changes in protein expression or activity with the
possible exception of 6α-hydroxylase activity. This lack of a compensatory response in
the Cyp2b9/10/13-null mice is probably due to low CYP2B hepatic expression, especially
in male mice. Overall, compensatory and regulatory CYP changes followed the order
CAR-null > Cyp3a-null > Cyp2b-null mice.

Keywords: metabolism, CAR; cytochrome P450, sexually dimorphic, Crispr, Cyp3a,
Cyp2b
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2.2 Introduction
Nullizygous mouse models have become commonplace in toxicology research
(Gaytan et al., 2014;Scheer et al., 2014), especially the use of xenobiotic receptor and Cyp
subfamily-null mice (Hernandez et al., 2009a;Mota et al., 2011;Scheer et al., 2010;Van
Herwaarden et al., 2007). These models are widely used in the study of the metabolism
and distribution of pharmaceuticals and hazardous environmental chemicals (Mota et al.,
2011;Scheer et al., 2010;Van Herwaarden et al., 2007). To properly interpret the data
observed, especially within absorption, distribution, metabolism, and excretion (ADME)
studies, it is critical to have an understanding of the compensatory changes in cytochrome
P450 (CYP) expression that occurs in these mouse models. The purpose of this study is in
part to evaluate changes that occur in constitutive androstane receptor (CAR)-null, Cyp3anull, and the newly developed Cyp2b9/10/13-null mouse models, estimate the impact that
compensatory changes may have on xenobiotic metabolism, and interpret the basis for
these changes.
The constitutive androstane receptor (CAR; NR1I3) is a xenobiotic sensor activated
either directly by ligand binding such as 1,4-bis [2-(3,5-dichloropyridoxy)] benzene
(TCPOBOP) (Tzameli et al., 2000) or indirectly in which the chemical of interest induces
nuclear translocation through changes in phosphorylation status such as phenobarbital
(Honkakoski et al., 1998;Mutoh et al., 2013;Sueyoshi et al., 2008). Modulators of CAR
activity include environmental pollutants, pharmaceuticals, natural products, and
endogenous chemicals such as steroids, bile acids, and fatty acids (Baldwin et al.,
2009;Finn et al., 2009;Hernandez et al., 2009a;Tien et al., 2006). CAR activation leads to
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increased transcription of genes involved in phase I-III detoxication, including the
cytochrome P450s (CYP) with greater CYP2B6 induction than CYP3A4 or CYP2C9
induction (Kretschmer et al., 2005;Wilson et al., 1998). We have observed compensatory
changes in CYP expression in CAR-null mice on the B6/SV129 background (Hernandez
et al., 2009b). Here we take a more comprehensive look at compensatory changes in CARnull mice, but on the B6 background.
CYP3A is the most predominant CYP in the liver encompassing 30-40% of the
total hepatic CYP content and metabolizing more than 60% of the drugs available on the
market (Maurel, 1996). In addition to the metabolism of numerous pharmaceuticals and
environmental pollutants (Hernandez et al., 2009a;Perloff et al., 2000)), CYP3A
metabolizes endogenous molecules such as lithocholic acid (Staudinger et al., 2001),
arachidonic acid (Bylund et al., 1998) and steroid hormones (Waxman, 1988). Recently,
knocking out Cyp3a was shown to increase Cyp2c-mediated metabolism of midazolam
(Van Waterschoot et al., 2008), potentially due to activation of the pregnane X receptor
(PXR). Because Cyp3a is the predominant hepatic CYP and of such importance in
toxicology, it is likely that loss causes compensatory mechanisms that alter the metabolism
of endogenous and exogenous substances. In some cases these alterations may not be (at
least in part) due to loss of Cyp3a, but instead increases in the production of other
metabolites produced through the induction of CYPs in subfamilies 2a, 2b, and 2c.
There are currently two different Cyp3a knockout mouse models; not including
humanized models. In the model produced by Van Herwaarden et al (Van Herwaarden et
al., 2007) on an FVB background, the Cyp3a members clustered in a 0.8Mb region of
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chromosome 5 were eliminated by Cre-lox, while Cyp3a13 located 7 Mb centromeric to
the cluster was deleted by traditional targeting methods (Van Herwaarden et al., 2007).
Another model produced on the C57Bl6 (B6) background, eliminated all of the Cyp3a
members on the chromosome 5 cluster by Cre-lox, but did not eliminate Cyp3a13
(Hasegawa et al., 2011;Scheer et al., 2010). For the purposes of the present study this
model is more attractive, because responses in this mouse can be compared to other mouse
strains on the B6 background.
CYP2B is probably the least studied of the hepatic detoxication CYPs in families
1-3 because it was traditionally considered to have <1% of total hepatic CYP expression
and in turn was called the overlooked or forgotten CYP (Wang et al., 2008). However,
recent studies using more sensitive probes and inhibitors have shown that CYP2B6
constitutes 2-10% of the total CYP expressed in the liver. It is estimated that CYP2B6
metabolizes approximately 25% of drugs available on the market (Wang et al., 2008) such
as efavirenz (Anakk et al., 2003), bupropion (Faucette et al., 2000) and cyclophosphamide
(Xie et al., 2003). In addition, CYP2B metabolizes environmental pollutants such as
nonylphenol (Lee et al., 1998), parathion (Foxenberg et al., 2007) and polychlorinated
biphenyls (Warner et al., 2009), and endogenous molecules such as testosterone (Mo et al.,
2009), arachidonic acid (Capdevila et al., 1990;Keeney et al., 1998), linoleic acid (Finn et
al., 2009) and epoxyeicosatrienoic acid (Du et al., 2005).
We produce and describe the first exclusive Cyp2b-null mouse model in this
manuscript. There are other models that lack Cyp2b or Cyp2b activity. These include P450
oxidoreductase-null mice (HRN or POR-null) that lack all CYP activity because they lack
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this crucial cofactor (Gu et al., 2003;Henderson et al., 2003), and the Cyp2a(4/5)bgs-null
mouse model that lacks a 1.2 megabase region of chromosome 7 containing Cyp2a4, 2a5,
2b9, 2b10, 2b13, 2b19, 2b23, 2g1, 2s1, Nalp9a, Nalp9c, Nalp4a, Vmn1r185, and
Vmn14184 (Wei et al., 2013). This mouse model lacks all of the Cyp2b members, but also
lacks other Cyp2 members (2a4, 2a5, 2g1, 2s1) as well as five non-CYP genes found
between the two Cyp clusters on chromosome 7 (Damiri et al., 2012). Our new mouse
model lacks three of the five Cyp2b members, 2b9, 2b10, and 2b13, which are the primary
hepatic Cyp2b’s found in tandem repeat (Damiri et al., 2012;Jarukamjorn et al., 2001;Peng
et al., 2012). There are six genes between the Cyp2b9/10/13 cluster and Cyp2b19 and
Cyp2b23 (S1 Fig). We did not delete Cyp2b19, which is primarily expressed in skin (Du
et al., 2005) and testes (Renaud et al., 1995), or Cyp2b23, which until recently was not
known to be expressed (Renaud et al., 1995). Recent work suggests Cyp2b23 is expressed
briefly at very low levels in the livers of young mice (Cui et al., 2012;Peng et al., 2012).
Many of the xenobiotic detoxifying CYPs are expressed in a sexually dimorphic
manner (Hernandez et al., 2006;Park et al., 1999;Wiwi et al., 2004a). Murine male
predominant hepatic CYPs include Cyp2d9 and 4a12 (Noshiro et al., 1986;Wiwi et al.,
2004a), which are not regulated by CAR. Murine female predominant hepatic CYPs
include Cyps 2a4, 2b9, 3a41, 2c40 and 3a44 (Burkhart et al., 1985;Hernandez et al.,
2006;Jarukamjorn et al., 2002;Noshiro et al., 1986;Wiwi et al., 2004a), of which several
are regulated by CAR (Hernandez et al., 2009b). Furthermore, CAR demonstrates greater
expression (Petrick et al., 2007) and activity in females than males (Ledda-Columbano et
al., 2003). This may be due to increased regulation of CAR by hepatocyte nuclear factor
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4α (HNF4α) in females (Kamiyama et al., 2007), estrogen activation of CAR (Kawamoto
et al., 2000), androgen inhibition of CAR (Baldwin et al., 2009;Forman et al., 1998), or a
combination of these factors. Taken together, this data indicates that CAR has greater
activity in female mice and therefore maintains basal expression of several CYPs in a
sexually dimorphic fashion. Therefore, changes in the basal expression of several CYPs,
including several female predominant CYPs will be compared between wild-type and
CAR/CYP-null mice.
The overall purpose of this manuscript is to compare and evaluate changes in CYP
gene expression, protein expression, and enzyme activity in three toxicology knockout
models; CAR, Cyp3a-null, and Cyp2b9/10/13-null mice. CAR is a key regulator of Cyp2b
and Cyp3a expression and therefore these CYP models are reasonable models to
investigate in order to discern how they are altered in comparison to CAR-null mice.

2.3 Materials and methods
2.3.1. Mice
All studies were carried out according to NIH guidelines for the humane use of
research animals and were pre-approved by the Baylor College of Medicine or Clemson
University Animal Care and Use Committee. Mice are on a C57/Bl6 (B6) background,
provided water and food ad libitum, and between 8-11 weeks old at the time of euthanasia.
Mice were euthanized by carbon dioxide asphyxiation followed by bilateral thoracotomy.
While each mouse is on a B6-background, each B6 mouse is from a different source. CARnull mice (Dong et al., 2009;Tzameli et al., 2000) and their B6 wild-type (WT) controls
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(B6) were housed at Baylor College of Medicine (BCM) on the B6 background bred at
BCM. Cyp3a-null mice (Scheer et al., 2010) and their respective B6-WT controls were
obtained from Taconic (Hudson, NY USA). These mice lack the Cyp3a57, Cyp3a16,
Cyp3a41, Cyp3a44, Cyp3a11, Cyp3a25, and Cyp3a59 genes all located within
approximately 0.8Mb of each other in a tandem repeat region on chromosome 5, but still
contain the Cyp3a13 gene located 7 Mb centromeric from the cluster on chromosome 5
(Scheer et al., 2010).
Cyp2b9/10/13-null mice were produced using the Crispr/Cas9 system.
Corresponding WT controls (B6) were obtained from The Jackson Laboratory (Bar Harbor,
ME) and used to produce the Cyp2b9/10/13-null mice. Cyp2b9, Cyp2b10, and Cyp2b13
are the three Cyp2b members primarily expressed in the liver (Cyp2b9/10/13) and found
in tandem repeat (Appendix A-1)(Damiri et al., 2012;Jarukamjorn et al., 2001;Peng et al.,
2012). Each of the three hepatic genes was targeted (Fig. 2.1). Cas9 mRNA from
Streptococcus pyogenes and a 20nt guide sequence that was specific to the target site with
an 83nt scaffold sequence, which was common to all the sgRNAs was injected into the
cytoplasm of the mouse blastocyst (Horii et al., 2014). The scaffold sequence was
guuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugc
uuuuuuu.

The Cyp2b10 guide sequence was: uguggaggagcggauucagg(AGG).

The

Cyp2b13 guide sequence was: (CCC)ugcaagagguuccccaagag, and the Cyp2b9 guide
sequence was: acattgatacctaccttctg(AGG). The protospacer adjacent motif (PAM) is
shown in parenthesis. The incorporation efficiency at each site in vitro was Cyp2b10,
47.6%, Cyp2b13, 33.3%, and Cyp2b9, 33.3%. The resultant injection of more than 100
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embryos produced two mice with a 287kB deletion lacking all three hepatic Cyp2b
members found in tandem repeat. Each mouse was genotyped to ensure the presence of the
knockout using the F2/R2 primer set (F2: 5’-gccagggtcagcatattcaccaa-3’ and R2: 5’gcacagacatcatgaggttctggtg-3’) that produces a 1066 bp band in triple-gene knockout mice.
To ensure we are not working with heterozygotes, we also genotyped for the presence of
Cyp2b13 (F: 5’-cagactcttgttagaccggaccat-3’ and R: 5’-ccccaaggaataaaattctacatg-3’) (Fig.
2.1).
Murine chromosome 7: 26,500 – 27,630K

Cyp2s1

Cyp2b10 Cyp2b9
Cyp2b13

Cyp2b10
sgRNA

Cyp2b23

Cyp2a4

Cyp2b13
sgRNA

Cyp2b19

Cyp2b9
sgRNA

287kb deletion of chromosome 7 containing Cyp2b10/13/9
Subsequent chromosome deletion
produces mouse lacking Cyp2b9/10/13

Cyp2s1

Cyp2a4

Cyp2b23
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Cyp2b19

B

C
D
Fig. 2.1: Construction of Cyp2b9/10/13-null mice. (A) Cyp2b9/10/13null mice were produced using Crispr/Cas9 with sgRNA target sites for all
three genes. A 287 kb deletion mutant was produced that lacks these three
Cyp2b genes found in tandem repeat on chromosome 7. (B) Two mice
heterozygote for a chromosome deletion lacking the three Cyp2b genes
(Cyp2b10, 2b13, 2b9) in tandem repeat were produced. PCR confirmation
of the 287kb deletion from the first null mice produced is shown in lanes 4
and 21 using the F2/R2 primer combination that produces a 1066 bp
fragment. (C) Subsequent breeding produced mice lacking Cyp2b9/10/13
as demonstrated by the presence of the 1066 bp PCR product. (D)
Heterozygotes were discerned from homozygotes by PCR of Cyp2b13
indicating a heterozygote.
2.3.2. Sample preparation
Eight to eleven-week old B6, CAR-null, and Cyp2b9/10/13-null male and female
mice (n = 4-6) were euthanized by CO2 asphyxiation. Livers were excised and diced into
several pieces and snap frozen for RNA extraction or microsome preparation and then
stored at -80oC. Eight to ten-week old Cyp3a-null and corresponding B6 controls from
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Taconic were euthanized at Taconic Biosciences (Hudson, NY USA), the livers were snap
frozen and shipped on dry ice to Clemson. RNA was extracted from a little less than half
of the liver using the Bio-Rad spin columns with DNAse (Bio-Rad, Hercules, CA USA)
according to the manufacturer’s instructions.

RNA concentrations were determined

spectrophotometrically at 260/280 nm (Molecular Devices, Ramsey, MN USA). Reverse
transcription was performed to make cDNA using 200 units MMLV-RT, a 10 mM dNTP
mixture, and 0.05 mg random hexamers (Promega Corporation, Madison, WI USA). For
microsome and cytosol preparation, approximately half of the liver was individually
homogenized with a Dounce Homogenizer and protein fractions were prepared as
described previously (Van der Hoeven et al., 1974).

Protein concentrations were

determined with the Bio-Rad protein assay (Bio-Rad) according to the manufacturer’s
instructions.
2.3.3. Quantitative Real-time Polymerase Chain Reaction (QPCR)
Quantitative real-time PCR (qPCR) was performed using primers for specific
isoforms to Cyp2a, Cyp2b, Cyp2c, and Cyp3a subfamily members, or 18S as the
housekeeping gene.

All the qPCR primers were previously published (Damiri et al.,

2012;Hernandez et al., 2006). Samples were diluted 1:10 and amplifications of the standard
curve performed in triplicate using a 96-well IQTM Real-Time PCR detection system (BioRad) with 0.25X RT2 SybrGreen (Qiagen Frederick, MD USA) as the fluorescent double
strand intercalating dye to quantify gene expression as described previously using Muller’s
equation to determine relative quantities of each CYP (Hernandez et al., 2007;Muller et al.,
2002).
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2.3.4. Western Blots
Western Blots were performed on 30 µg of microsomal protein to measure CYP
levels. Proteins were separated by polyacrylamide gel electrophoresis (SDS-PAGE) in a
10% gel, and transferred to 0.45 µm nitrocellulose (Bio-Rad) where the blot was blocked
using 1% skim milk/0.1% Tween 20 dissolved in phosphate buffered saline. Pre-stained
protein standards (Bio-Rad) were used as molecular weight markers. Primary antibodies
were obtained from a variety of sources. Rabbit anti-mouse Cyp2b10 antibody was
produced by our laboratory and previously characterized (Mota et al., 2011;Mota et al.,
2010). Rabbit anti-rat CYP3A1 and rabbit anti-human CYP2C8/9/19 were obtained from
Chemicon International (Temecula, CA USA). Mouse anti-human CYP2A6 was originally
obtained from Gentest™ Corporation (San Jose, CA USA) and used with the CAR-null
and Cyp3a-null mice.

CYP2A6 antibody was later obtained from Thermo-Fisher

(Rockford, IL) for use with the Cyp2b9/10/13-null mice when the original stock from
Gentest was no longer available. Rabbit anti-mouse β-actin (Sigma Aldrich, St. Louis, MO
USA) was used to ensure equal loading of samples. Goat anti-rabbit IgG (Bio-Rad)
alkaline-phosphatase coupled secondary antibodies were used for recognizing CYP2A6,
Cyp2b10, CYP3A1, and CYP2C8/9/19 primary antibodies. Goat anti-mouse (Bio-Rad)
IgG were used to recognize the β-Actin primary antibodies. Primary antibodies were
diluted 1:1000, and secondary antibodies were diluted 1:500. Bands were visualized using
a chemiluminescent kit according to the manufacturer’s directions (Bio-rad).
Chemiluminescence was quantified on a Chemi-Doc system with Quantity One software
(Bio-Rad). Western blot results regarding specific CYP protein data are referred to as
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subfamilies (i.e. CYP3A) instead of a specific protein because the antibodies most likely
recognize several different subfamily members (Acevedo et al., 2005;Damiri et al., 2012).
2.3.5. Testosterone hydroxylase assays
Testosterone hydroxylase assays were used to measure CYP activity as previously
described (Hernandez et al., 2006). [4-14C]Testosterone (Perkin-Elmer, Waltham, MA)
was used to visualize testosterone metabolites separated by thin-layer chromatography and
quantify. testosterone metabolites with a LS5801 liquid scintillation counter (Beckman,
Fullerton, CA USA).
2.3.6. Microarrays
There were 3 or 4 biological replicates used for each of the genotype-sex groups
(GSE90614). Liver RNA was isolated by mechanical disruption followed by RNAzol and
was further purified using silica membrane spin columns (RNeasy®, Qiagen, Valencia,
CA).

RNA integrity was assessed by the RNA 6000 LabChip® kit using a 2100

Bioanalyzer (Agilent Technologies, Palo Alto, CA). Gene expression in the livers of the
mice was evaluated using Affymetrix mouse 430PM arrays. Procedures for labeling,
hybridization, washing and scanning were carried out according to the manufacturer's
recommendations. Gene expression results were analyzed in Partek Genomic Suite by
standard methods. Briefly, .cel files were imported and normalized by Robust Multichip
Average (RMA). Differentially expressed genes (DEGs) were determined by ANOVA
with a false discovery rate of 0.05, and a fold change cutoff of +/- 1.2 fold.
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2.3.7. Assembly of Cyp expression data from microarray studies carried out in CAR-null
mice
Comparisons of publicly available gene expression profiles were conducted using the metaanalysis function of the Illumina BaseSpace Correlation Engine. The meta-analysis
function allows for specified gene expression profiles (called “biosets” within Correlation
engine) to be examined for gene expression changes. We compared biosets from CAR-null
mice (GSE40120) and from 28 and 91-day old CAR/PXR-null mice (GSE60684), which
most closely approximate the ages of the mice used in this study, and then filtered gene
expression data to investigate changes in expression of Cyp family members.
2.3.8. Statistical Analysis
Statistical tests were performed with GraphPad Prism software 6.0 (La Jolla, CA
USA). ANOVA was used to compare three or more treatment groups followed by Fisher’s
PLSD as the post-hoc test, and a p-value of < 0.05 was regarded as significantly different
from control values.

2.4 Results and discussion
2.4.1. CAR-null mice
CAR regulates the expression of Cyp2a, Cyp2b, and Cyp3a subfamily members
(Hernandez et al., 2009a). We examined the expression of these subfamily members in
part based on the work of ourselves and others that indicates HNF4α regulates CAR
expression with HNF4α > CAR > PXR regulation of constitutive Cyp expression
(Hernandez et al., 2009b;Wortham et al., 2007). Thus, we examined the expression of
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CYPs previously shown to be constitutively regulated by HNF4α (Wiwi et al., 2004a) and
hypothesized that CAR-null mice would show changes in constitutive CYP gene
expression, corresponding protein expression and enzyme activity. HNF4α and to a lesser
extent CAR are crucial transcription factors in the sexually dimorphic expression of hepatic
CYPs, including Cyp2a4, Cyp2b9, Cyp2b10, Cyp2b13, Cyp3a41, and Cyp3a44
(Hernandez et al., 2009b;Wiwi et al., 2004a). CAR-null female mice show significant
down-regulation of Cyp2b9, Cyp2b10, Cyp2b13, and Cyp3a11 compared to WT-B6 mice.
Interestingly, Cyp3a11 showed slight female predominance, about 1.7X, in two of our three
studies in the WT (B6) mice (Tables 2.1-2.3). Previous work with B6/SV129 mice
indicated that Cyp3a11 is female predominant (Hernandez et al., 2009b); however studies
with FVB/NJ mice indicate that Cyp3a11 expression is gender neutral (Hernandez et al.,
2006).
CAR-null females show nearly a complete loss of Cyp2b13 and 6- and 19-fold
decrease in Cyp2b9 and Cyp2b10, respectively. CAR-null males show a similar trend with
respect to these Cyp2b members, although the data were not significant (Table 2.1), most
likely because most Cyp2b members show lower expression in males (Hernandez et al.,
2009a). Cyp2c40 expression decreased nearly 2-fold in CAR-null female mice, but these
mice still showed higher expression of this female predominant CYP than male mice. Of
the female predominant CYPs examined only Cyp2a4 showed increased expression in
CAR-null mice (Table 2.1). This result suggests that CAR negatively regulates Cyp2a4
expression.

Results from HNF4a-null mice indicate that Cyp2a4 is also negatively

regulated by HNF4α (Wiwi et al., 2004a). Given HNF4α’s role in regulating CAR
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(Wortham et al., 2007), it is possible that HNF4α in part regulates Cyp2a4 by regulating
CAR expression and activity.
Table 2.1: Compensatory changes in CYP gene expression in CAR-null mice.
MALES
Gene

WT

FEMALES
CAR-null

WT

CAR-null

1.00 + 0.241

5.276 + 0.904

13.983 + 0.762

15.241 + 3.940b

Cyp2b9 1.00 + 0.353

0.424 + 0.096

18.35 + 2.898c

0.151 + 0.063b

Cyp2b10 1.00 + 0.692

0.196 + 0.027

10.186 + 2.249c

0.054 + 0.011b

Cyp2b13 1.00 + 0.312

0.021 + 0.006

4.139 + 0.798c

0.009 + 0.004b

Cyp2c29 1.00 + 0.251

0.395 + 0.388

0.306 + 0.091

0.188 + 0.082

Cyp2a4

c

c

Cyp2c40 1.00 + 0.950

0.805 + 0.753

6.992 + 0.551

3.174 + 0.936b

Cyp3a11 1.00 + 0.341

0.461 + 0.085

1.805 + 0.283c

0.904 + 0.176b

Cyp3a41 1.00 + 0.475

430.0 + 405.8

81.01 + 33.43c

442.0 + 178.9

Data are presented as relative mean + SEM. Statistical significance determined by
ANOVA followed by Fisher’s LSD as the post-hoc test (n=5-6).
‘b’ indicates WT females different than CAR-null females
‘c’ indicates WT males different than WT females
Letter with no asterisk indicates a p-value < 0.05
Protein expression and testosterone hydroxylase activity generally corresponded
well to the qPCR results. Cyp2b9, 2b10, and 2b13 were all repressed in CAR-null female
mice, CYP2B protein concentrations were significantly reduced as determined by Western
blots (Fig. 2.2) and 16α- and 16β-hydroxylase activities (Fig. 2.3), both of which are
associated with CYP2B or CYP2B induction were repressed as expected (Acevedo et al.,
2005;Waxman, 1988). In addition, Cyp3a mRNA expression, CYP3A protein expression,
and 6β-hydroxylase activity were all higher in WT females than WT males (Table 2.1;
Fig. 2.2 and 2.3). However, 6β-hydroxylase activity in CAR-null males compared to WT
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males were not consistent with protein expression, but comparable to the qPCR data. In
addition, CYP2A protein was significantly down-regulated in CAR-null females (Fig. 2.2),
while Cyp2a4 mRNA was increased (Table 2.1). There was no significant difference in
the Cyp2a-mediated, 15α -hydroxylase activity between WT and the corresponding CARnull mice of the same sex. Overall, these minor discrepancies may be due to preferential
antibody recognition of specific Cyp3a or 2a subfamily members such as Cyp3a13, 41, and
44, or Cyp2a5.

WT (B6)
1.00

CAR-null WT (B6) CAR-null
1.31

1.00

0.38*
Cyp2a

1.00

0.65

1.00

0.08**
Cyp2b

1.00

0.91

1.00

0.88
Cyp2c

1.00

1.00

1.35

1.94
Cyp3a
b-actin

Fig. 2.2: Compensatory changes in CYP protein expression in CARnull mice. Western blots of male and female CAR-null mice show
significant changes in CYP expression relative to their WT counterparts.
Results are expressed as relative mean of the WT compared to CAR-null
mice of the same sex. Statistical differences were determined by Student’s
t-tests (n = 2) with * (p < 0.05) ** (p < 0.01) indicating significant
differences.
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A

B

Fig. 2.3: Testosterone hydroxylation is perturbed in CAR-null mice in
a gender-specific manner. (A) Testosterone hydroxylation was determined
in male and female WT and CAR-null mice as described in the Materials
and Methods. Data are presented as mean specific activity (µmol/min/mg
protein) + SEM (n = 5). (B) Ratio of 6α/15α-hydroxytestosterone as a
biomarker of CYP sexual dimorphism in the liver. An aindicates a
significant difference between WT male and CAR-null male mice,
b
indicates a significant difference between WT female and CAR-null
female mice, cindicates a significant difference between male and female
WT mice and dindicates a significant difference between the male and
female CAR-null mice. Statistical differences were determined by two-way
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ANOVA followed by Fisher’s LSD as the post-hoc test in (A) and one-way
ANOVA followed by Fisher’s LSD in (B). A letter without an asterisk
indicates a significance of p < 0.05, asterisk indicate significance of
*p<0.01, **p<0.001, and *** p<0.0001, respectively.
Sexual dimorphism is observed in WT mice in the production of 6β-, 6α-, and 16αOH testosterone (Fig. 2.3). Sexual dimorphic differences in testosterone hydroxylation are
also clear in the CAR-null mice. For example, we observed significant induction of 15αOH testosterone in CAR-null females, and a drop in 6β-OH testosterone production in
CAR-null males compared to WT males (Fig. 2.3). Therefore, we examined the 6α/15αOH testosterone ratio, which is much greater in females than males, controlled by androgen
status, and considered a biomarker of androgen disruption in mice (Wilson et al., 1999).
The 6α/15α-OH testosterone ratio is 3.2-fold higher in WT females than WT males.
However, 6α/15α-OH testosterone ratio is 5.1-fold higher in WT females than CAR-null
females and in turn the 6α/15α-OH testosterone ratio is 1.2-fold higher in CAR-null males
than CAR-null females; the opposite direction of what is expected. Thus, the CAR-null
females have a lower 6α/15α-OH testosterone ratio than WT males because of
masculinization of CYP profiles in the liver in CAR-null females. However, the CAR-null
females show no differences in liver concentrations of testosterone (Appendix A-2).
Overall, the masculinization of hepatic testosterone metabolism profiles reflects the
systematic loss of female predominant CYPs in the CAR-null mice (Table 2.1). CAR may
regulate sexual dimorphism in the liver in mice through androgen inhibition in males as
several different androgens are CAR inverse agonists (Forman et al., 1998), including
androgens used as performance enhancing drugs (Baldwin et al., 2009). Interestingly,
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PXR-null mice also show sexual dimorphic effects by promoting estrogenic activity due to
the loss of sulfotransferase-mediated estrogen metabolism through activated PXR
(Kodama et al., 2011;Wang et al., 2014). However, more likely sexually dimorphic
differences or loss of sexual dimorphism is directly due to the loss of CAR and its role in
regulating female predominant CYPs in conjunction with HNF4α (Hernandez et al.,
2009b;Wiwi et al., 2004a;Wortham et al., 2007).
Sexual dimorphism of hepatic CYPs is primarily regulated by the periodization of
growth hormone release that regulates Stat5b (Choi, 2000;Oshida et al., 2016;Park et al.,
1999;Wiwi et al., 2005). Other transcription factors regulated in a sexually dimorphic
fashion that in turn regulate sexually dimorphism include HNF4α, FoxA2, and CAR
(Hashita et al., 2008;Hernandez et al., 2009b;Wiwi et al., 2004a;Wiwi et al., 2004b). For
example, FoxA2 promotes the expression of the female specific hepatic CYP, Cyp2b9;
HNF4α positively regulates the expression of several CYPs including Cyp2b10, Cyp2b13,
Cyp3a41, and Cyp3a44 in females and negatively regulates Cyp2b9 and Cyp2a4 in males
(Wiwi et al., 2004a); and CAR is thought to positively regulate Cyp2b13, Cyp2c29, and
potentially Cyp2b10 (Hernandez et al., 2009b). Some of CAR’s sexually dimorphic
activity may be direct, but some may also be due to HNF4α’s regulation of CAR (Wortham
et al., 2007). Independent studies by Baldwin’s (Hernandez et al., 2006;Hernandez et al.,
2009b) and Corton’s laboratories (Oshida et al., 2016) have shown chemical activation of
CAR can induce feminization of the liver. Taken together, masculinization of the liver
does not necessarily involve testosterone.
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The presence of microarray data from CAR-null mice in GEO allowed us to
perform comparisons between our data and female CAR-null and WT mice (GSE40120),
and male CAR/PXR double-null and WT mice (Luisier et al., 2014)(GSE60684) from
previous studies. In all comparisons, the expression of the Car gene was suppressed (~314-fold) in the null mice, as expected. Cyp genes increased in expression included Cyp2a5,
Cyp2c38, Cyp2c39, Cyp2g1, Cyp4a14, Cyp51, and Cyp7a1. Cyp genes decreased in either
CAR-null or CAR/PXR-null mice included Cyp2a12, Cyp2b10, Cyp2b9, Cyp2c29,
Cyp2c37, Cyp2c50, Cyp2c54, Cyp2c70, Cyp2u1, Cyp4a12a, Cyp4v3, and Cyp7b1.
Cyp2c55 was increased in male CAR-null mice and suppressed in female CAR/PXR-null
mice. Genes in the Cyp2c subfamily were differentially expressed in both directions. This
may account for discrepancies between the qPCR and Western blots for Cyp2c, and it is
also possible that a drop in 16α-hydroxylase activity is in part due to a drop in Cyp2c
expression or Cyp2b expression.
Overall, CAR is a regulator of the hepatic Cyp2b genes and loss of CAR causes a
considerable drop in Cyp2b expression.

Furthermore, CAR may regulate sexual

dimorphism in the liver as loss of CAR activity decreases the 6α/15α-OH testosterone ratio,
a biomarker of masculinization of the liver (Hernandez et al., 2009b;Wilson et al., 1999)
that may also reflect an overall drop in CYP activity (Wortham et al., 2007). CAR
expression is female predominant emphasizing the need to include both genders in drug
trials and toxicant biotransformation studies (Meibohm et al., 2002;Petrick et al., 2007).
This is important as it provides data that may help us inform translational studies or
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physicians when prescribing personalized medicines. It may also reveal the mechanism
behind specific chemical sensitivities in patients with low CAR or CYP activities.
2.4.2. Cyp3a-null mice
CYP3A accounts for 30-40% of hepatic CYP expression (Maurel, 1996). We
hypothesized that the loss of seven Cyp3a genes would perturb the hepatic P450 profile
and lead to compensatory changes. One of the compensatory changes observed is an
increase in Cyp3a13 expression (Table 2.2). Cyp3a13 is the only Cyp3a member not
deleted, as it is 7Mb upstream from the 7-Cyp3a gene cluster (Scheer et al., 2010).
Cyp3a13 is almost certainly the basis for recognition of CYP3A in Western blots (Fig. 2.4)
and the observation that 6β-hydroxylase activity only decreased 67% in males and 74% in
females. Although other CYPs also produce 6β-hydroxytestosterone (Shou et al., 2000),
data indicates that approximately 90% of 6β-hydroxytestosterone is produced by CYP3A
enzymes in humans (Gelboin et al., 1995;Shou et al., 2000).
Table 2: Compensatory changes in CYP gene expression in Cyp3a-null mice.
MALES
FEMALES
Gene
WT
Cyp3a-null
WT
Cyp3a-null
a
Cyp2a4 1.00 + 0.328 47.957 + 16.267 14.326+ 0.708
70.06 + 20.30b
Cyp2b9 1.00 + 0.321 7.743+ 7.319
117.96+7.899c*** 115.134+20.868d***
Cyp2b10 1.00 + 0.310 6.247 + 4.831
9.7+ 1.447c
13.435 + 2.435
Cyp2c29 1.00 + 0.457 29.431+15.874
5.193 + 2.213
23.586 +7.049
Cyp2c40 1.00 + 0.413 25.913+15.709
21.722+12.568
38.772 + 4.732
a*
c
Cyp3a11 1.00 + 0.168 0.000
1.68 + 0.336
0.000b***
Cyp3a13 1.00 + 0.371 26.143+ 9.424a
6.294+1.12
28.882 + 8.366b
a**
Cyp3a25 1.00 + 0.247 0.002 + 0.001
0.75 + 0.121
0.001 + 0.001b*
Cyp3a41 1.00 + 0.131 0.000
14.138+3.967c** 0.000b**
Data represented as mean +/- SEM (n = 4). Statistical significance determined by one-way
ANOVA followed by LSD as the post-hoc test.
‘a’ indicates WT males different than Cyp3a-null males
‘b’ indicates WT females different than Cyp3a-null females
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‘c’ indicates WT males different than WT females
‘d’ indicates Cyp3a-null males different than Cyp3a-null females
Letter with no asterisk indicates a p-value < 0.05 and * indicates a p-value < 0.01, **
indicates a p-value <0.001,***indicates a p-value <0.00001
Other CYPs also went through compensatory changes in the Cyp3a-null mice.
qPCR data demonstrates significant induction (48- and 70-fold) of Cyp2a4 in Cyp3a-null
female and male mice, respectively compared to their corresponding WT counterparts
(Table 2.2). Western blots confirm the increase in CYP2A in females but not males (Fig.
2.4).

Cyp2a4 up-regulation is similar to the observations made in CAR-null mice,

suggesting either a drop in CAR activity in Cyp3a-null mice or more likely an increase in
PXR activity. CAR and PXR crosstalk and there is weak but insignificant induction of
several other CAR/PXR regulated CYPs (Hernandez et al., 2009b;Mota et al., 2011;Xie et
al., 2000) including Cyp2b10, Cyp2c29, and Cyp2c40 (Table 2.2) with increased protein
levels of CYP2B (Fig. 2.4). Therefore, we consider it more likely that PXR activity is
increased potentially due to a lack of metabolism of a CYP3A metabolized endobiotic such
as bile acids that in turn activate PXR (Hashimoto et al., 2013;Je et al., 2015;Staudinger et
al., 2001).
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Cyp2a
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β-actin
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Fig. 2.4: Compensatory changes in CYP protein expression in Cyp3anull mice. Western blots of male and female Cyp3a-null mice show
significant changes in CYP expression relative to their WT counterparts.
Results are expressed as relative mean of the WT compared to Cyp3a-null
mice of the same sex. Statistical differences were determined by Student’s
t-tests (n = 3) with * (p < 0.05) ** (p < 0.01) *** (p < 0.001) indicating
significant differences.
Testosterone hydroxylase activity was greatly diminished at the 6β-position as
expected because of the loss of CYP3A. Few other testosterone hydroxylase activities are
perturbed

significantly

with

the

exception

of

2a-hydroxylase

activity

(Fig.

2.5). Hydroxylation of testosterone in the 2α-position is primarily considered a product of
CYP2C. An increase in CYP2C protein was not measured; however, Cyp2c members were
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up to 29-fold higher by qPCR. This may be due to the CYP2C antibody preferentially
recognizing CYP2C members not induced in the Cyp3a-null mouse model. CYP2C is
increased in Cyp3a-null mice exposed to the PXR activator midazolam (Van Waterschoot
et al., 2008;Vrzal et al., 2010), but CYP2C induction may be muted or lacking in untreated
Cyp3a-null mice.

Another possibility is that there are interactions between the

hydroxylated products of testosterone. For example, 2α-hydroxylation of testosterone may
be inhibited by 6β-hydroxytestosterone, and in turn the loss of CYP3A activity allows for
increased 2α-hydroxylation. Ultimately, the data suggests the potential for compensatory
CYP activity in the Cyp3a-null model complicating the interpretation of xenobiotic
metabolism data. This observation is supported by previous work (Van Waterschoot et al.,
2008;Vrzal et al., 2010).
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A

B

Fig. 2.5: Changes in testosterone hydroxylation in Cyp3a-null mice. (A)
Testosterone hydroxylation was determined in male and female WT and
Cyp3a-null mice as described in the Materials and Methods. Data are
presented as mean specific activity (µmol/min/mg protein) + SEM (n = 4).
(B) Ratio of 6α/15α-hydroxytestosterone as a biomarker of CYP sexual
dimorphism in the liver. An aindicates a significant difference between WT
male and Cyp3a-null male mice, bindicates a significant difference between
WT female and Cyp3a-null female mice, cindicates a significant difference
between male and female WT mice and dindicates a significant difference
between the male and female Cyp3a-null mice. Statistical differences were
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determined by ANOVA followed by Fisher’s LSD as the post-hoc test. A
letter without an asterisk indicates a significance of p < 0.05, asterisk
indicate significance of *p<0.01, **p<0.001, and *** p<0.0001,
respectively.
6α- and 15α-hydroxylation were increased in Cyp3a-knockout mice, but not
significantly despite a significant increase in Cyp2a4 mRNA and CYP2A protein in Cyp3anull female mice compared to WT female mice (Fig. 2.4; Table 2.2). These hydroxylase
activities are mediated by sexually dimorphic CYP2A members in mice (Baldwin et al.,
1992;Burkhart et al., 1985). Therefore, we examined the 6α/15α ratio. The 6α/15α-OH
testosterone ratio is 2.03-fold higher in WT females than WT males; however, the ratio
drops to 1.29 when comparing Cyp3a-null females to Cyp3a-null males (not significantly
different). The changes are not nearly as large as observed in the CAR-null mice, but the
loss of significant sexual dimorphism suggests the potential for a small to moderate
increase in hepatic masculinization of the females coupled with a small amount of
feminization of the males.

No differences in hepatic testosterone were observed

(Appendix A-2).
CYP3A metabolizes 50-60% of drugs available in the market (Maurel, 1996) and
is inhibited by fatty liver disease (Patoine et al., 2013) and diabetes mellitus (Dostalek et
al., 2011). Because CYP3A plays such a prominent role in drug metabolism, changes in
CYP3A expression and activity are crucial during the development of pharmaceuticals.
Overall, the loss of CYP3A caused minor changes in the expression of the other CYPs
examined with minimal changes in activity at least under untreated (pristine) conditions.
There is minimal masculinization of liver testosterone hydroxylase activities; however,
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these changes are not as strong as observed in CAR-null mice. Taken together, Cyp3a-null
mice may show compensatory metabolism of drugs by other CYPs that may compound the
interpretation of the metabolism data; however, most of the lost CYP activity is directly
attributable to the loss of CYP3A members (Fig. 2.5).
2.4.3. Cyp2b9/10/13-null mice
CYP2B metabolizes approximately 25% of drugs available in the market despite
making up only 5-10% of the total CYPs expressed in the human liver (Wang et al., 2008).
We hypothesized that the lack of Cyp2b9, Cyp2b10 and Cy2b13 will lead to compensatory
changes by altering CYP expression levels in the liver. In addition to a decrease in Cyp2b9,
10 and 13 gene expression, we also observed significant down regulation of Cyp2a4,
Cyp2c40 and Cyp3a13 mRNA in Cyp2b9/10/13-null female mice compared to WT female
mice (Table 2.3). However, significant changes were not observed in Cyp2b9/10/13-null
male mice potentially because these Cyp2b subtypes, especially Cyp2b9 and Cyp2b13 are
primarily expressed in female liver (Hernandez et al., 2009b;Renaud et al., 2011).

Table 2.3: Compensatory changes in CYP gene expression in Cyp2b9/10/13-null mice.
MALES
Gene

WT

Cyp2a4
Cyp2b9
Cyp2b10
Cyp2b13
Cyp2c29
Cyp2c40
Cyp3a11
Cyp3a13

1.00 + 0.187
1.00 + 0.692
1.00 + 0.655
1.00 + 0.709
1.00 + 0.091
1.00 + 0.123
1.00 + 0.124
1.00 + 0.170

FEMALES
Cyp2b9/10/13null
5.162 + 3.948
0.054 + 0.018
0.041 + 0.014
0.059 + 0.048
2.277 + 0.760
0.911 + 0.636
0.790 + 0.173
0.551 + 0.114

WT
18.864+4.066c*
3.007 + 0.897c
2.274 + 0.678
36.189 + 7.478c***
0.628 + 0.123
5.202 + 2.169c
0.828 + 0.101
1.088 + 0.121
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Cyp2b9/10/13null
7.217 + 2.294b
0.047 + 0.020b*
0.035 + 0.015b*
0.082+ 0.078b**
1.472 + 0.792
1.620 + 0.846b
0.524 + 0.045
0.536 + 0.077b

Cyp3a25 1.00 + 0.346 0.983 + 0.350 0.991 + 0.083
0.515 + 0.126
Cyp3a41 1.00 + 0.756 0.112 + 0.107 19.459 + 5.931c*
11.168 + 1.627d
Data represented as mean +/- SEM (n = 4). Statistical significance determined by one-way
ANOVA followed by LSD as the post-hoc test.
‘b’ indicates WT females different than Cyp2b9/10/13-null females
‘c’ indicates WT males different than WT females
‘d’ indicates Cyp2b9/10/13-null males different than Cyp2b9/10/13-null females
Letter with no asterisk indicates a p-value < 0.05 and * indicates a p-value < 0.01, **
indicates a p-value <0.001,***indicates a p-value <0.00001
Western blots confirm the null genotype of the hepatic CYP2B proteins (Fig. 2.6).
Cyp2b is expressed at low levels in males and was not detectable in our western blots, but
is clearly deleted in the Cyp2b9/10/13-null females. Western blots also confirm the downregulation of Cyp2a mRNA in females shown by qPCR. Protein levels of Cyp2a genes
dropped 41-46% in female Cyp2b9/10/13-null mice and protein levels of Cyp2a genes
increased significantly (about 3-fold) in male Cyp2b9/10/13-null mice (Fig. 2.6). This new
Cyp2a antibody recognizes two bands in our Western blots unlike first antibody used with
the CAR-null and Cyp3a-null mice. B6 mice have several Cyp2a isoforms and Cyp2a22,
which is primarily hepatic (Cui et al., 2012;Peng et al., 2012) is 50kDa in C57Bl6/J mice
(XP_006539922.1) while the other Cyp2a isoforms (4/5/12) are 56 kDa. Messenger RNA
levels of Cyp2a4 were not significantly altered in males, but Cyp2a4 mRNA increased 5fold (Table 2.3), consistent with the increase in protein expression. Western blots did not
confirm decreases in Cyp2c40 or Cyp3a13 protein expression in females; however, there
are many Cyp2c and Cyp3a genes. Many of these other CYP isoforms were either not
significantly changed, not tested, or in the case of the Cyp2c subtypes showed opposing
trends (Table 2.3). It is also possible that the antibodies preferentially recognize specific
isoforms that are not differentially expressed.
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BL6

Cyp2b9/10/13-null

1.00
1.00

BL6

1.65
2.96*

Cyp2b9/10/13-null

1.00

0.59

1.00

0.54

Cyp2a
0.00

1.00

0.00

0.00***

Cyp2b
1.00

1.00

0.99

0.93

Cyp2c
1.00

1.00

0.94

1.05

Cyp3a

b -actin

Females

Males

Fig. 2.6: CYP protein expression in WT and Cyp2b9/10/13-null mice.
Western blots of male and female Cyp2b9/10/13-null mice show significant
changes in CYP expression relative to their WT counterparts. Cyp2a
isoforms show two bands as Cyp2a22 is 50kDa in B6 mice and the other
Cyp2a isoforms are 56 kDa. Results are expressed as relative mean of the
WT compared to CAR-null mice of the same sex. Statistical differences
were determined by Student’s t-tests (n = 3) with * (p < 0.05) *** (p <
0.001) indicating significant differences.
Global gene expression was measured in the livers of the null mice and compared
to that in wild-type mice because there are so few compensatory changes in the
Cyp2b9/10/13-null mice. Microarray data showed that in males, there are no statistically
significant differentially expressed genes between the Cyp2b-null mice and wild-type mice
consistent with the qPCR data. In female mice, Cyp2b9, Cyp2b10, and Cyp2b13 were all
significantly down-regulated in the Cyp2b9/10/13-null strain. Cyp2a4 and Cyp2c40 were
both significantly down-regulated in the female Cyp2b9/10/13-null strain compared to wild
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type females by qPCR. These genes were not detected as differentially expressed by
microarray, possibly because probe sets for both genes are not isoform specific. Probe ID
142230_s_at targets both Cyp2a4 and 2a5, and Probe ID 1423244_at targets Cyp2c40 and
Cyp2c68. Additionally, 22 probe sets corresponding to 18 genes were also differentially
expressed (Table 2.4). Importantly, the microarrays show no detectable compensatory
increases in expression of other CYP genes. Overall, there are very few compensatory
changes in the Cyp2b9/10/13-null mice.

Table 2.4: Genes differentially expressed in Cyp2b9/10/13-null female mice compared to
WT female mice following microarray analysis.
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Gene Symbol

RefSeq Transcript ID

p-value

Fold-Change

Cyp2b10

NM_009999

2.38E-06

-13.1906

Cyp2b9

NM_010000

1.49E-10

-49.0951

AI132709

AI132709

2.80E-10

-43.2901

Dbp

NM_016974

2.27E-08

15.2984

Rnf170

NM_029965

1.45E-06

-7.01792

Lgalsl

NM_173752

3.46E-06

-1.77298

Prpf38b

NM_025845

2.92E-06

-1.42665

C77080

NM_001033189

1.14E-05

1.52239

Prlr

NM_001253781

1.71E-05

-1.59243

Dnmt3b

NM_001003960

3.07E-06

-1.8115

Sf1

NM_001110791

2.07E-05

1.3156

Pa2g4

NM_011119

4.66E-06

1.59872

Tef

NM_017376

1.19E-05

2.43846

Gstm3

NM_010359

9.57E-06

1.65659

Nr1d2

NM_011584

9.22E-06

2.49315

Slc25a37

NM_026331

2.56E-05

1.63321

Aldh1a7

NM_011921

1.93E-05

1.2603

Inpp5f

NM_178641

2.30E-05

-1.37761

Iqgap1

NM_016721

1.78E-05

-1.51826

Foxq1

NM_008239

2.36E-05

2.43071

Testosterone hydroxylation activity did not show any significant changes in the
triple knockout mice except for the expected drop in testosterone 16α-hydroxylase activity
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in female mice compared to male mice (Fig. 2.7). Surprisingly, no significant changes
were observed in 16β-hydroxytestosterone levels in Cyp2b9/10/13-null mice (Fig. 2.7).
Cyp2b subfamily members are known to hydroxylate at the 16α- and 16β-positions
(Acevedo et al., 2005;Smith et al., 1998;Waxman et al., 1983).

Phenobarbital and

TCPOBOP, powerful CAR activators are known to induce both 16α- and 16β-hydroxylase
activity, especially 16β-hydroxylase activity in part because of its induction of Cyp2b10
(Hernandez et al., 2009b;Waxman et al., 1983). CYP2B, CYP2C and CYP2D members
contribute to 16-position hydroxylation of testosterone (Hernandez et al., 2009b;Lee et al.,
2006;Yamada et al., 2002); however, Cyp2d9 is the only male specific 16-hydroxylase
indicating that this CYP is the primary 16α- and 16β-OH in males (Hernandez et al.,
2009b). Therefore, our data suggests that CYP2B is not the primary 16-hydroxylase;
instead it is the inducible 16-hydroxylase (Hernandez et al., 2006;Hernandez et al.,
2009b;Imaoka et al., 1989).
Interestingly, we also observed a significant (p<0.01) reduction in 6α-OH
testosterone activity in the Cyp2b9/10/13-null mice compared to their WT counterparts
using one-way ANOVA followed by Fisher’s LSD post-hoc (p < 0.05) instead of the twoway ANOVA showed in the figure. This either suggests that Cyp2b members are involved
in the constitutive metabolism of testosterone in the 6α-position or that there is a drop in
Cyp2a members crucial in 6a-hydroxylation. Testosterone 6α-hydroxylase activity was
also decreased in CAR-null mice, but not Cyp3a-null mice (Fig. 2.3). A drop in Cyp2a
was measured in Cyp2b9/10/13-null females but not males (Fig. 2.6; Table 2.3). In turn,
6α/15α ratio was significantly higher in WT females than Cyp2b9/10/13-null females
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(2.6X), suggesting weak to moderate hepatic masculinization of Cyp2b9/10/13-null
females. There were no differences in serum or hepatic testosterone concentrations
between WT and Cyp2b9/10/13-null mice indicating that the difference in 6α/15α ratio is
directly due to the drop in Cyp2a protein expression or loss of Cyp2b’s.
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µmol/min/mg protein

A

B

Fig. 2.7: Testosterone hydroxylation determined in WT and
Cyp2b9/10/13-null mice. (A) Testosterone hydroxylation was determined
in male and female WT and Cyp2b9/10/13-null mice as described in the
Materials and Methods. Data are presented as mean specific activity
(µmol/min/mg protein) + SEM (n = 4). (B) Ratio of 6α/15αhydroxytestosterone as a biomarker of CYP sexual dimorphism in the liver.
An aindicates a significant difference between WT male and Cyp2b9/10/13null male mice, bindicates a significant difference between WT female and
Cyp2b9/10/13-null female mice, cindicates a significant difference between

67

male and female WT mice and dindicates a significant difference between
the male and female Cyp2b9/10/13-null mice. Statistical differences were
determined by two-way ANOVA followed by Fisher’s LSD as the post-hoc
test in (A) and one-way ANOVA followed by Fisher’s LSD in (B). A letter
without an asterisk indicates a significance of p < 0.05, asterisk indicate
significance of *p<0.01, **p<0.001, and *** p<0.0001, respectively.

2.5 Conclusions
CAR-null mice show greater changes in CYP expression and activity relative to
their WT counterparts than Cyp3a-null and Cyp2b-null mice. This is probably because
CAR directly regulates the expression of several CYPs either constitutively or through
activation by endogenous and exogenous substrates. Because CAR regulates constitutive
CYP expression the use of CAR-null mice alone could cause incorrect interpretations of
chemical metabolism. In addition, CAR appears to regulate sexual dimorphism of CYP
expression within the liver as lack of CAR caused masculinization. Given that CAR
activation is feminizing (Hernandez et al., 2006;Hernandez et al., 2009b;Oshida et al.,
2016), CAR has greater transcriptional activity in females than males (Ledda-Columbano
et al., 2003), CAR regulates a number of female predominant CYPs (Hernandez et al.,
2009b), and CAR is inhibited by androgens (Baldwin et al., 2009;Forman et al., 1998), it
may not be all that surprising that the loss of CAR causes masculinization of the liver (Fig
3).

Overall, CAR-null mice may show significant changes in CYP-mediated drug

metabolism following exposure because of the significant changes in CYP expression.
Cyp3a-null mice show some compensatory changes in CYP expression and
testosterone metabolism. We would not expect the changes to be as broad as the CAR-null
mice because the regulation of the other CYPs is not direct. However, the small changes

68

observed in 2α-OH and 16α-OH testosterone levels suggest that the loss of CYP3A activity
alters liver substrate profiles for CAR, PXR, and potentially other nuclear
receptors/transcription factors that regulate CYP expression. Alternatively, several CYPs
may show changes in CYP activity because they compensate for the loss of CYP3A and
the lack of competition for the substrate. Based on the changes in expression profiles such
as significant increases in Cyp2a4 and Cyp3a13 (the only Cyp3a gene retained in the
knockout mouse model), we would predict that the lack of CYP3A is causing the activation
of PXR and potentially a drop in CAR activity. Additionally, the observed increase, though
not significant, in expression of Cyp2b10, Cyp2c29 and Cyp2c40 suggest increase in PXR
activity in Cyp3a-null mice.
Cyp2b-null mice show very few overall changes in CYP expression outside the loss
of CYP2B (Tables 3 and 4; Figs 6 and 7). Unlike CYP3A, which is the most abundant
CYP in murine livers, CYP2B shows relatively low expression, lower than CYP3A, 2C,
and 2D subfamily members (Wang et al., 2008). Therefore, we would expect fewer
compensatory changes. Overall, most if not all changes in drug metabolism in the
Cyp2b9/10/13-null mice would reflect the loss of Cyp2b.
In conclusion, toxicology models such as CAR-null and various CYP-null mice
show changes in other CYPs due to direct control of expression or compensatory changes
in expression. These changes in CYP expression, especially those regulated by CAR, may
alter hepatic CYP expression, CYP-mediated xenobiotic metabolism, and hepatic CYP
masculinization. Perturbations in non-CYP3A/2B-mediated metabolism of xenobiotics
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may occur in these models with significant changes in metabolism more likely in CARnull compared to Cyp3a-null or Cyp2b-null mice.
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CHAPTER THREE
HIGH FAT DIET-INDUCED OBESITY IS MITIGATED IN CYP3A-NULL FEMALE
MICE
This manuscript is under revision at Chemical-biological interactions journal

3.1 Highlights:
•

Cyp3a-null female mice are resistant to the effects of a high-fat diet

•

Cyp3a-null females show improved metabolic responses, including glucose
tolerance

•

In contrast, Cyp3a-null male mice show increased liver triglycerides

•

Gene expression changes indicate decreased lipid metabolism and increased uptake
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3.2 Abstract
Recent studies indicate a role for the constitutive androstane receptor (CAR),
pregnane X-receptor (PXR), and hepatic xenobiotic detoxifying CYPs in fatty liver disease
or obesity. In addition, Cyp3a-null mice express hepatic Cpt1a at much greater levels
regardless of gender (18-123X greater) than WT mice. Therefore, we examined whether
Cyp3a-null mice show increased obesity and fatty liver disease following 8-weeks of
exposure to a 60% high-fat diet (HFD). Surprisingly, HFD-fed Cyp3a-null females fed a
HFD gained 50% less weight than wild-type (WT; B6) females fed a HFD. In contrast,
Cyp3a-null males gained more weight than WT males, primarily during the first few weeks
of HFD-treatment. Cyp3a-null females also recovered faster than WT females from a
glucose tolerance test; males showed no difference in glucose tolerance between the
groups. Serum concentrations of the anti-obesity hormone, adiponectin are 60% higher and
b-hydroxybutyrate levels are nearly 50% lower in Cyp3a-null females than WT females,
in agreement with reduced weight gain, faster glucose response, and reduced ketogenesis.
In contrast, Cyp3a-null males have higher liver triglyceride concentrations and lipidomic
analysis indicates an increase in phosphatidylinositol, phosphatidylserine and
sphingomyelin. None of these changes were observed in females. Last, Pxr, Cyp2b, and
IL-6 expression increased in Cyp3a-null females following HFD-treatment. Cyp2b and
Fatp1 increased, while Pxr, Cpt1a, Srebp1 and Fasn decreased in Cyp3a-null males
following a HFD, indicating compensatory biochemical responses in male (and to a lesser
extent) female mice fed a HFD. In conclusion, lack of Cyp3a has a positive effect on
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acclimation to a HFD in females as it improves weight gain, glucose response and
ketoacidosis.

Keywords: P450, non-alcoholic fatty liver disease (NAFLD), ketosis, toxicology

Abbreviations:
Acox

Acyl-CoA oxidase

ApoE

Apolipoprotein E

Cpt1a

Carnitine palmitoyl transferase 1 a

CYP

Cytochrome P 450

EET

Epoxyeicosatrienoic acid

Fabp4

Fatty acid binding protein 4

Fasn

Fatty acid synthase

Fatp

Fatty acid transporter protein

Foxa2

Forkhead box protein A2

HETE

Hydroxyeicosatetraenoic acid

HFD

High fat diet

HODE

Hydroxyoctadecadienoic acid

Pepck1

Phosphoenolpyruvate carboxykinase 1

Pparα

Peroxisome proliferator activated receptor alpha

Pparγ

Peroxisome proliferator activated receptor gamma

PXR

Pregnane X receptor
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Srebp1

Sterol regulatory element-binding protein 1

WT

Wildtype
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3.3 Introduction
Obesity is a complex disorder that affects nearly 1 out of 3 Americans [1] and is
considered an epidemic throughout much of the developed world [2, 3]. For example, the
percent of obese individuals is increasing in Latin America (i.e. Panama 35%, Chili 22%),
Europe (Greece 23%, Malta 26%), and the Middle East (United Arab Emirates 34%, Saudi
Arabia 36%, Egypt 30%) [2]. In turn, the rates of dyslipidemia, hypertension, diabetes,
and other metabolic disorders increased dramatically placing a large burden on our
healthcare systems [4, 5].
The primary problem is excess food coupled with inactivity. Therefore, healthier
food choices and lifestyle changes are common treatment regimens used to control obesity.
However, there are multiple internal and external factors that regulate metabolic activity
and allocation of dietary lipid and carbohydrate resources [6, 7]. Understanding these
forces provides targets for initiating dietary and environmental changes and tackling this
disease. Many cytochrome P450s (CYPs) are crucial detoxication enzymes that metabolize
drugs [8], environmental chemicals [9], steroids [10] and fatty acids [11], and changes in
CYP activity and expression are observed during obesity and diabetic conditions [12-15].
The constitutive androstane receptor (CAR) [16, 17] and pregnane X-receptor
(PXR) [18] are two nuclear receptors involved in chemical detoxication, and associated
with metabolic diseases although possibly in opposing directions.

CAR activation

alleviates symptoms of obesity and fatty liver disease and murine PXR activation increases
obesity [15, 19, 20], although there are conflicting reports on PXR’s effects on obesity and
insulin resistance [21]. These nuclear receptors are key regulators of CYPs such as Cy2b
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and Cyp3a subfamily members [18, 22, 23]. In a world in which we are exposed to
numerous environmental toxicants each and every person may show different CYP activity
and in turn show differential metabolism of xeno- and endobiotics, including unsaturated
fatty acids because of the different diets and chemicals to which they have been exposed
[24, 25]. Therefore, it is possible that chemicals that modulate CYP activity are obesogens
or metabolic disruptors [5, 26].
Interestingly, complete loss of hepatic CYP activity in a conditional
knockout of P450-oxidoreductase (HRN) caused enlarged livers, and hepatic steatosis,
especially after the mice were fed sunflower oil (88% unsaturated fatty acids). In turn,
increased hepatic concentrations of unsaturated fatty acids in the HRN mice activated CAR
and induced Cyp2b10 and Cyp3a11 providing a putative new role for CAR in the
recognition of unsaturated fatty acids and suggests that CYP induction may be a protective
mechanism from fatty acid toxicity [20]. Subsequent studies also demonstrated CYP3A
induction by fatty acids in human cells [27]. Further, Cyp3a expression and activity is
decreased in obese guinea pigs and diabetic humans [28, 29], but increased in diabetic mice
[15, 30]. These results suggest a role for Cyp3a in obesity given that Cyp3a expression
changes with diet, loss of hepatic CYPs causes fatty liver disease, and the Cyp3a’s are the
most abundant hepatic CYPs.
CYP3A4 accounts for approximately 30-40% of total CYP protein in the human
liver and is responsible for the metabolism of more than 60% of the drugs on the market
[31]. Cyp3a subfamily members produce a number of epoxidated products of linoleic acid
and arachidonic acid in human and rodents. CYP3A4 primarily metabolizes linoleic acid
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to 11-hydroxy-octadecadienoic acid (11-HODE), and the production of 11-HODE is
increased 10X by the CYP3A inducer, dexamethasone, in rats [32]. CYP3A4 oxygenates
arachidonic acid to a number of metabolites including 13-, 10-, and 7hydroxyeicosatrienoic acid (13-HETE, 10-HETE, 7-HETE) [32]. The epoxides formed are
stable, but also metabolized by epoxide hydrolases to diols [32]. Whether these epoxides
have a specific purpose in the liver is unknown; however, inhibition assays suggest that a
Cyp3a-mediated arachidonic acid metabolite is in part responsible for relaxation of arterial
endothelium [33]. A Cyp3a and Cyp2j produced metabolite of linoleic acid is a key product
in the activation of nociception [34], and CYP3A4 metabolizes the arachidonic acid
derivative, anandamide, to a high affinity cannabinoid ligand [35-37].

Thus, Cyp3a

metabolizes unsaturated fatty acids for specific functions and disruption of this metabolism
by xenobiotics or genetic impairments may have consequences that perturb fatty acid
metabolism, distribution, and use [38, 39].
Ultimately, we decided to investigate the role of Cyp3a in obesity because Hepatic
P450 Reductase-null (HRN) mice with no P450 activity show hepatic steatosis with
increased Cyp2b10 and Cyp3a11 expression, perturbations in liver size, lipid homeostasis,
and increased polyunsaturated fatty acids (PUFAs) [20]. In addition, activation of PXR,
the key regulator of Cyp3a members, increases obesity in females but not males[14, 19].
This implicates detoxification CYPs in obesity, and Cyp3a members are the most
prominent hepatic CYPs. However, the potential role of Cyp3a on obesity and diet-induced
fatty liver disease has not been investigated. We used mice lacking seven of the eight Cyp3a
genes on a B6 background to monitor the effects of a high-fat diet (HFD) (diet-induced
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obesity) on weight gain, glucose and insulin tolerance, fatty liver, and alterations in hepatic
gene expression consistent with metabolic disorders.

3.4 Materials and methods
3.4.1. Livers from untreated WT and Cyp3a-null mice
Frozen livers from untreated 8-9 week old WT and Cyp3a-null mice were
purchased from Taconic (Hudson, NY USA) and shipped on dry ice. These mice lack the
Cyp3a11, Cyp3a16, Cyp3a25, Cyp3a41, Cyp3a44, Cyp3a57, and Cyp3a59 genes located
within 0.8Mb from each other on chromosome 5. Cyp3a13, which is separate from the rest
of the Cyp3a cluster by 7Mb, is still present within this knockout mouse model (Hasegawa
et al., 2011;Scheer et al., 2010). The liver tissue was diced into three fractions such that
half a liver was frozen for microsome preparation, a quarter of a liver was stored in TriReagent (Sigma, St. Louis, MO USA) for RNA extraction while the remaining liver was
frozen immediately and stored at -80°C.
3.4.2. High-fat Diet Treatment of WT and Cyp3a-null mice
All mice studies were done according to the National Institute of Health guidelines
for humane use of research animals and were pre-approved by Clemson University’s
Institutional Animal Care and Use committee. Seven - nine week old male and female, WT
(C57Bl/6) and Cyp3a-null mice (n=8) were purchased from Taconic and housed for a week
for acclimation prior to HFD treatment.
Eight-ten week-old acclimated WT and Cyp3a-null mice were fed pelleted adjusted
calorie diet (60% kcal from fat, TD.06414; Harlan, Madison, WI USA) for eight weeks.
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One male Cyp3a-null mouse was eight weeks old and all other mice were 9-10 weeks old.
This mouse also lost weight early in the study and therefore was eliminated from the study.
Thus, all remaining mice were 9-10 weeks old at the start of the HFD treatment. Changes
in body weight, feed consumption rate, and metabolic tests such as glucose (GTT) and
insulin tolerance tests (ITT) were performed. A timeline of procedures is provided
(Appendix B-1).

Weight gain was monitored weekly and feed consumption was

determined every other day. Fasting plasma glucose levels were determined during week
2, 4 and 6. Glucose and insulin tolerance tests were performed during weeks 4 and 6,
respectively. At the end of the study the mice were anesthetized, blood collected by heart
puncture, euthanized and liver, kidney, white adipose tissue and testis were excised and
weighed. The organs were immediately frozen on dry ice and stored at -80°C or placed in
10% formalin (Fisher, Fairlawn, NJ USA) for further studies. The liver was dissected into
four fractions and frozen immediately on dry ice for microsome preparation, RNA
isolation, and lipidomics. The portion of the liver used for RNA extraction was stored in
Tri-Reagent (Sigma Aldrich). The last portion of the liver was placed in formalin for
histopathology.
3.4.3. Glucose and Insulin tolerance tests
Mice were fasted for 4-5 hr prior to GTT or ITT during weeks four and six of the
HFD study, respectively. Fasting blood glucose was determined using an Alphatrak 2
(Chicago, IL USA) blood glucose meter following a tail bleed. Glucose tolerance was
determined following an intraperitoneal injection of 1 g/kg of their body weight of Dglucose (Sigma Ultra) with blood glucose readings every 20 minutes for the first hour and
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every 30 minutes for the second hour. ITT was determined after intraperitoneal injection
of 0.75 U/g of their body weight of Novolin N (Nova Nordisk, Bagsvaerd, DK) followed
by blood glucose measurements every 30 min for 2 hours.
3.4.4. cDNA and microsome preparation
RNA was extracted using Tri-Reagent (Sigma Aldrich) according to the
manufacturer’s instruction and residual genomic DNA was removed by DNase (Bio-Rad,
Hercules, CA USA) treatment. RNA was quantified by determining 260/280 using a
spectrophotometer (Molecular devices, Ramsey MN USA).

Microsome and cytosol

fractions were prepared by homogenization with a dounce homogenizer followed by
differential centrifugation as previously described (Van der Hoeven et al., 1974). Protein
concentrations were determined with Bradford reagent (Bio-Rad).
3.4.5. Quantitative real-time PCR (qPCR)
qPCR was used to quantify changes in gene expression. Briefly, cDNA was
prepared from 2 µg RNA with 200 units of MMLV reverse transcriptase, 10mM dNTP
mixture and 0.5 mg random hexamers (Promega corporation, Madison WI USA). Changes
in gene expression were determined using previously published primers for CYPs (Damiri
et al., 2011;Hernandez et al., 2006) and key genes related to energy homeostasis and lipid
metabolism (Appendix B-2). Samples were diluted 1:5 and amplified in triplicates using a
96-well plate IQTM Real-Time PCR detection system (Bio-Rad) with 0.25X RT2 SybrGreen
(Qiagen Frederick, MD USA) to quantify gene expression compared to a reference gene as
previously described using Muller’s equation to determine changes in gene expression
(Muller et al., 2002). PCR efficiency was determined based on a standard curve prepared
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using a sample mixture containing all the cDNA samples diluted at 1:1, 1:5, 1:25, 1:125,
1:625 and 1:3125 dilutions (Kumar et al., 2017).
3.4.6. Serum concentrations of testosterone, adiponectin and b-hydroxybutyrate
Serum testosterone and b-hydroxybutyrate concentrations were detected by using
Enzyme Immunoassay (EIA) and colorimetric kits, respectively, purchased from Cayman
Chemical Co (Cayman Chemical, Ann Arbor, MI USA).

Serum adiponectin

concentrations were determined using an EIA kit from Bertin pharma (Montigny Le
Bretonneux, FR).
3.4.7. Histopathological analysis using H&E and oil red O
A clean slice of liver was made following necropsy and was placed in 10% formalin
(Fisher). Hematoxylin and Eosin (H&E) and oil red O staining was performed at Colorado
Histoprep (Fort Collins, CO USA).
3.4.8. Quantification of liver triglycerides and polar lipids
Liver triglyceride concentrations were determined using a colorimetric kit from
Cayman Chemical Co. Liver tissue (40-60 mg) was homogenized in a dounce homogenizer
with 0.5 ml phosphate buffer mixed with 0.5 ml of a 3:2 mix of hexane: isopropyl alcohol.
The homogenate was transferred into a fresh tube and the extraction repeated with 3:2
hexane: isopropyl alcohol. The organic layer was transferred into a fresh tube and the
hexane extraction was repeated twice. The combined organic layers were then dried under
nitrogen and re-constituted using standard diluent provided in the kit to determine liver
triglyceride concentrations according to the manufacturer’s protocol.
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Polar lipids were extracted from microsomes (2 mg/ml) by the addition of
chloroform (0.1% butylated hydroxytoluene) and methanol in 1:2 parts into a glass tube.
The contents of the tube were vortexed and centrifuged at 600 rpm for a minute. The lower
layer was transferred into a fresh tube the chloroform extraction was repeated 3X. The
combined lower layers were washed with 1M potassium chloride and then with water.
Samples were dried under nitrogen and shipped on dry ice to the Kansas Lipidomics
Research Center for analysis by electrospray ionization triple quadruple mass spectrometry
(Applied Biosystems API 4000) as described previously (Isaac et al., 2007;Sengupta et al.,
2016).
3.4.9. Statistical Analysis
Data are presented as mean + SEM (n = 7 - 8). Statistical analyses were performed
by Student’s t-test using Graphpad Prism version 6. A p-value < 0.05 was considered
statistically significant.

3.5. Results
3.5.1. Changes in the expression of hepatic energy metabolism-related genes in untreated
Cyp3a-null mice
Mice lacking all hepatic CYP activity have steatosis (Finn et al., 2009) and several
CYPs are either regulated by transcription factors involved in energy homeostasis or
metabolize crucial lipids and bile acids involved in digestion, absorption and utilization of
lipids (Hafner et al., 2011). Therefore, we first investigated whether the liver of 8-9 week
old Cyp3a-null mice show differences in the expression of several energy metabolism-
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related genes compared to WT mice by qPCR. Most of the genes investigated were not
changed. However, carnitine palmitoyl transferase (Cpt1a) is significantly up-regulated
by 134X and 18X in Cyp3a-null male and female mice, respectively, compared to their
WT counterparts. Fatty acid binding protein-4 (Fabp4) is up-regulated in Cyp3a-null
females 13X compared to their WT counterparts (Table 3.1). Pparα and Srebp1c regulate
Cpt1a and Fabp4, respectively, suggesting compensatory changes in liver lipid metabolism
in Cyp3a-null mice that help metabolism of excess lipids (Ayala-Sumuano et al.,
2011;Kumar et al., 2017;Rakshandehroo et al., 2009).

Table 3.1: Compensatory changes in energy and lipid metabolism genes in Cyp3a-null
mice.
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FEMALES

MALES

Genes

WT

Cyp3a-null

WT

Cyp3a-null

Acox

1.00+0.428

0.326+0.054

1.00+0.520

1.318+0.431

Cpt1a

1.00+0.388

18.706+5.562*

1.00+0.265

134.76+60.91*

Fabp4

1.00+0.215

12.923+5.297*

1.00+0.954

2.441+1.697

Fasn

1.00+0.259

1.537+0.258

1.00+0.330

0.855+0.053

Foxa2

1.00+0.348

4.808+2.486

1.00+0.713

6.512+4.854

Pparα

1.00+0.266

1.424+0.374

1.00+0.558

3.366+1.545

Pparγ

1.00+0.342

2.616+1.791

1.00+0.988

0.172+0.143

Srebp1

1.00+0.256

0.908+0.228

1.00+0.245

1.342+0.272

Data represented as relative mean +/- SEM (n = 4). Statistical significance determined by
Student’s t-test. *Indicates a p-value < 0.05.

3.5.2. Weight gain is mitigated in HFD-treated Cyp3a-null female mice in comparison to
HFD-treated WT female mice
Weight gain was monitored in WT and Cyp3a-null male and female mice fed a
HFD over eight-weeks. Female Cyp3a-null mice gained significantly less weight than their
WT counterparts as early as week one and by the seventh week Cyp3a-null female mice
only gained 3.13g while WT mice gained 6.13g (Fig. 3.1). In contrast, Cyp3a-null male
mice did not show a significant change in weight compared to their WT counterparts over
the full course of the study; however, Cyp3a-null male mice gained more weight (p-value
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= 0.06) initially and weighed more than their WT counterparts over the course of the study
(Fig. 3.1). Differences in weight gain are irrespective of feed consumption as there are no
significant differences in feed consumption between the genotypes (Appendix B-3).
Overall, gender plays a role in the Cyp3a-null mice’s response to a HFD.

Fig. 3.1: Gender is crucial in the response of Cyp3a-null mice to HFD
treatment in comparison to WT mice. Change in body weight of female
(A) and male (B) mice during eight-weeks of HFD-treatment. Changes in
body weight are also represented as area under the curve to confirm results
in females (A) and males (B). Data are presented as mean + SEM.
Statistical significance was determined by Student’s t-tests (n = 7 or 8) (*
p<0.05, ** p<0.01).
3.5.3. Cyp3a-null female mice, but not Cyp3a-null male mice, respond faster to a glucose
challenge than their WT counterparts
Fasting blood glucose concentrations were similar between the different genotypes
after 2, 4, or 6-weeks of HFD-treatment (Appendix B-4). A GTT was performed on the
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fourth week of the HFD treatment because of differences in weight gain. Interestingly,
Cyp3a-null female mice recover faster than the WT mice at the 40-90 minute intervals
following the initial glucose injections (p-value = 0.03 – 0.07). Area under the curve
measurements confirmed the rapid recovery in the Cyp3a-null female mice (Fig. 3.2), and
indicates higher lean mass in the Cyp3a-null female mice than their WT counterparts
(McGuinness et al., 2009). In contrast, there was no significant difference in glucose
tolerance between the male genotypes (Fig. 3.2).
An insulin tolerance test was performed on week 6 to determine insulin sensitivity
(Bowe et al., 2014). There were no significant differences in insulin tolerance between the
Cyp3a-null and WT mice in either gender (Fig. 3.3). We also did not find any differences
in fasting insulin levels between the Cyp3a-null and WT mice in either gender (Appendix
B-4). This suggests that the faster glucose recovery observed in the Cyp3a-null female mice
is independent of insulin response.
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Fig. 3.2: Cyp3a-null female mice, but not Cyp3a-null male mice, fed a
HFD show increased sensitivity to a glucose challenge in comparison to
WT mice. A GTT was performed as described in the Materials and Methods
after 4-weeks of HFD-treatment in female (A) and male (B) mice. GTT
results are also represented as area under the curve (AUC) to confirm results
for females (C) and males (D). Data are presented as mean blood glucose
levels + SEM. Statistical significance was determined by Student’s t-tests
(n = 7-8) (* p<0.05).
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Fig. 3.3: HFD does not significantly perturb insulin concentrations or
action in Cyp3a-null mice. An ITT was performed as described in the
Materials and Methods after 6-weeks of HFD-treatment in female (A) and
male (B) mice. ITT results are also represented as area under the curve
(AUC) to confirm results for females (C) and males (D), and ITTs are not
different between WT and Cyp3a-null mice of either gender. Data are
presented as mean + SEM. Statistical significance was determined by
Student’s t-test (n = 7-8).
3.5.4. Differences in organ weights between WT and Cyp3a-null mice
Liver, kidney, spleen, abdominal and inguinal white adipose tissue (WAT), and
testis were excised and weighed (Table 3.2). WAT weighed 30% more in the WT females
compared to their Cyp3a-null counterparts consistent with increased weight gain in WT
females; however, increased WAT was not statistically significant (p-value = 0.12). In
contrast, the kidneys of Cyp3a-null females are 20% heavier than kidneys from WT
females, suggesting compensation for a toxic burden such as ketoacidosis (Adrogue et al.,
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1984). In addition, testes weights are 29.2% lower in Cyp3a-null males than WT males
fed a HFD although the decreased testes weights are primarily due to two males that
showed very low testis weights. A drop in testis weights sometimes in only one testis is
not uncommon in rodent HFD studies (Datar et al., 2017). In contrast, liver weights are 8%
higher in Cyp3a-null males than WT males fed a HFD and this result is consistent (Table
3.2).
Table 3.2: Organ weights determined at the termination of study after 8 weeks of HFD
treatment.

a

Models

Body

Liver

Kidney

WATa

WT-F

23.75+1.03

0.91+0.04

0.25+0.01

1.13+0.20

Cyp3a-null F

23.88+1.34

0.88+0.04

0.30+0.01***

0.78+0.23

WT-M

35.88+1.22

1.39+0.06

0.40+0.01

3.20+0.36

0.24+0.01

Cyp3a-null M

39.14+0.74*

1.50+0.54*

0.42+0.01

3.57+0.32

0.17+0.02**

Testis

White adipose tissue (WAT)

Data represented as mean +/- SEM (n = 7 or 8). Statistical significance determined by
Student’s t-test. *Indicates a p-value < 0.05, **indicates a p-values < 0.01, and
***indicates a p-value < 0.001.
3.5.5. Serum concentrations of testosterone, adiponectin, and b-hydroxybutyrate
Adiponectin increases insulin sensitivity and is frequently increased in lean
compared to obese individuals (Nigro et al., 2014). The leaner Cyp3a-null females have
1.7X greater serum adiponectin concentrations than WT females further demonstrating that
the lower weight gain and adipose levels had physiological/endocrine effects (Fig. 3.4A).
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b-hydroxybutyrate (B-OHB) is produced along with acetoacetate from fatty acids as an
alternative fuel source during fasting, low carbohydrate diets, or exercise. Because the
kidney eliminates B-OHB we hypothesized that the increase in kidney weight in the Cyp3anull females was due to an increase in B-OHB. Instead, Cyp3a-null female mice show
significantly lower B-OHB concentrations (49% lower) than the WT females (Fig. 3.4B),
indicating that the WT mice have significantly more ketoacidosis, potentially due to
increased WAT and consistent with the slower response to the glucose challenge. In
contrast, we did not observe any significant changes in serum adiponectin and B-OHB
levels in male mice. Furthermore, we did not observe a significant change in serum
testosterone concentrations in the male mice despite smaller testes (Fig. 3.4C), probably
because the lower testes weights were due to two outlier individuals.
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Fig. 3.4: Serum adiponectin, b-hydroxybutyrate and testosterone in
WT and Cyp3a-null mice fed a HFD. Commercial kits were used to
measure (A) adiponectin, (B) b-hydroxybutyrate and (C) testosterone in
serum samples as described in the Materials and Methods. Data are
presented as mean + SEM. Statistical significance was determined by
Student’s t-tests (n = 7 - 8) (* p<0.05).
3.5.6. Liver triglyceride concentrations are higher and accompanied by macrovesicular
steatosis in Cyp3a-null male mice
Higher adiponectin and lower WAT coupled with a faster response to a glucose
challenge and lower ketones in HFD-treated Cyp3a-null female mice indicate lower liver
triglycerides and steatosis, and greater feedback inhibition of b-oxidation in HFD-treated
WT female mice (Xu et al., 2008). Therefore, liver triglyceride concentrations were
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measured. Surprisingly, there was no significant difference in liver triglycerides between
the WT and Cyp3a-null female mice (Fig. 3.5A).
In contrast, Cyp3a-null males showed a (1.5X) increase in liver triglycerides
compared to WT males (Fig. 3.5B) that was coupled with a 8% greater liver weight. Oil
Red O and H&E staining were used to determine zonation and types of steatosis
(microvesicular and macrovesicular) in the liver tissue, which is one of the significant
markers for the development of metabolic syndrome (Levene et al., 2012). Histopathology
results (Fig. 3.5C-I) indicate mild macrovesicular steatosis without inflammation in the
midzonal regions of the liver in male mice while female mice showed diffuse
microvesicular steatosis without inflammation in HFD-fed mice. These changes were more
visible following Oil red O staining and indicate accumulation of lipid droplets due to
HFD-treatment in both the genders although in different ways. However, histopathological
analysis did not associate increased steatosis with the absence of Cyp3a genes.
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Females

Males

Fig. 3.5: Hepatic lipid levels and histopathological changes observed in
WT and Cyp3a-null mice fed a HFD. Liver triglycerides in female (A)
and male (B) mice were determined as described in the Materials and
Methods. Data are represented as mean + SEM. Statistical significance was
determined by Student’s t-tests (n = 7 - 8) (* p<0.05). Histopathological
changes were evaluated by H&E or Oil red O staining of liver tissues
following 8-weeks of HFD treatment in WT and Cyp3a-null mice. WT
(C,D) and Cyp3a-null (E,F) female liver slices stained with H&E and Oil
red O, respectively. WT (G,H) and Cyp3a-null (I,J) male liver slices stained
with H&E and Oil Red O, respectively. Scale 0.2 mm
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3.5.7. Phosphatidylserine and phosphatidylinositol are increased in Cyp3a-null male mice
Fatty acids are responsible for the formation of lipid signaling molecules.
Lipidomic analysis demonstrated a few significant changes between the lipid profiles of
WT and Cyp3a-null males fed a HFD; however no differences were observed between WT
and Cyp3a-null females (Table 3.3). Cyp3a-null males display a two-fold increase in total
polar lipids as well as an increase in the concentrations of several specific lipid groups
including total phosphatidylserine (PS; 2.65X), phosphatidylinositol (PI; 2.3X),
sphingomyelins (SM; 2.7X), phosphatidylglycerol (PG; 2.7X), and phosphatidic acid (PA;
3.44X) in comparison to WT males (Table 3.3). Principle component analysis (PCA)
indicates lipid species are primarily clustered by gender; not genotype with the exception
of large-chain PS, some sphingomyelin, and mid-chain phosphatidylcholine (PC) species
(Appendix B-5). When normalizing to relative concentrations to look for changes in
composition between WT and Cyp3a-null males, differences are observed only in PS, PI,
and SM concentrations by 1.6X, 1.3X and 1.98X respectively (Appendix B-6). The
relative increases in polar lipids is primarily due to higher concentrations of long chain
lipid species containing 38:4 and 40:4 in PS and PI, respectively (Fig. 3.6).

Table 3.3: Lipidomics measured after eight weeks of HFD treatment on Cyp3a-null mice.
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FEMALES

MALES

Lipids

WT

Cyp3a-null

WT

Cyp3a-null

Total LysoPC

0.775+0.240

0.466+0.297

1.083+0.239

1.834+0.424

Total PC

45.200+10.050

36.980+16.570

58.750+11.550

98.720+13.940

Total SM /

3.115+0.691

2.272+1.217

2.855+0.961

7.739+1.398*

Total ePC

1.459+0.312

1.317+0.509

2.082+0.434

3.359+0.517

Total LysoPE

0.217+0.061

0.195+0.111

0.358+0.087

0.631+0.114

Total PE

8.005+2.107

7.912+4.225

11.950+2.681

19.840+3.300

Total ePE

0.144+0.042

0.156+0.086

0.309+0.076

0.535+0.093

Total PI

2.512+0.487

2.348+1.220

3.907+0.961

9.007+1.437*

Total PS

0.510+0.118

0.553+0.241

0.542+0.138

1.434+0.286*

Total ePS

0.003+0.001

0.003+0.001

0.005+0.002

0.014+0.003*

Total PA

0.021+0.003

0.026+0.010

0.025+0.004

0.086+0.020*

Total PG

0.009+0.004

0.013+0.007

0.034+0.012

0.092+0.020*

Total lipids

61.97+14.01

52.06+24.45

81.89+16.97

163.6+7.685**

DSM

Data represented as mean signal per mg of protein +/- SEM (n = 5). Statistical significance
determined by Student’s t-test. *Indicates a p-value < 0.05 and ** indicates a p-value <
0.01.
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Fig. 3.6: Phosphatidylinositol and phosphatidylserine are increased in
Cyp3a-null male mice. Data are represented as mean + SEM. Statistical
significance was determined by Student’s t-tests (n=5) (* p<0.05, **
p<0.01).
3.5.8. Changes in the expression of hepatic energy metabolism related genes in HFDtreated Cyp3a-null mice
Following HFD-treatment for 8-weeks, Cpt1a, as well as Fasn, ApoE, Pxr and
Srebp1a are down-regulated by approximately 0.5X in Cyp3a-null male mice compared to
their WT counterparts (Table 3.4). In contrast, IL-6 and Pxr is upregulated about 2.0X in
Cyp3a-null females, but not males. Fatp1 is up-regulated 2.1X in males and 2.25X in
females; however only the up-regulation in males is significant. Overall, the expression
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data suggests a decrease in lipid oxidation and synthesis and an increase in transport in the
male mice, which may explain the increase in liver triglycerides. These changes in gene
expression are consistent with a decrease in AMPK activity. However, we found no
significant change in AMPK phosphorylation levels between the WT and Cyp3a-null mice
(Appendix B-7). Because recent studies indicated that several Cyps are regulated by a
HFD (Deol et al., 2015;Finn et al., 2009), we also investigated the expression of several
Cyps. With the exception of the knocked out Cyp3a members, there are only a few Cyps
that showed changes in gene expression and only Cyp2b protein expression in males (2.8X)
was increased significantly; consistent with increases in Cyp2b9, a gene controlled by the
metabolic receptors, FoxA2 and CAR (Appendix B-7) (Hashita et al., 2008;Hernandez et
al., 2009;Jarukamjorn et al., 2001). The lower PXR expression in males may also help
explain minor steatosis coupled with no increase in apoptosis or inflammation (Gautam et
al., 2018).
Because recent studies indicated that several Cyps are regulated by a HFD (Deol et
al., 2015;Finn et al., 2009), we also investigated the expression of several Cyps (and PXR).
With the exception of the knocked out Cyp3a members, there are only a few Cyps that
showed changes in gene expression and only Cyp2b protein expression in males (2.8X)
was increased significantly; consistent with increases in Cyp2b9, a gene controlled by the
metabolic receptors, FoxA2 and CAR, or potentially Cyp2b10, a gene controlled by the
nuclear receptors CAR and PXR (Appendix B-7) (Hashita et al., 2008;Hernandez et al.,
2009;Jarukamjorn et al., 2001;Mota et al., 2011).
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Table 3.4: Dysregulation of energy and lipid metabolism genes in Cyp3a-null mice after
eight weeks of HFD treatment.
FEMALES

MALES

Genes

WT

Cyp3a-null

WT

Cyp3a-null

Acox

1.00+0.111

0.885+0.145

1.00+0.140

0.623+0.111

ApoE

1.00+0.160

1.411+0.273

1.00+0.156

0.437+0.107*

Car

1.00+0.116

1.769+0.430

1.00+0.198

0.564+0.052

Cpt1a

1.00+0.093

1.152+0.196

1.00+0.129

0.510+0.083**

Fasn

1.00+0.152

0.871+0.164

1.00+0.184

0.450+0.067*

Fatp-1

1.00+0.312

2.259+0.637

1.00+0.217

2.088+0.416*

Foxa2

1.00+0.182

1.354+0.247

1.00+0.202

1.052+0.137

IL-6

1.00+0.150

2.018+0.454*

1.00+0.222

0.640+0.141

Pepck1

1.00+0.193

1.199+0.327

1.00+0.298

0.397+0.105

Pparα

1.00+0.122

1.201+0.164

1.00+0.211

0.970+0.168

Pparγ

1.00+0.053

1.296+0.207

1.00+0.327

0.878+0.153

Pxr

1.00+0.158

1.919+0.386*

1.00+0.234

0.407+0.075*

Srebp1

1.00+0.127

0.967+0.213

1.00+0.145

0.567+0.058*

Srebp1a

1.00+0.254

1.118+0.346

1.00+0.188

0.466+0.120*

Srebp1c

1.00+0.127

1.355+0.266

1.00+0.160

0.536+0.131

Cyp2b9

1.00+0.137

1.495+0.154*

1.00 +0.340

4.250+3.585

Cyp2b10

1.00+0.210

1.283+0.176

1.00 +0.202

1.819+0.331

Data represented as relative mean +/- SEM (n = 7 or 8). Statistical significance determined
by Student’s t-test. * Indicates a p-value < 0.05 and ** Indicates a p-value < 0.01.
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3.6 Discussion
Cyp3a-null female mice gained 50% less weight than WT female mice and Cyp3anull male mice are slightly heavier than their WT counterparts following treatment with a
HFD (diet-induced obesity) (Fig. 3.1). This indicates gender specific responses to the HFD
and demonstrates a role of Cyp3a in the metabolism and utilization of fatty acids. Diverse
gender responses might be expected as several Cyp3a members are sexually dimorphic in
the liver. For example, Cyp3a41 and Cyp3a44 are both female specific (Anakk et al.,
2006;Hernandez et al., 2006;Hernandez et al., 2009) and human CYP3A4 is expressed
slightly more in females than males (Wolbold et al., 2003;Zanger et al., 2013).
Cyp3a-null female mice reacted to a glucose challenge more rapidly than WT mice,
which is consistent with their reduced weight gain and 30% lower WAT weight. In
addition, plasma adiponectin concentrations are higher and serum B-OHB concentrations
are lower in Cyp3a-null female mice, which is consistent with lower WAT, faster recovery
from glucose, and rapid b-oxidation (Ceddia et al., 2005;Meidenbauer et al., 2014;Sweeney
et al., 2004). Adiponectin plays a central role as it increases hepatic glucose and fatty acid
utilization, and in turn protects the liver from fatty liver disease (Kadowaki et al., 2006).
Interestingly, resveratrol protects from alcohol-induced fatty liver disease in part
by increasing fatty acid oxidation as observed through greater B-OHB coupled with
enhanced adiponectin, and increased expression of Cpt1a as well as other genes associated
fatty acid oxidation (Ajmo et al., 2008;Yao et al., 2014). Adiponectin also decreases lipid
uptake by the liver in part by decreasing CD36 and this could provide a mechanism for
compensating for a diet rich in fatty acids (Tarn et al., 2014). In addition, the Cyp3a
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inhibitor naringin found in grapefruit and other citrus also reduces serum B-OHB
concentrations (Kwatra et al., 2012;Murunga et al., 2016), is associated with reduced
adiposity, weight gain in mice and humans, and increased Cpt1a expression through Ppara
activation coupled with Srebp-1 inhibition (Alam et al., 2014;Cho et al., 2011;Murphy et
al., 2014). However, Cpt1a expression was much greater in Cyp3a-null mice than WT
mice prior to the HFD, but no significant difference in Cpt1a or other energy-related genes
was found after a HFD in female mice. It is also possible that the liver is not the only organ
in which Cyp3a plays a role in the metabolism and utilization of fatty acids in HFD-fed
female mice as several of the perturbed parameters are regulated by WAT, kidney and
skeletal muscle (Auguet et al., 2014;Ceddia et al., 2005;Reid et al., 2008).
In contrast to females, Cyp3a-null male mice gained weight relative to WT mice;
albeit a relatively small amount. In addition, Cyp3a-null male mice have increased liver
lipids including a 1.5X increase in liver triglycerides (Fig. 3.5B) and 2X increase in total
polar lipids (Table 3.3). Specific lipid groups (PI, PS, SM) and long chain fatty acids that
are 38-40 carbons are increased in the livers of Cyp3a-null male mice relative to WT mice
(Fig. 3.6). An increase in long-chain fatty acids is consistent with increased storage and
increased metabolism (Montgomery et al., 2013), perturbations in the transport of longchain fatty acids is associated with liver disease (Odaib et al., 1998), and increased SM is
associated with obesity (Choi et al., 2015;Iqbal et al., 2017). However, while SM is
associated with obesity, PI is associated with anti-obesity effects by regulating hepatic lipid
metabolism genes (Shimizu et al., 2010). Therefore, most but not all lipid markers are
consistent with fatty liver disease and obesity.
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Furthermore, down-regulation of Cpt1a, ApoE, Fasn, Pxr and Srebp-1 genes
indicates a down-regulation of lipid metabolism associated genes while Fatp1 is upregulated and indicates an increase in fatty acid transport genes involved in accumulation
(Kohjima et al., 2007;Xie et al., 2010). These changes in gene expression are consistent
with increased liver lipids (Anstee et al., 2006;Vallim et al., 2010). Interestingly, a drop in
Srebp1 was also observed in steatotic HRN mice lacking all hepatic CYP activity (Kishi et
al., 2005), probably due to the increased retention of unsaturated fatty acids in the liver
(Hannah et al., 2001). Typically, increases in free fatty acids are associated with increases
in Srebp1 and Fasn (Zhang et al., 2011) leading to increased Srebp1c activation that causes
increased deposition of fat in the liver (Knebel et al., 2012). This suggests that there are
other forces regulating the hepatic increase in triglycerides in Cyp3a-null mice or the downregulation of Srebp is a compensatory response to the increased liver lipids. Overall, most
but not all of these lipid markers are consistent with increased weight, liver triglycerides
and polar lipids, and it is likely that decreased Cyp3a-mediated liver metabolism plays a
role in the increased liver lipids through changes in metabolism.
In addition to xenobiotics, CYP3A isoforms are involved in the metabolism of
steroids, bile acids, and unsaturated fatty acids (Guengerich, 2002;Hafner et al., 2011).
CYP3A4 has been shown to metabolize fatty acids such as arachidonic acid to generate
epoxyeicosatrienoic acids (EETs) that have anti-inflammatory effects (Thompson et al.,
2012). High-fat diets generate an endogenous fatty acid molecule, anandamide that can be
converted to arachidonic acid by fatty acid amide hydrolase that can be further
epoxygenated by Cyp3a to EETs. Anandamide and Cyp3a-mediated metabolites (Pratt-

110

Hyatt et al., 2010) bind cannabinoid receptors such as cannabinoid receptor 1 (CB1) in
order to alter nociception, cognition, memory and orexigenic effects in the peripheral and
central nervous system; however, there were no differences in food consumption between
WT and Cyp3a-null mice. For example, CB1 regulates adiponectin activity in obese mice,
and Rimonabant, a CB1 inverse agonist causes weight loss, increases Cpt1a, while
decreasing Fasn in WT male mice, but not adiponectin-null mice (Tarn et al., 2014).
Cannabinoid receptor 2 (CB2) is associated with immunosuppression and agonists reduce
obesity (Zhang et al., 2016). Given that the fatty acid, anandamide and its Cyp3a
metabolites are potent activators of CB1/2, it is possible that the loss of Cyp3a plays a role
in perturbing fatty acid metabolism and epoxidation, including the production of
anandamide and other fatty acid derivatives, that typically would act as signaling molecules
(Brizzi et al., 2011;Snider et al., 2009), and reduce obesity.
However, this does not explain why males and females react differently except for
the possibility that the gender specific Cyp3a members in mice differentially metabolize
steroids, arachidonic acid, anandamide, and other fatty acids. Murine 6b-hydroxylation of
testosterone is significant higher in females than males demonstrating the higher Cyp3a
activity in females than males (Kumar et al., 2017). Of course, this difference in 6bhydroxylation is lost in Cyp3a-null mice, indicating the differences between males and
females for obesity and NAFLD is not directly caused by Cyp3a metabolism of steroids,
but may be due to the metabolic differences that lead to sexually dimorphic differences in
Cyp3a expression. It is possible that there are distinct differences in Cyp3a-mediated fatty
acid metabolism in males compared to females as females express different Cyp3a
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isoforms, primarily Cyp3a41 and Cyp3a44. However, the substrate profiles for these
murine isoforms are not known and that includes their metabolism of anandamide,
arachidonic acid, and other PUFAs.
Gender differences in PXR regulation and feedback within Cyp3a-null mice may
also play a role in the sexually dimorphism of weight gain. For example, mPXR is
associated with increased weight gain and hPXR with protection from weight gain in male
mice with increased Cpt1a and PPARa levels (Spruiell et al., 2014b). In contrast, hPXR
activation/presence causes greater weight gain than mPXR in female mice (Spruiell et al.,
2014a). Because PXR positively regulates Cyp3a, the PXR studies are consistent with our
data in which loss of Cyp3a increased obesity in males and protected females. Therefore,
while we don’t know the exact mechanism of the sexually dimorphic weight gain in Cyp3anull mice, it appears that differential PXR/Cyp3a activation and subsequent regulation of
gene expression plays a role.
In summary, the loss of seven Cyp3a genes lead to sexual dimorphic changes during
the eight weeks of high fat diet treatment with Cyp3a-null female mice showing a healthier
acclimation to a high fat diet through decreased weight gain, higher adiponectin, lower BOHB levels, and a better response to glucose; while the Cyp3a-null males succumb to
increased fatty liver including slightly increased weight, higher hepatic polar lipids and
triglycerides, and greater liver weight. Overall, the changes in HFD-induced health
parameters in females are consistent with other studies showing that compounds that inhibit
Cyp3a or perturb Cyp3a-mediated fatty acid metabolism protect from obesity (Murunga et
al., 2016;Zhang et al., 2016), and the increases in weight in males are moderate.
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Interestingly, PXR activation and subsequent CYP3A induction is associated with weight
gain (Spruiell et al., 2014a). Ultimately, inhibition of CYP activity by environmental
compounds or drugs may alter hepatic and non-hepatic lipid levels with different effects in
males than females in which males may present increased steatosis and females show a
mitigation of the effects of a HFD.
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CHAPTER FOUR
CYP2B9/10/13-NULL MALE MICE ARE SUSCEPTIBLE TO HIGH-FAT DIETINDUCED OBESITY

4.1 Abstract
CYP2B metabolizes pesticides, plasticizers, unsaturated fats and more than 25% of
drugs available in the market. Recent studies using the cytochrome P450 oxidoreductase
knockout mouse treated with unsaturated fatty acids shows activation of CAR and a
profound increase of Cyp2b10 presumably to ameliorate hepatic lipid accumulation. Data
from our laboratory using RNAi-mediated Cyp2b-knockdown mouse indicated that the
older knockdown mice were heavier and contain greater serum lipid concentrations,
especially males. To investigate the role played by CYP2B in lipid metabolism we have
developed a CYP2B triple knockout lacking Cyp2b9, 10 and 13 using CRISPR/Cas9. We
treated them with a 60% fat diet (HFD) for 10 weeks. We determined physiological,
metabolic and molecular level changes in WT and Cyp2b-null mice. Male but not female
Cyp2b-null mice weigh approximately 15% more than WT counterparts fed a HFD,
primarily due to an increase in white adipose tissue. Serum parameters indicate increased
b-hydroxybutyrate in Cyp2b-null HFD-fed mice, a marker of ketoacidosis. In addition,
leptin, adiponectin, and cholesterol were increased in HFD-fed Cyp2b-null male mice
compared to HFD-fed WT mice. Cholesterol, primarily due to increased HDL is increased
in both normal diet and HFD fed male and female mice. Liver triglycerides were
significantly higher than their similarly treated WT counterparts (ND and HFD), indicating
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a role for Cyp2b in fatty acid metabolism regardless of diet. This probably contributed to
the lower levels of triglycerides in Cyp2b-null mice. Overall our data indicates that the
repression or chemical inhibition of CYP2B may exacerbate metabolic disorders and cause
obesity.

Keywords: Non-alcoholic fatty liver disease (NAFLD), P450, Triglycerides, ketoacidosis
Obesity.

Abbreviations:
Cyp

Cytochrome P450

ND

Normal diet

HFD

High fat diet

WAT

White adipose tissue

B-OHB

b-hydroxybutyrate

CAR

Constitutive androstane receptor

EET

Epoxyeicosatrienoic acid

ALT

Alanine aminotransferase

122

4.2 Introduction
The World Health Organization (WHO) defines obesity as “abnormal or excess
accumulation of fat that may impair health”. According to National Center for Health
Statistics (NCHS) more than 40% of adults and 18.5% youth are obese in United States as
of 2015-2016 (Hales et al., 2017). Factors that cause obesity include poor diet, changes in
lifestyle, genetics, and the environment (Choquet et al., 2011;Grun et al., 2009;Romieu et
al., 2017). The primary problem is excess food coupled with inactivity. However, data
indicates there are other anthropogenic factors, including environmental toxicants that
exacerbate obesity by modulating the use and allocation of nutrient resources leading to
increased white adipose tissue and obesity(Grun et al., 2009;Hatch et al., 2010;Sharp,
2009;Wahlang et al., 2013a). This led to the terms “obesogen” or “metabolic disruptor”
(Grun et al., 2009;Hatch et al., 2010;Wahlang et al., 2013a;Wahlang et al., 2013b) that
refers to a new subclass of endocrine disruptors that perturb metabolic signaling, energy,
and lipid homeostasis (LeBlanc et al., 2012b;Riu et al., 2011). In turn, the Organization for
Economic Cooperation and Development (OECD) considers metabolic disorders one of
three critical areas in toxicology in addition to testicular dysgenesis and autism spectral
disorders (LeBlanc et al., 2012a).
Chemical exposures shown to cause obesity (Baillie-Hamilton, 2002;Grun et al.,
2009), include perinatal exposure to bisphenol A that increases lipogenic gene expression
and hepatic steatosis in male rats (Marmugi et al., 2012). Tributyltin activation of PPARγ
induces obesity in part through increased adipocyte differentiation (Chamorro-Garcia et
al., 2013), and TCDD activation of AhR induces obesity and steatosis through increased
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uptake of fatty acids (Angrish et al., 2012;Ayala et al., 2010;Chang et al., 2016).
Inactivation of the xenobiotic receptor, the constitutive androstane receptor (CAR), and
activation of the pregnane X-receptor (PXR) are also associated with obesity(Dong et al.,
2009;Spruiell et al., 2014a;Spruiell et al., 2014b). Furthermore, perturbations in hepatic
Cytochrome P450 (CYP) activity were recently associated with lipid accumulation(Finn et
al., 2009;Hoek-van den Hill et al., 2015;Hoek-van den Hill et al., 2014;Wang et al.,
2005;Zong et al., 2012).
CYPs, primarily in families 1-3, metabolize pharmaceuticals (Zanger et al., 2013),
environmental pollutants (Foxenberg et al., 2007) and endobiotics such as fatty acids
(Arnold et al., 2010), bile acids and steroids (Waxman, 1988). Several CYP1-3 members
are crucial in fatty acid metabolism. For example, CYP3A4 metabolizes arachidonic acid
(anandamide), CYP2J2 metabolizes arachidonic acid to epoxyecosatrienoic acid (EET) in
cardiomyocytes(Wu et al., 1996), and Cyp2b members metabolize arachidonic acid with
high affinity(Capdevila et al., 1990;Keeney et al., 1998). For example, Cyp2b19 expressed
by mouse keratinocytes, epoxygenates arachidonic acid to 11,12 and 14,15 EET that plays
a vital role in cornification of epidermal cells (Du et al., 2005;Ladd et al., 2003)and
CYP3A4 metabolizes arachidonic acid to 13- hydroxyeicosatrienoic acid (HETE),10HETE and 7-HETE (Bylund et al., 1998).
Recent studies implicate Cyp2b in obesity. For example, CYP2Bs are inducible by
anti-obesity transcription factors (CAR; FoxA2) (Hernandez et al., 2007;Hernandez et al.,
2009;Mota et al., 2010;Mota et al., 2011) . CAR is a key regulator of Cyp2b, including
Cyp2b9 and Cyp2b10(Hernandez et al., 2009;Mota et al., 2010;Oshida et al., 2015), and
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CAR activation by TCPOBOP ameliorates obesity, diabetic activity and fatty liver disease
in ob/ob mice, but not ob/ob mice null for CAR(Dong et al., 2009). FoxA2, which is
activated by fasting and fatty acids, is inhibited by insulin, implicated in sporadic cases of
early onset Type II diabetes, and hepatic FoxA2-null mice are age-dependent
obese(Bochkis et al., 2008;Bochkis et al., 2013;Wolfrum et al., 2004). Thus, Cyp2B
expression is induced by CAR and Foxa2 during nutritional or metabolic stress, potentially
as a protective mechanism. Furthermore, cytochrome P450 oxidoreductase (HRN-null)
conditional knockout mice that lack all the CYP activity in the liver show activation of
CAR and significant increases in Cyp2B mRNA during treatment with PUFA-rich
sunflower oil (Finn et al., 2009). Similarly, treatment with soybean oil (rich in 55% linoleic
acid) resulted in weight gain, increased white adipose tissue and glucose intolerance in
association with a significant increase in Cyp2b9 and 13 (Deol et al., 2015). Cyp2b9 is also
the most highly induced gene in a couple of diet-induced obesity studies(Hoek-van den
Hill et al., 2015;Leung et al., 2016). Last, studies in our lab using a Cyp2b RNAi-based
knockdown mouse model (Damiri et al., 2012) shows increases in body weight and
adiposity with age and a reduced propensity to eliminate corn oil that is rich in PUFAs such
as linoleic acid (Damiri, 2011). Taken together, the Cyp2b enzymes are associated with
obesity and we predict that lack of Cyp2b either by gene knockout or repression by
inhibitors coupled with high-fat diet treatment will perturb lipid metabolism, increase body
weight and lead to the development of obesity.
In our study, we have used our newly developed Cyp2b9/10/13-null mice that is
missing important hepatic Cyp2B members, Cyp2b9, Cyp2b10 and Cyp2b13 to
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demonstrate the significance of Cyp2B in hepatic lipid metabolism. We treated these mice
with 60% fat rich diet for 10-weeks. We hypothesize that lack of Cyp2b9, Cyp2b10 and
Cyp2b13 will increase susceptibility to high fat diet-induced obesity in Cyp2b9/10/13-null
mice compared to wild-type mice. We determined physiological changes such as
bodyweight changes and organ weight changes, metabolic changes such as ability to
metabolize glucose, insulin tolerance and hormone changes and gene expression changes.
Our results show that lack of Cyp2b9,10,13 in mice causes gender-based differences in
response to high fat diet. Male Cyp2b9/10/13-null mice show increase in body weight,
increase in white adipose tissue weight and increase in liver triglycerides. However, female
Cyp2b9/10/13-null did not show increase in body weight but did show increase in liver
lipids.

4.3 Materials and Methods:
4.3.1. High-fat diet treatment of Cyp2b9/10/13-null mice
All mice studies followed National Institute of Health guidelines for humane use of
research animals and were pre-approved by Clemson University’s Institutional Animal
Care and Use Committee (IACUC). Cyp2b9/10/13-null (Cyp2b-null) mice were developed
using Crispr/cas 9 technology on C57/Bl6 background mice as described earlier (Kumar et
al., 2017). Briefly, the liver predominant Cyp2b genes, Cyp2b10, 13 and 9 present as
tandem repeat sequences on chromosome seven, were targeted individually using small
guide RNA sequences (sg RNA). Each sgRNA sequence was made up of Cas9 mRNA
from Streptococcus pyogenes, 20 nt guide sequence specific for the target gene and 83nt

126

scaffold sequence. The three sgRNA’s were delivered into the cytoplasm of mouse
blastocyst and successful transgenic embryo had 287 kb deletion due to the lack of three
Cyp2b genes. The successful homozygous knock-out mice were screened using primers
published in our earlier manuscript (Kumar et al., 2017).

Wildtype C57/Bl6 were

purchased from The Jackson Laboratory at 4 weeks of age (Bar Harbor, ME, USA).
Mice were acclimated for 4-weeks prior to the dietary treatments. Nine-ten week
old male and female mice (n=9) from WT and Cyp2b9/10/13-null mice were divided into
normal diet (Harlan Madison WI USA) and high-fat diet (TD.06414 Adjusted Calorie Diet
(60/Fat)) groups. ND consisted of 18.6% protein, 6.2% fat and 44.2% carbohydrates
providing 3.1 Kcal/g.

HFD consisted of 60.3% fat (37% saturated fat, 47%

monounsaturated fat and 16% polyunsaturated fats), 21.3% carbohydrates and 18.4%
protein providing 5.1 Kcal/g.
All mice were fed either the ND or HFD for ten weeks. Feed consumption was
measured every other day and mice were weighed every week to determine their weight
gain. Following a 4-5 hour fast, fasting plasma glucose concentrations were determined
during weeks 2, 5 and 8 with an Alphatrek-2 glucometer (AlphaTRAK, Chicago IL USA).
Glucose tolerance tests (GTT) were performed on weeks 5 and 8. At the end of the study
mice were anesthetized, blood was collected by heart puncture and euthanized by carbon
dioxide asphyxiation. Organs such as liver, kidney, white adipose tissue and brain were
excised and weighed. Organs were stored on dry ice and then moved to -80°C freezers or
stored in 10% formalin (Fisher, Fair Lawn NJ USA) until further analyses were performed.
Livers were dissected into five fractions and snap frozen in liquid nitrogen for microsome
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preparation, RNA extraction and lipidomics. Liver sections for histopathology were stored
in 10% formalin (Fisher) while the remaining liver was stored on dry ice and stored in 80°C until required. A timeline of experimental procedures performed on the mice is
provided (Appendix C-1).
4.3.2. Glucose tolerance and insulin tolerance tests
Glucose tolerance tests were performed during weeks 5 and 8. Briefly, the mice
were fasted for 5 hr and then injected i.p. with 1g/kg of their bodyweight with D-glucose
(Sigma Ultra, St. Louis MO USA). The blood glucose levels were measured using
Alphatrek-2 glucometer (AlphaTRAK) in 30 min intervals for 2 hours for GTT. The mice
were fasted for 5 hr and then injected i.p. with 0.75 U/kg of their bodyweight of novolin
(Nova Nordisk, Bagsvaerd, DK) for ITT. The blood glucose levels were measured using
Alphatrek-2 glucometer (Alpha TRAK) in 30 min intervals for 1 hour.
4.3.4. Sample preparation
RNA was extracted from the liver using BioRad spin columns and DNAse (BioRad, Hercules, CA) digestion to remove genomic DNA by following the manufacturer’s
instructions. RNA concentrations were determined spectrophotometrically by measuring
absorbance at 260/280 nm (Molecular Devices, Ramsey, MN USA). cDNA was prepared
by treating 2 µg of RNA with 200 units of MMLV, 10mM dNTP and 0.5mg of random
primers (Promega corporation, Madison WI USA). Microsomes were prepared by
homogenizing frozen livers in 3ml buffer followed by differential centrifugation as
described previously (Van der Hoeven et al., 1974). Protein concentration was determined
using Bradford reagent (Bio-Rad).
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4.3.5. Histopathological analysis
A clean slice of liver was made following necropsy and was placed in 10% formalin
(Fisher). Hematoxylin and Eosin (H&E) and oil red O staining was performed at Colorado
Histoprep (Fort Collins, CO USA). The pathological study was done on these slides at
Colorado Histoprep (Fort Collins).
4.3.6. Quantitative real time polymerase chain reaction (qPCR)
Gene expression changes were determined by qPCR using previously published
primers (Hernandez et al., 2009). Samples were diluted 1:5 and amplified in triplicates
using 96 well plates on the IQTM real time system (BioRad) with 0.25X RT2 Sybr Green
(Qiagen Frederick, MD USA) as the intercalating dye. Relative gene expression changes
were quantified by comparing the gene of interest to geometric mean of 18S and
glyceraldehyde 3-phosphate dehyhydrogenase (GAPDH) as the reference genes and using
Muller’s equation as previously described (Muller et al., 2002). qPCR efficiency was
determined with a standard curve made from a sample mixture containing all cDNA
samples diluted 1:1, 1:4, 1:16, 1:64, 1:256, and 1:1024 as described previously (Hernandez
et al., 2009).
4.3.7. Immunoblots
Immunoblots were performed using 30 µg of microsomal protein separated on 12%
SDS-polyacrylamide gels (BioRad). Protein was transferred onto 0.2µm polyvinylidene
difluoride (PVDF) membrane and were recognized using polyclonal antibodies to Cyp3a
(Chemicon International, Temecula CA USA), Cyp2b (previously developed in
house)(Hernandez et al., 2009), Cyp4a (Thermofisher Scientific, Rockford IL USA). β-
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actin was used as the reference protein. Chemiluminescent western blot detection was done
using alkaline phosphatase conjugated secondary antibodies, where in anti-mouse IgG
(Immunostar, Bio-Rad) was used to determine β-actin and anti-rabbit IgG (Immunostar,
Bio-Rad) was used to determine CYPs. Protein was quantified by densitometry (Quality
One, BioRad, Hercules, CA).
4.3.8. Serum lipid panel
Blood samples were collected by heart puncture and incubated at room temperature
for 30 min followed by centrifugation at 6000 rpm for 10 minutes. Serum samples were
transferred into fresh tubes and 100µl aliquots were shipped on dry ice to Baylor College
of Medicines Comparative Pathology Laboratory (Houston, TX) for determination of
serum

cholesterol,

triglycerides,

alanine

aminotransferase

(ALT),

aspartate

aminotransferase (AST), High density lipoprotein (HDL) and Low density lipoprotein
(LDL).
4.3.9. Serum concentrations of adiponectin, leptin, b-hydroxybutyrate and liver
triglycerides
Serum adiponectin and leptin concentrations were determined using an EIA kit
from Bertin Pharma (Montigny Le Bretonneux, FR), and serum b-hydroxybutyrate
concentrations were determined by using a colorimetric kit from Cayman Chemical Co
(Ann Arbor, MI). Liver triglyceride concentrations were quantified following organic
extraction (Chapter three) with a colorimetric kit (Cayman Chemical, Ann Arbor, MI).
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4.3.10. Statistical Significance
Data are presented as mean + SEM (n = 8-9). Statistical analysis was performed by
one-way and two-way ANOVA followed by Fisher’s LSD as the post-hoc using Graphpad
Prism version 6. A p-value < 0.05 was considered statistically significant.

4.4 Results
4.4.1. High-fat diet increases body and white adipose tissue weight
Cyp2b9/10/13-null male mice fed a HFD weighed 15% more than WT male mice
fed a HFD (Fig. 4.1A). Cyp2b9/10/13-null male mice weighed significantly more after
only 4-weeks of HFD treatment and stayed heavier for the rest of the study period
compared to WT male mice fed a HFD (Fig. 4.1A). Much of this weight gain is from
increased abdominal and inguinal white adipose tissue, which increased 55% more in the
Cyp2b9/10/13-null HFD mice compared to the WT HFD treated mice (Table 4.1A).
Exposure to a ND for 10-weeks did not cause a significant increase in weight gain in
Cyp2b9/10/13-null mice compared to WT mice. Mice fed a HFD consumed more calories
compared to their normal diet counterparts (Appendix C-2A); however, Cyp2b9/10/13null mice had similar calorie intake compared to WT mice when examined by diet (HFD
or ND). Therefore, alterations in dietary intake do not explain increased weight gain in
Cyp2b9/10/13-null mice.
Cyp2b9/10/13-null and WT female mice fed a HFD gained significantly more
weight and had higher white adipose tissue mass compared to mice fed a ND. However,
genotype had no effect on body weight gain or white adipose tissue mass, indicating that
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the loss of Cyp2b9/10/13 did not cause obesity in female mice; only male mice (Fig. 4.1B;
Table 4.1B).

A

B

Fig. 4.1: Changes in body weight during the 10-weeks of dietary
treatments. Body weight of A) male and B) female, WT, and
Cyp2b9/10/13-null mice were monitored during the 10-week feeding study.
Male but not female Cyp2b-null mice show increased weight during HFD
treatments. Data are represented as mean + SEM. Statistical significance
was determined by one-way ANOVA followed by Fisher’s LSD as the posthoc test (n= 8-9). An ‘a’ indicates WT-ND are different than Cyp2b9/10/13null-ND, ‘b’ indicates WT-ND are different than WT-HFD, ‘c’ indicates
Cyp2b9/10/13-null-ND are different than Cyp2b9/10/13-null-HFD, ‘d’
indicates WT-HFD are different than Cyp2b9/10/13-null-HFD.
Table 4.1: Organ weights determined in WT and Cyp2b9/10/13-null mice after 10-weeks
of dietary treatment
A
Mouse model

Body weight

WAT

Liver

Kidney

Brain

WT-ND M
Cyp2b-null ND M
WT-HFD M
Cyp2b-null HFD
M

26.48+0.57
25.75+0.39
30.43+0.92b**
34.12+0.88c***d*

0.51+0.06
0.69+0.06
1.96+0.22b***
3.04+0.19c***d***

1.23+0.03
1.08+0.03a*
1.06+0.04b*
1.08+0.04

0.34+0.01
0.31+0.01
0.37+0.01
0.37+0.02c**

0.48+0.03
0.46+0.01
0.44+0.00
0.43+0.01
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B
Mouse model
WT-ND F
Cyp2b-null ND F
WT-HFD F
Cyp2b-null HFD F

Body weight
20.47+0.44
20.29+0.22
23.17+0.87b*
24.15+0.93c**

WAT
0.36+0.06
0.33+0.03
0.95+0.15b*
1.22+0.24c**

Liver
0.87+0.03
0.83+0.02
0.84+0.03
0.87+0.04

Kidney
0.26+0.01
0.25+0.01
0.26+0.01
0.28+0.01c

Brain
0.44+0.00
0.45+0.00
0.45+0.00
0.45+0.01

Data represented as mean +/- SEM (n = 8/9). Statistical significance determined by twoway ANOVA followed by Fisher’s LSD as the post-hoc test. The test for interaction
between treatments and serum lipids is significant (p < 0.0001)
‘a’ indicates WT ND different than Cyp2b9/10/13-null ND
‘b’ indicates WT ND different than WT HFD
‘c’ indicates Cyp2b9/10/13-null ND different than Cyp2b9/10/13-null HFD
‘d’ indicates WT HFD different than Cyp2b9/10/13-null HFD,
No asterisk indicates a p-value < 0.05, * indicates a p-value < 0.01,** indicates a p-value
< 0.0001 and *** indicates a p-value < 0.00001.

4.4.2. High-fat diets decrease glucose tolerance
Fasting plasma glucose levels were determined during weeks 5 and 8.
Cyp2b9/10/13-null male mice fed a ND show a 20% increase in fasting glucose
concentrations compared to their WT counterparts on both weeks 5 and 8. Perturbation in
fasting glucose concentrations was consistent and male specific (Appendix C-3A). HFD
did not significantly increase fasting glucose with the exception of Cyp2b9/10/13-null
females fed a HFD compared to Cyp2b-null females fed a ND.
Glucose tolerance tests (GTT) were done to determine if the loss of hepatic Cyp2b
members reduced the mouse’s ability to respond to a glucose challenge as a biomarker of
metabolic disease. In males, a HFD increased response times leading to increased glucose
retention in the serum. In addition, the Cyp2b9/10/13-null male mice fed HFD were not
able to lower their serum glucose concentrations back to normal (at 2 hr) in comparison to
the other groups such as the WT male mice fed a HFD on week 5, indicating perturbed
glucose tolerance. However, this effect was not significant overall by area under the curve
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(AUC), nor was this effect repeatable on week 8. Instead we observed that Cyp2b-null ND
males showed decreased glucose tolerance relative to WT ND-fed males at 30 minutes;
however, these mice responded normally after this initial time point. We also performed
insulin tolerance tests on ND treated WT and Cyp2b9/10/13-null male mice due to the
minor differences in the 30-minute blood glucose levels on week 8, but there were no
significant differences in insulin sensitivity between WT and Cyp2b9/10/13-null males
(Appendix C-4).
In females, a HFD had no significant effects on glucose clearance until week 8 and
the lack of Cyp2b enzymes had no effect on glucose tolerance (Fig. 4.2B). Overall,
Cyp2b9/10/13-null female mice showed no particular changes in glucose tolerance
compared to WT mice. Cyp2b9/10/13-null male mice showed changes in fasting glucose
and some minor differences in serum glucose clearance time in males; however, some of
these measured changes were not consistent between weeks 5 and 8 (Fig. 4.2).
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Week 5

Females

Blood glucose mg/dl

A

Males

Area under the curve

Time (min)

Males

Week 8

Females

Area under the curve

Blood glucose mg/dl

B

Time (min)

Fig. 4.2: Glucose tolerance tests shows significant changes in
Cyp2b9/10/13-null male mice Glucose tolerance tests were performed on
weeks 5 (A) and 8 (B) as described in the Materials and Methods. Results
are shown for males and females over the time course of the assay and as
area under the curve (AUC). Data are presented as mean + SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher’s
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LSD as the post-hoc test (n= 8-9). ** Indicates a p-value < 0.01. An ‘a’
indicates WT-ND are different than Cyp2b9/10/13-null-ND, ‘b’ indicates
WT-ND are different than WT-HFD, ‘c’ indicates Cyp2b9/10/13-null-ND
are different than Cyp2b9/10/13-null-HFD, ‘d’ indicates WT-HFD are
different than Cyp2b9/10/13-null-HFD.
4.4.3. Lack of hepatic Cyp2b9/10/13 increases hepatic triglycerides
Cyp2b9 and Cyp2b10 are induced during high fat diet treatment, presumably to
help clear fatty acids from the liver (Finn et al., 2009;McGregor et al., 2013). The lack of
Cyp2b9/10/13 in the knockout mice increased liver triglycerides by 2.3X in the ND-fed
Cyp2b9/10/13-null male mice compared to ND-fed WT males (Fig. 4.3A). HFD
exacerbated liver triglyceride concentrations; however, there were no differences between
HFD-fed Cyp2b9/10/13-null male mice and WT male mice (Fig. 4.3A). In females, HFDfed mice had significant increases in liver triglycerides compared to ND-fed mice;
however, genotype had little effect on liver triglycerides (Fig. 4.3B). Histopathological
analysis did not show significant morphological changes indicative of fat deposition either
by H&E or Oil Red O overall with the exception of a few mice that showed increased Oil
Red O staining indicative of increased liver lipids (Fig. 4.3CD). Surprisingly, liver weight
was decreased in all male HFD groups and in the male Cyp2b9/10/13-null mice compared
to WT ND-fed mice (Table 4.1A).
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B

A

Genotype
C Normal diet

High fat diet

D Normal diet

High fat diet

WT

Cyp2b9/10
/13-null

Females

Males

Fig. 4.3: Liver triglyceride concentrations are significantly increased in
Cyp2b9/10/13-null mice. Liver triglycerides were extracted and
determined as described in the Materials and Methods using commercial
kits. Histopathology analysis using H&E staining procedure did not show
any significant changes between the genotypes (C-D). Data are presented
as mean + SEM. Statistical significance was determined by one-way
ANOVA followed by Fisher’s LSD as the post-hoc test (n= 8-9). * indicates
a p-value < 0.05, *** indicates p-value < 0.001 and **** indicates p-value
< 0.0001. An ‘a’ indicates WT-ND are different than Cyp2b9/10/13-nullND, ‘b’ indicates WT-ND are different than WT-HFD, ‘c’ indicates
Cyp2b9/10/13-null-ND are different than Cyp2b9/10/13-null-HFD, ‘d’
indicates WT-HFD different than Cyp2b9/10/13-null-HFD.
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4.4.4. Serum lipids were perturbed in Cyp2b9/10/13-null mice
Serum triglyceride levels were significantly decreased in Cyp2b9/10/13-null male
mice compared to WT mice following ND (28%) or HFD (25%) treatments (Table 4.2A),
in contrast to the increased triglyceride levels found in the liver (Fig. 4.3A). This indicates
either decreased metabolism and distribution of hepatic lipids or increased uptake of serum
lipids into the liver. Female mice also showed a similar decrease (29%) in serum
triglycerides in ND-Cyp2b9/10/13-null mice compared to ND-WT mice (Table 4.2);
however, this was not statistically significant. In addition, HFD-fed Cyp2b9/10/13-null
female mice show a 31% increase in serum triglycerides compared to HFD-fed WT mice.
In contrast, serum cholesterol and HDL increased 14% and 18%, respectively, in
ND-fed Cyp2b9/10/13-null male mice compared to ND-fed WT male mice. Serum
cholesterol and HDL increased 8% and 12%, respectively, in HFD-fed Cyp2b9/10/13-null
male mice compared to HFD-fed WT male mice. (Table 4.2A). Despite lower weight gain
and white adipose tissue mass, females showed greater changes in serum cholesterol and
HDL concentrations. HFD-fed Cyp2b9/10/13-null female mice significantly increased
cholesterol (19%) and HDL (106%) and cholesterol (19%) was increased though not
statistically significant compared to HFD-fed WT mice (Table 4.2B). There were no
significant changes in LDL or VLDL serum levels only in the relatively healthy HDL
serum concentrations. In addition, ALT, a biomarker of liver damage, was increased only
in Cyp2b9/10/13-null females fed a HFD, indicating that these mice suffered some liver
damage such as apoptosis or necrosis. Overall, serum lipid concentrations were perturbed
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in Cyp2b9/10/13-null mice often regardless of dietary treatment, indicating that Cyp2b
members are crucial in normal lipid metabolism.
Table 4.2: Serum lipid levels in Cyp2b9/10/13-null compared to WT mice treated with
normal diet (ND) or high fat diet (HFD)
A
Lipid panel
ALT

WT ND M
17.00 + 1.48

Cyp2b-null ND M
17.80 + 0.97

Cholesterol
HDL
LDL
Triglycerides
VLDL

103.80 + 1.63
97.00 + 2.21
10.98 + 0.58
80.40 + 7.88
16.04 +1.59

118.60 + 6.27a*
114.02 + 4.45a*
16.34 + 1.09
58.00 + 5.93a***
11.56 + 1.19a

WT HFD M
15.00 + 0.55

Cyp2b-null HFD M
14.00 + 1.00

170.4 + 7.00b***
150.76 + 6.24b***
26.34 + 2.46b*
69.60 + 3.96b
13.94 + 0.80

182.75 + 3.61c***d
168.60 + 4.94c***d*
30.20 + 1.57c
52.25 + 3.15d*
10.45 + 0.61

B
Lipid panel

WT ND F

ALT
Cholesterol
HDL
LDL
Triglycerides
VLDL

20.20 + 1.69
76.40 + 3.70
72.48 + 4.09
8.68 + 1.82
80.80 + 17.74
16.16 + 3.53

Cyp2b-null ND F
17.80 + 0.80
77.40 + 1.94
77.36 + 2.57
10.20 + 1.46
57.40 + 12.70
11.46 + 2.52

WT HFD F

Cyp2b-null HFD F

37.20 + 8.49
98.00 + 12.63
54.18 + 22.92
8.58 + 3.24
78.40 + 18.58
15.68 + 3.75

52.00 + 27.91c
116.60 + 8.52c
109.98 + 9.00cd**
12.48 + 0.59
102.40 + 17.69c*
20.48 + 3.55

Data represented as mean +/- SEM (n = 5). Statistical significance determined by two-way
ANOVA followed by Fisher’s LSD as the post-hoc test. The test for interaction between
treatments and serum lipids is significant (p < 0.0001).
‘a’ indicates WT ND different than Cyp2b9/10/13-null ND.
‘b’ indicates WT ND different than WT HFD
‘c’ indicates Cyp2b9/10/13-null ND different than Cyp2b9/10/13-null HFD.
‘d’ indicates WT HFD different than Cyp2b9/10/13-null HFD,
No asterisk indicates a p-value < 0.05 and * indicates a p-value < 0.01, ** indicates a pvalue of < 0.0001.
4.4.5. Serum concentrations of adiponectin, leptin and b-hydroxybutyrate:
Adiponectin was significantly increased in HFD-fed Cyp2b9/10/13-null males
compared to their normal diet counterparts and HFD-fed WT males by 13% and 17% (Fig.
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4.4A). The significant increase in white adipose tissue weight by 55% in the HFD-fed
Cyp2b9/10/13-null males (Table 4.1A) could have increased the amount of adiponectin in
these mice. ND-fed Cyp2b9/10/13-null females had 16% significant increase in
adiponectin levels compared to ND-fed WT females (Fig. 4.4A). But HFD-fed
Cyp2b9/10/13-null females had 25% decrease in adiponectin compared to ND-fed
Cyp2b9/10/13-null females and this may be due to significant increase in WAT in the
HFD-fed Cyp2b9/10/13-null females compared to ND-fed Cyp2b9/10/13-null females.
Leptin regulates metabolic responses for satiety and energy expenditure during
starved and fed states, but HFD consumption increases leptin levels and leads to the
development of leptin resistance(Kahn et al., 2000).We observed a similar trend of
significant increase in serum leptin levels in HFD fed mice compared to their ND
counterparts in both the genders, however, Cyp2b9/10/13-null males on HFD had 75.5%
more serum leptin compared to WT males on HFD (Fig. 4.4B).
Beta-hydroxybutyate (B-OHB) is generated by the liver from fatty acids during
prolonged exercise or starvation to meet the energy requirements and compensate for lower
carbohydrate levels. B-OHB can be utilized as energy source by active tissues such as brain
and muscles. Cyp2b9/10/13-null males fed a HFD had significant increase in B-OHB levels
by 2.3-fold compared to WT males on HFD (Fig. 4C). The significant increase in B-OHB
could be related to significant increase in WAT in the Cyp2b9/10/13-null males on HFD,
which could provide fatty acids to fuel ketogenesis in the liver.
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A

B

C

Genotype

Fig. 4.4: Serum adiponectin, leptin and b-hydroxybutyrate
concentrations in WT and Cyp2b9/10/13-null mice. Commercial kits
were used to determine (A) adiponectin, (B) leptin and (C) bhydroxybutyrate concentrations in serum samples. Data are presented as
mean + SEM. Statistical significance was determined by one-way ANOVA
followed by Fisher’s LSD as the post-hoc test (n= 8-9). * Indicates a p-value
< 0.05, ** indicates a p-value < 0.01, *** indicates a p-value < 0.001 and
**** indicates p-value < 0.0001. An ‘a’ indicates WT-ND are different than
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Cyp2b9/10/13-null-ND, ‘b’ indicates WT-ND are different than WT-HFD,
‘c’ indicates Cyp2b9/10/13-null-ND are different than Cyp2b9/10/13-nullHFD, ‘d’ indicates WT-HFD are different than Cyp2b9/10/13-null-HFD.
4.4.6. Gene expression changes:
Cyp2a4 increased by 4.2X in ND-fed Cyp2b9/10/13-null male mice compared to
ND-fed WT male mice that is consistent with our earlier studies characterizing
Cyp2b9/10/13-null mice (Kumar et al., 2017). This similar comparison was not statistically
significant between the HFD-fed WT and HFD-fed Cyp2b9/10/13-null male mice (Table
4.3A). However, Cyp2a4 was significantly up-regulated in ND-fed Cyp2b9/10/13-null
female mice by 2.6X and HFD-fed Cyp2b9/10/13-null female mice by 1.8X compared to
their corresponding WT female counterparts (Table 4.3B). We also performed western
blots to determine compensatory changes in Cyp protein expression but there were no
significant changes in Cyp proteins, except for the down regulation of Cyp2b protein in the
Cyp2b9/10/13-null mice compared to the WT male mice (Appendix C-5).
We observed a significant increase in FoxO1 gene expression in the HFD-fed
Cyp2b9/10/13-null male mice compared to HFD-fed WT male mice by more than 2.8X
(Table 4.3A). FoxO1 induces adipogenesis along with regulating gluconeogenesis.
Therefore, increases in FoxO1 may be associated with higher liver triglycerides and the
increase in WAT in HFD-fed Cyp2b9/10/13-null male mice (Table 4.1A).
CD68 and Col27a1, biomarkers associated with innate immune response or
inflammation and tissue growth and repair, respectively (Pace et al., 2003;Pietilainen et al.,
2006) were perturbed in the HFD-fed Cyp2b9/10/13-null mice compared to their HFD-fed
WT mice in both males and females. Col27a1 was almost exclusively induced in the
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Cyp2b9/10/13-null mice while female showed induction of of Col27a1 and downregulation of CD68. (Table 4.3AB). These genes are early markers of inflammation and
tissue repair and suggest that liver damage is starting to occur in the HFD-fed female mice
and Cyp2b9/10/13-null HFD-fed male mice (Table 4.3AB).

Table 4.3: Changes in gene expression in (A) male and (B) female Cyp2b9/10/13-null
mice compared to WT mice fed a normal diet (ND) or a high-fat diet (HFD)
A
Genes
CD68
Col27a1
Cpt1a
Cyp2a4
Fasn
Foxo1
Pparα
Srebp1

WT ND M
1.00 + 0.18
1.00 + 0.20
1.00 + 0.32
1.00 + 0.32
1.00 + 0.13
1.00 + 0.21
1.00 + 0.40
1.00 + 0.49

Cyp2b-null ND M
2.00 + 1.28
1.34 + 0.36
3.07 + 1.13
5.16 + 1.99a
1.23 + 0.40
1.16 + 0.16
1.68 + 0.63
1.56 + 0.59

WT HFD M
1.39 + 0.27
0.94 + 0.07
4.48 + 0.83b
2.07 + 0.57
0.94 + 0.14
0.98 + 0.20
0.81 + 0.15
1.91 + 0.53

Cyp2b-null HFD M
10.19 + 2.50c**d**
2.83 + 0.98d
2.73 + 1.00
3.92 + 1.38
1.59 + 0.59
2.81 + 0.57c*d*
2.21 + 1.17
4.00 + 1.91

B
Genes
WT ND F
Cyp2b-null ND F
WT HFD F
Cyp2b-null HFD F
CD68
1.00 + 0.26
0.39 + 0.14
5.32 + 1.69b* 0.26 + 0.04d**
Col27a1 1.00 + 0.09
1.66 + 0.31
0.73 + 0.19
2.72 + 0.76d*
Cpt1a
1.00 + 0.34
1.49 + 0.26
4.14 + 2.81
1.18 + 0.21
a
Cyp2a4
1.00 + 0.11
2.63 + 0.20 ***
1.14 + 0.14
2.06 + 0.29d*
Fasn
1.00 + 0.18
1.22 + 0.10
1.31 + 0.59
0.51 + 0.07
Foxo1
1.00 + 0.12
0.90 + 0.16
1.34 + 0.25
1.24 + 0.22
Pparα
1.00 + 0.13
2.97 + 0.39
3.62 + 1.80b 2.25 + 0.19
Srebp1
1.00 + 0.32
1.17 + 0.05
4.29 + 2.63
1.32 + 0.19
Data represented as mean +/- SEM (n = 5). Statistical significance determined by one-way
ANOVA followed by Fisher’s LSD as the post-hoc test.
‘a’ indicates WT ND different than Cyp2b9/10/13-null ND.
‘b’ indicates WT ND different than WT HFD
‘c’ indicates Cyp2b9/10/13-null ND different than Cyp2b9/10/13-null HFD.
‘d’ indicates WT HFD different than Cyp2b9/10/13-null HFD,
No asterisk indicates a p-value < 0.05 and * indicates a p-value < 0.01, ** indicates a pvalue of < 0.0001, *** indicates a p-value of < 0.00001.
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Discussion:
HFD-fed Cyp2b9/10/13-null male mice gained 15% more body weight than HFDfed WT male mice and most of the weight gain was contributed to a 55% increase in WAT
mass in the HFD-fed Cyp2b9/10/113-null male mice (Fig. 4.1A; Table 4.1A). This
demonstrates that the loss of the primarily hepatic Cyp2b members increases WAT that in
turn leads to obesity and suggests that inhibition of these enzymes by environmental
chemicals or pharmaceuticals may have similar obesogenic effects.
HFD-fed female mice gained significantly more body weight and WAT mass
compared to the ND-fed female mice. However, the lack of Cyp2b enzymes did not
exacerbate weight gain as HFD-fed Cyp2b9/10/13-null mice weighed the same as HFDfed WT mice. In addition, ND-fed Cyp2b9/10/13-null male mice and female mice did not
show significant differences in body weight gain compared to ND-fed WT mice.
Interestingly, the increased body weight and WAT mass was not associated with poor
glucose tolerance or the development of diabetes (Fig. 4.2).
The increased weight gain in Cyp2b9/10/13-null mice was accompanied by an
perturbations in serum lipids. For example, serum triglycerides were significantly downregulated in both ND- and HFD-fed Cyp2b9/10/13-null male mice compared to their WT
male counterparts.

The decrease in serum triglycerides was accompanied by a

corresponding increase in liver triglycerides (Fig. 4.3; Table 4.2A). This effect on serum
and liver triglycerides was not observed in HFD-treated WT mice, but only the
Cyp2b9/10/13-null mice indicating a reduced capacity of the liver to metabolize fats.
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Cyp2b9/10/13-null females showed a similar trend as males when provided a ND,
but not when provided a HFD as instead serum triglycerides were increased along with
liver triglycerides in the Cyp2b9/10/13-null female mice. The HFD-fed Cyp2b9/10/13null mice were the only group with increased ALT, suggesting that the combination of a
HFD and Cyp2b-knockout caused minor liver damage in females.
Serum cholesterol and HDL were significantly increased in the Cyp2b9/10/13-null
male mice compared to WT male mice (Table 4.2A). Increased serum cholesterol coupled
with decreased serum triglycerides was previously in HFD-studies performed in C57/Bl6
mice (Eisinger et al., 2014). The increased serum cholesterol was associated with increased
liver damage. Recent studies indicate that high cholesterol is associated with progressive
NAFLD and a potential marker for NASH (Kerr et al., 2012;Walenbergh et al., 2015).
However, we did not observe significant changes in LDL and VLDL, the typical biomarkes
of cardiovascular disease, between WT and Cyp2b9/10/13-null mice. Instead only HDL
was significantly raised when comparing HFD-fed WT and Cyp2b9/10/13-null mice.
Therefore, the increased liver triglycerides and serum cholesterol indicating the
Cyp2b9/10/13-null male mice are progressing towards hepatic steatosis and NASH, but the
typically accompanied cardiovascular disease may not be a chronic issue (Kawano et al.,
2013).
However, histopathology did not show any pathological changes indicative of
significant liver injury and only a few mice, WT or Cyp2b9/10/13-null, showed significant
lipid accumulation as measured by oil red O (Fig. 4.3). However, the gene expression of
Col27a1 and CD68 increased significantly in HFD-fed Cyp2b9/10/13-null male mice
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compared to HFD-fed WT male mice (Table 4.3B). Col27a1 and CD68 are associated with
tissue repair and the presence of activated kupffer cells respectively and increase in gene
expression suggests tissue damage and increased inflammatory responses in the livers of
male HFD-fed Cyp2b9/10/13-null mice. We suspect that based on increased serum
cholesterol, increased liver triglycerides, and increased expression of Col27a1 and CD68
that the males are at an early stage of liver damage that was not evident by H&E.
Changes in adipokines such as adiponectin and leptin contribute to the development
of obesity and insulin resistance (Fig. 4.4) (Kahn et al., 2000). Serum leptin acts as a
metabolic regulator of satiety and energy expenditure, and a HFD induced serum leptin in
both genotypes and genders. HFD-fed Cyp2b9/10/13-null males showing the highest
levels, significantly greater than HFD-fed WT males in agreement with increased WAT
mass found in HFD-fed Cyp2b9/10/13-null mice relative to other HFD-fed WT mice and
mice not provided a HFD. Serum adiponectin and B-OHB, biomarker of ketogenesis, were
also significantly increased in HFD-fed Cyp2b9/10/13-null male mice, but not females
(Fig. 4.4AB). Taken together, WAT, liver triglycerides, leptin, and B-OHB levels were all
increased in Cyp2b9/10/13-null mice, primarily in males, indicating an unhealthy lipid
state with increased b-oxidation.
Cyp2a4 was induced in ND-fed Cyp2b9/10/13-null and both ND- and HFD-fed
Cyp2b9/10/13-null female mice (Table 4.2B). Cyp2a4 is female predominant and the lack
of three hepatic Cyp2b genes leads to increased expression of Cyp2a4 gene (Kumar et al.,
2017). Cyp2b9 is highly induced following obesogenic diets (Leung et al., 2016;McGregor
et al., 2013), and Cyp2a4 may also be compensating for the lack of Cyp2b9 in HFD-fed
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Cyp2b9/10/13-null females. HFD-fed Cyp2b9/10/13-null male mice also show increased
gene expression of FoxO1 compared to HFD-fed WT male mice and ND-fed
Cyp2b9/10/13-null male mice (Table 4.3AB). FoxO1 regulates gluconeogenesis via
glucokinase, and adipogenesis via Pparg. Inhibition of foxO1 using the chemical inhibitor,
AS1842856 suppresses white adiposite differentiation and generates healthier white
adipocytes (Zou et al., 2014). Thus, induction in FoxO1 might be associated with increased
WAT mass in the HFD-fed Cyp2b9/10/13-null mice (Table 4.2A).
In summary, Cyp2b9/10/13-null mice are diet-induced obese and more susceptible
to obesity than WT mice because of perturbed hepatic lipid homeostasis, indicating that
these hepatic Cyp2b genes are important in fatty acid metabolism (Fig. 4.5).
Cyp2b9/10/13-null mice were obese with increased WAT mass, liver triglycerids, serum
cholesterol, leptin, and B-OHB. Cyp2b9/10/13-null male mice show increased
accumulation of liver triglycerides and decrease in serum triglyceride suggests difficulty
in allocating and utilizing the fatty acids. Therefore, it is possible that chemical inhibition
of Cyp2b members by pesticides, plasticizers, and pharmaceuticals could elicit similar
effects on lipid metabolism and lead to obesity.
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Fig. 4.5: Schematic representation of changes in Cyp2b9/10/13-null male mice.
ND-fed Cyp2b9/10/13-null males develop early stage hyperlipidemia and show that just
the lack of Cyp2b9,10 and 13 causes change sin lipid homeostasis. HFD-fed
Cyp2b9/10/13-null males show that lack of Cyp2b coupled with 60% fat diet leads to the
development of obesity and hyperlipidemia.
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CHAPTER FIVE
DISCUSSION
The overall purpose of this research was to demonstrate the significance of Cyp2b
and Cyp3a in hepatic lipid metabolism. Cyp3a-null and Cyp2b9/10/13-null mouse models
indicate that these enzymes contribute to hepatic lipid homeostasis and their absence
increases susceptibility to dyslipidemia and obesity at least in the male knock out mouse
models. The key findings from the Cyp3a study implied that the lack of seven Cyp3a genes
in the mouse model led to gender-based differences in response to HFD-treatment. The
Cyp3a-null female mice gained significantly less weight compared to WT females, while
the Cyp3a-null males were slightly heavier compared to WT males. Cyp3a-null females
acclimate better to a HFD diet while Cyp3a-null males had significant perturbations in lipid
metabolism. The findings from the Cyp2b study suggests that the lack of three Cyp2b genes
alters lipid homeostasis in the Cyp2b9/10/13-null male irrespective of their dietary
treatment compared to WT male mice. Cyp2b9/10/13-null male mice fed a HFD gained
significantly more weight and white adipose tissue mass compared to their HFD-fed WT
counterparts. Cyp2b9/10/13-null males developed diet-induced obesity and suffered from
perturbations in lipid metabolism while Cyp2b9/10/13-null females mostly did not show
any changes to the lack of Cyp2b genes.
Cyp2b and Cyp3a are highly polymorphic showing inter-individual, ethnic, and
gender variability (Hernandez et al., 2009;Jarukamjorn et al., 2006;Mo et al., 2009;Wiwi
et al., 2004;Zanger et al., 2013).These genes are also highly inducible during HFDtreatment (Deol et al., 2015;Finn et al., 2009;Hoek-van den Hill et al., 2015) or exposure
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to specific chemical inducers (Hernandez et al., 2007;Wang et al., 2008). Mice lacking all
CYP activity in the liver shows increased accumulation of unsaturated fatty acids in the
liver but induced Cyp2b10 via CAR to reduce lipotoxicity (Finn et al., 2009). Cyp3a genes
are altered during the development of metabolic disorders such as obesity and diabetes
(Dostalek et al., 2011;Patoine et al., 2013). In addition, dysregulation in Cyp3a and Cyp2b
genes are observed during soybean oil diet treatment in mice that suffer from increase in
adiposity, body weight and fatty liver disease (Deol et al., 2015). Therefore, dysregulation
of CYP gene expression leads to endocrine disruption by increasing adiposity and alters
lipid homeostasis during the development of metabolic syndromes such as obesity and
diabetes. Cyp2b and Cyp3a are crucial in lipid metabolism and their roles in PUFA
metabolism need further study. In addition, their substrate classification may ultimately
need to be further clarified as they are more than just xenobiotic CYPs (Guengerich et al.,
2011).

5.1 Aim 1
We characterized the three mouse models used in this study - CAR-null, Cyp3anull and Cyp2b9/10/13-null mouse models. CAR regulates expression of genes such as
Cyp2a, Cyp3a and Cyp2c other than its biomarker gene, Cyp2b10. CAR-null mice show
downregulation of Cyp2a4, Cy2b9, Cyp2b10, and Cyp3a11 and these changes in gene
expression were consistent with a significant drop in protein expression and enzyme
activity studies performed using western blots and testosterone hydroxylase assays,
respectively. Lack of CAR leads to masculinization of the liver in females as measured by
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the increase in the 6a/15a-OH testosterone ratio (Hernandez et al., 2009;Wilson et al.,
1999). This is probably because CAR predominantly regulates the expression of the female
predominant CYPs, potentially because androgens are known inhibitors of CAR activity.
Thus, CAR-null studies indicate that CAR is instrumental in regulating sexual dimorphic
expression of CYP enzymes in the liver along with HNF4α and Foxa2 (Hashita et al.,
2008;Wiwi et al., 2004) similar to earlier studies (Hernandez et al., 2009;Mota et al., 2010).
Cyp2a4 gene expression is significantly increased in Cyp3a-null mice similar to
CAR-null mice. This suggests that there is a drop in CAR activity or more likely an increase
in PXR activity in the Cyp3a-null mice. Testosterone hydroxylation in the 6b-position is
lower, which is generated primarily by Cyp3a members. We also observed a significant
drop in 6a/15a-OH testosterone ratio in the Cyp3a-null mice suggesting some loss of
sexual dimorphism in the knockout mice. Overall, Cyp3a-null shows minor compensatory
changes compared to the CAR-null mouse because even though Cyp3a constitutes 30-40%
of hepatic CYPs, it does not directly regulate the expression of other genes. However, lack
of certain Cyp3a-metabolites could alter the liver substrate profile for nuclear receptors
such as CAR and PXR that regulate CYP expression. Additionally, the observed increase,
though not significant, in expression of Cyp2b10, Cyp2c29 and Cyp2c40 suggest increase
in PXR activity in Cyp3a-null mice. We predict that the lack of Cyp3a increases PXR
activation and potentially represses CAR activity through increased hepatic androgens
based on CYP gene expression changes observed in these mice.

157

The Cyp2b9/10/13-null mouse model shows very few compensatory changes in
CYP gene expression and activity. Global gene expression studies performed using
microarray and qPCR studies shows no statistically significant differentially expressed
genes in the Cyp2b9/10/13-null mice compared to WT mice. Cyp2b is expressed at lower
levels than Cyp3a, Cyp2d, and Cyp2c subfamily members, and therefore the lack of Cyp2b
probably has few effects and in turn induces fewer compensatory changes. We observed a
weak to moderate masculinization in the Cyp2b9/10/13-null mice.
The findings from aim 1 strongly suggest the importance of estimating changes in
xenobiotic metabolism using a combination of nuclear receptor and CYP mouse models
to determine the contribution of specific CYP genes to xenobiotic and endobiotic
metabolism.
Changes in gene
expression

Mouse
model
CAR-null
female mice

Cyp2b10,9,13
Cyp2c40,
Cyp3a11

Changes in
protein
expression
Cyp2b,
Cyp2a

Changes in
activity
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6b-OH
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4
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Masculinization of liver
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Fig. 5.1: Characterization of CAR-null female mice. CAR is the
regulator of Cyp2b and lack of CAR decreases Cyp2b expression. CAR also
regulates sexually dimorphic genes in the liver. Thus, lack of CAR induces
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masculinization of liver CYP expression as measured by the 6a-/15a-OH
ratio.
5.2 Aim 2
HRN-null mice missing hepatic cytochrome P450 oxidoreductase gene show lack
of all the CYP activity in the liver and significant increase in accumulation of unsaturated
fatty acids in their liver. These mice show increase in expression of Cyp2b10 and Cyp3a11
by activating CAR, which may be to reduce fatty acid build up and a protective mechanism
to regulate lipid homeostasis (Finn et al., 2009). Cyp3a constitutes 30-40% of hepatic Cyps
and metabolizes more than 60% of drugs available in the market (Guengerich, 2002).
Therefore, purpose of this aim was to demonstrate the significance of Cyp3a in hepatic
lipid metabolism. We treated Cyp3a-null mice with HFD for 8-weeks to determine if lack
of Cyp3a genes increases susceptibility to diet-induced obesity.
Over the 8-weeks of HFD treatment, Cyp3a-null females gained 50% less body
weight than WT females; however, the Cyp3a-null males were slightly heavier compared
to WT males. This sexually dimorphic response was not surprising, since some Cyp3a
genes show gender specific expression such as Cyp3a41 and Cyp3a44 that are female
predominant (Anakk et al., 2006;Hernandez et al., 2006;Hernandez et al., 2009).
Our data indicates that the Cyp3a-null females were healthier compared to WT
females, which is evident from their ability to respond faster to a glucose challenge, greater
(60%) serum adiponectin concentrations and lower (50%) serum b-hydroxybutyrate after
8-weeks of HFD-treatment. However, we did not observe any changes in the gene
expression of key lipid metabolism genes between WT and Cyp3a-null females. Hence,
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the observed healthier trend in the Cyp3a-null females may be due to a 30% decrease in
white adipose tissue mass that leads to an increase in adiponectin with better regulation of
glucose and fatty acid utilization (Kadowaki et al., 2006); some of which may be extrahepatic. These anti-obesity responses in Cyp3a-null females are consistent with other
studies using well-known Cyp3a inhibitors such as naringin found in grapefruit (Alam et
al., 2014;Fujioka et al., 2006) that decreases serum b-hydroxybutyrate and is associated
with increasing lipid oxidation mediated through Ppara activation (Alam et al., 2014;Cho
et al., 2011).
In contrast, liver lipids increased 1.5X in Cyp3a-null males compared to WT males.
Cyp3a-null male mice had significant increases in phosphatidylinositol (PI) sphingomyelin
(SM) and phosphatidylserine (PS), especially long chain fatty acids of 38-40 carbons. Thus,
these mice had increased storage and metabolism of lipids. PI is associated with antiobesity and SM is associated with obesity by regulating lipid metabolism genes (Shimizu
et al., 2010). Cyp3a-null males also had a significant decrease in fatty acid metabolism
genes such as Cpt1a, Srebp1 and Fasn coupled with a significant increase in the lipid
transporter, Fatp1. This would be consistent with the observed increased in liver lipids in
the males. Thus, lipidomic and qPCR studies indicate that lack of Cyp3a increases liver
lipids by increasing uptake and decreasing metabolism.
The findings from this aim propose that Cyp3a enzymes indirectly alter the gene
expression through their products such as EETs can alter key lipid metabolism gene
expression and contribute to the development of metabolic syndrome. High fat diets
generate an endogenous fatty acid molecule, anandamide that is further metabolized by
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Cyp3a to produce EETs. Anandamide and EETs activate CB1/2 receptors that regulate
nociception, cognition, memory and orexigenic effects in peripheral and central nervous
system. Recent studies indicate that CB1 receptor in the presence of its inverse agonist,
regulates adiponectin activity leading to weight loss (Tarn et al., 2014) and CB2 receptor
in the presence of its agonist reduces obesity (Zhang et al., 2016). Since Cyp gene
expression shows sexual dimorphism, it is not surprising that we observe gender-based
differences in response to HFD and these crucial signaling molecules may be generated by
the sexually dimorphic Cyps.
5.2.1 Future studies
Our Cyp3a-null mice still have Cyp3a13 intact and may be its presence is reducing
the impact of loss of the other CYP genes especially because we observe a significant
increase in its expression in our qPCR data, therefore, it will be interesting to see if the loss
of Cyp3a13 in this model would amplify the compensatory changes in the liver due to the
loss of Cyp3a members.
Basal metabolic rate (BMR) could be determined using respirometry to test if that
contributed to weight loss in Cyp3a-null females. We conducted behavioral tests to
determine differences in ambulatory movement, boldness and anxiety in WT and Cyp3anull mice on week 8. Preliminary data indicates significantly more ambulatory movements
made by Cyp3a-null females compared to WT females (unpublished data). Therefore,
increase in activity in Cyp3a-null females may have altered energy expenditure to induce
weight loss in these mice.
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Fig. 5.2: Mechanistic changes observed in Cyp3a-null mice genderbased differences is observed in responses to HFD and lack of Cyp3a genes
which is shown at physiological level, molecular and biochemical changes
and predictive mechanistic changes that lead to the development of sexually
dimorphic phenotype.
5.3 Aim 3
Earlier studies by Finn et al. group using HRN-null mice lacking Cytochrome P450
oxidoreductase null mice shows lack of all hepatic CYP activity in the liver, which led to
significant increase in accumulating fatty acids in the liver. Unsaturated fatty acids in the
liver activated CAR, which induced Cyp2b10 expression in these mice in order to prevent
fatty acid induced toxicity (Finn et al., 2009). In addition, Cyp2b-knockdown mouse model
developed in our own lab had difficulty in clearing out corn oil rich in unsaturated fatty
acids and showed increased adiposity and weight gain. This was observed in aging male
knockdown mice (Damiri, 2011). Therefore, the purpose of this aim was to demonstrate
the significance of Cyp2b in hepatic lipid metabolism using a Cyp2b9/10/13-null mice
developed in our lab using Crispr-Cas9 and sgRNA technology (Kumar et al., 2017).
We determined whether Cyp2b9/10/13-null mice provided a HFD for 10-weeks are
more susceptible to diet-induced obesity than WT mice. Key findings from this study show
that HFD-fed Cyp2b9/10/13-null male mice gain 15% more body weight and have 55%
more WAT mass than HFD-fed WT male mice. Cyp2b9/10/13-null male mice show
significant increases in liver triglyceride, which is complemented by a significant decrease
in serum triglycerides in comparison to WT male mice.
ND-fed Cyp2b9/10/13-null male mice show significant increase in fasting plasma
glucose, serum cholesterol, HDL and liver triglycerides compared to ND-fed WT male
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mice. An increase in liver triglycerides by 2.3-fold may have led to mild glucose
intolerance in these mice that is indicated by an increase in fasting glucose levels in the
ND-fed Cyp2b9/101/3-null mice. However, we did not observe any differences in glucose
tolerance.

Also, increases in liver triglycerides without significant changes in b-

hydroxybutyrate indicates that these mice are not generating greater levels of ketones.
Thus, ND-fed Cyp2b9/10/13-null mice suffer from perturbations in lipid metabolism and
distribution but do not develop obesity.
The key finding of our work is that HFD-fed Cyp2b9/10/13-null male mice are
obese in comparison to HFD-fed WT mice. In addition, HFD-fed Cyp2b9/10/13-null mice
show significant increases in serum cholesterol, HDL, and adipokines such as leptin and
adiponectin, and b-hydroxybutyrate. The increase in adipokines may be due of significant
increase in WAT and the increase in b-hydroxybutyrate indicates occurrence of ketosis in
HFD-Cyp2b9/10/13-null mice. This suggests that hepatic Cyp2b enzymes are anti-obesity
enzymes involved in lipid signaling, the metabolism of lipids, and obesity.
There was significant increase in CD68, surface marker for macrophages and
activated kupffer cells and Col27a1, a gene associated with tissue repair and growth in the
HFD-fed Cyp2b9/10/13-null male mice suggesting that inflammatory responses were
triggered due to liver damage, however, we did not observe any changes in ALT in these
mice (Gruben et al., 2014;Pietilainen et al., 2006). FoxO1, transcription factor associated
with gluconeogenesis and adipogenesis was significantly increased in the HFD-fed
Cyp2b9/10/13-null mice compared to HFD-fed WT male mice. FoxO1 induces
adipogenesis by activating Pparg and increases hepatic glucose production by inducing
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gluconeogenic genes such as phosphoenol pyruvate kinase-1 (Pepck-1). Recent studies
done on 3T3L1 cells show that inhibition of FoxO1 by the chemical inhibitor, AS1842856,
generates smaller, healthier white adipose tissue by regulating Pparg (Zou et al., 2014).
Thus, up-regulation of FoxO1 may be associated with significant increase in WAT in the
HFD-fed Cyp2b9/10/13-null mice.
The female data shows treatment with HFD induces changes in body weight, WAT
and liver triglycerides but did not show any genotypic changes. However, serum HDL was
significantly increased in HFD-fed Cyp2b9/10/13-null females compared to HFD-fed WT
females while serum cholesterol, triglyceride and ALT were increased in HFDCyp2b9/10/13-null females compared to ND-fed Cyp2b9/10/13-null females. Adiponectin
was increased in ND-fed Cyp2b9/10/13-null females compared to HFD-fed Cyp2b9/10/13null. Thus, females show diet-based differences in different parameters.
Overall, Cyp2b9/10/13-null male mice demonstrate perturbations in lipid
metabolism, distribution and utilization compared to WT male mice and HFD treatment
exacerbates these responses contributing to the development of diet-induced obesity in
HFD-fed Cyp2b9/10/3-null male mice.

Our data indicates that the hepatic Cyp2b

subfamily are anti-obesity CYPs and the chemical inhibition of these CYPs could
exacerbate obesity in males.
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5.3.1 Future studies
Most of the changes observed in HFD-fed Cyp2b9/10/13-null male mice are
associated with increased WAT in these mice, therefore it will be interesting to study gene
expression changes in WAT and even brown adipose tissue (BAT) by RNA- sequencing.
Recent time course study performed on BAT to monitor molecular changes during the
development of diet-induced obesity has shown induction of Cyp2b9, thus, Cyp2bs are
involved in inducing obese phenotype in the BAT (McGregor et al., 2013).
Our lab is currently determining global gene expression changes and changes in
lipidomic profile in Cyp2b9/10/13-null and WT mice. The results from these studies could
help us determine major metabolic pathways altered due to lack of hepatic Cyp2b9,10 and
13. Our lab is planning to perform lipidomic analysis on liver tissue to determine if there
are any changes in phospholipid species and oxylipids due to lack of hepatic Cyp2b9,10
and 13 or due to HFD treatment.
Recent lipidomic studies performed on C57/Bl6 that developed diet-induced
obesity shows significant changes in lipidomic profile in obese-individuals and especially,
individual lipid species such as phosphatidylcholine and phosphatidylinositols associated
with pro-obesity were increased (Eisinger et al., 2014). In addition, intracellular location
of lipids such as diacylglycerol and fatty acid composition of the liver such as
monounsaturated fatty acids/saturated fatty acids have been shown to influence insulin
resistance and obesity phenotype (Gruben et al., 2014). Therefore, we predict that
lipidomic profiles from our study will help us identify unique lipid biomarkers that are
generated by Cyp2bs.
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Further studies using chemical inhibitors of Cyp2b such as endosulfan, atrazine and
chlorpyrifos could be combined with HFD-treatment to demonstrate the interaction
between chemical exposure and diet can be done to closely replicate a more realistic
situation of human exposure.
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Fig. 5.3: Mechanistic changes observed in Cyp2b9/10/13-null mice
gender-based differences is observed in responses to HFD and lack of
Cyp2b genes which is shown at physiological level, molecular and
biochemical changes and predictive mechanistic changes that lead to the
development of sexually dimorphic phenotype. The significance percentage
mentioned is Cyp2b9/10/13-null compared to WT of the corresponding diet
treatment.
5.4 Conclusion
Obesity is a world-wide problem, more than 1/3rd of adults in US are obese. The
annual medical expenses for obesity related disorders account for $147 million in 2008.
The common treatment procedures involving healthy diet and active lifestyle, which have
not been able to control the growing number of obese individuals. But our results from
Cyp3a-null and Cyp2b9/10/13-null mouse models indicate the importance of considering
environmental exposure to chemicals along with current treatment of obesity to tackle this
disease.
Characterization of the Cyp3a-null and Cyp2b9/10/13 null mouse models indicate
that Cyp3a and Cyp2b are involved in fatty acid metabolism. Lack of Cyp3a protects
Cyp3a-null female mice from diet-induced obesity but induces moderate weight gain in
Cyp3a-null males. Lack of Cyp2b9/10/13-null induces perturbations in lipid metabolism,
distribution and utilization and HFD worsens the progression to obesity.
Cyp3a and Cyp2b regulate lipid metabolism via epoxide metabolites or by altering
ratio of mono unsaturated/ polyunsaturated fatty acids or by altering phospholipid ratio in
the liver. Further research would enable us to determine if chemical inhibitors of Cyp3a or
inducers of Cyp2b could be used to design effective obesity treatment procedures. Studies
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using chemical inhibitors will add some more potential environmental obesogens that
induce obesity through Cyp3a or Cyp2b to the growing list of obesogens.
Overall, Cyp2b has a protective role against the development of obesity and Cyp3a
has a pro-obesity role in males, but anti-obesity role in females.
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Appendix A
Supplementary figures from Chapter Two

Appendix A-1: A cluster of Cyp2b genes are found on chromosome 7 (26,500K –
27,630K). All five Cyp2b subfamily members are located in the 7A region of chromosome
7. However, there are six genes between two Cyp2b regions; Therefore, we knocked out
the three-predominant hepatic CYPs (Cyp2b9/10/13) via partial chromosomal deletion
using Crispr/Cas9 because it would not impact other genes.
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Appendix A-2: Testosterone concentrations in nullizygous mice.

Testosterone

concentrations in the liver of CAR-null (A), Cyp3a-null (B), Cyp2b9/10/13-null (C) and
serum of Cyp2b9/10/13-null mice were measured and compared to their WT counterparts.
Testosterone concentrations from liver cytosol or serum were measured by EIA using a kit
from Cayman Chemical Company (Ann Arbor, MI).

Data are presented as mean

testosterone concentrations + SEM (n = 3-4). A cindicates a significant difference between
male and female WT mice and dindicates a significant difference between male and female
nullizygous mice. There are no significant differences between nullizygous mice and their
WT counterparts. Statistical differences were determined by one-way ANOVA followed
by Fisher’s LSD as the post-hoc test A letter without an asterisk indicates a significance of
p < 0.05, asterisk indicate significance of **p<0.001, and *** p<0.0001, respectively.
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Appendix B
Supplementary figures from Chapter Three

Appendix B-1: Timeline showing procedures performed during the eight weeks of
high fat diet treatment.
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Appendix B-2: Primer Sequences used to determine changes in gene expression
using qPCR.
Gene

Forward primer

Reverse primer

Tm (°C)a

Acox

CAGGAAGAGCAAGGAAGTGG

CCTTTCTGGCTGATCCCATA

61

ApoE

GCCTAGCCGAGGGAGAGCCG

TGTGACTTGGGAGCTCTGCAGC

69

Car

GGAGCGGCTGTGGAAATATTGCAT

TCCATCTTGTAGCAAAGAGGCCCA

56.5

Cpt1a

TTGATCAAGAAGTGCGGGACGAGT

GTCCATCATGGCCAGCACAAAGTT

53.9

Fabp4

AGCCCAACATGATCATCAGC

TTTCCATCCCACTTCTGCAC

59.5

Fatp1

GGCGTTTCGATGGTTATGTT

CAGCTCGTCCATCACTAGCA

60

Fasn

GTGTCCAAGAAGTGCAGCAA

GGAGCGCAGGATAGACTCAC

57

Foxa2

AACCTCCCTACTCGTACATCTC

AGGTCCATGATCCACTGATAGA

59

IL6

TTGTACAGTCCCAGTCAGGCAACA

TCAAGCTACTGCAGGCCAGTTACA

58

Pepck1

GTCAACACCGACCTCCCTTA

CCCTAGCCTGTTCTCTGTGC

60.6

Ppar α

TTTCCCTGTTTGTGGCTGCTA

CCCTCCTGCAACTTCTCAATG

60

Ppar γ

TGGGTGAAACTCTGGGAGATTC

AATTTCTTGTGAAGTGCTCATAGGC

58

Pxr

GACGCTCAGATGCAAACCTT

TCTTCTCCGCGCAGCTGCA

64.7

Srebp1

ACGAAGTGCACACAAAAGCA

GCCAAAAGACAAGGGGCTAC

57

Srebp1a

TAGTCCGAAGCCGGGTGGGCGCCGGCG

GATGTCGTTCAAAACCGCTGTGTGTCCAGT

59

CCA

TCT

ATCGGCGCGGAAGCTGTCGGGGTAGCG

ACTGTCTTGGTTGTTGATGAGCTGGAGCAT

Srebp1c

62.6

TC
a

Annealing temperature

b

Primer sequences (Chamorro-Garcia et al., 2013;Damiri et al., 2012;Fan et al.,

2011;Hernandez et al., 2009;Ito et al., 2012;Matsebatlela et al., 2015;Sui et al.,
2014;Zhang et al., 2013;Zhou et al., 2009)
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Appendix B-3: Feed consumption rate of female (A) and male (B) WT and Cyp3anull mice. Feed consumed was measured every other day during the entire eight-week
period. Data are presented as mean + SEM per week. There are no differences in feed
consumption between genotypes. Statistical significance was determined by Student’s ttests (n=7 - 8).
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Appendix B-4: Fasting blood glucose and insulin levels. Blood glucose concentrations
were determined during weeks 2, 4 and 6 (A-C) as described in the Materials and Methods.
Blood insulin concentrations were determined using ELISA (D) kit from EMD Millipore
Corporation (EMD Millipore Corporation, Billerica MA). Mice were fasted 4 -5 h during
weeks 2, 4 and 6 and fasting plasma glucose levels determined each time by tail bleed and
serum fasting insulin determined using blood collected by tail bleed during week 6. Data
are presented as mean blood plasma + SEM. Statistical significance was determined by
Student’s t-tests (n=7 - 8).
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Appendix B-5: Principal component analysis (PCA) indicates gender differences in
hepatic lipid species. Hepatic lipid species are primarily influenced by gender not the lack
of Cyp3a with the exception of a few SM, PS, and PC species.
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Appendix B-6: Relative change in lipid levels after eight weeks of HFD treatment on
Cyp3a-null mice.
FEMALES

MALES

Lipids

WT

Cyp3a-null

WT

Cyp3a-null

Total LysoPC

1.221+0.161

0.820+0.184

1.339+0.120

1.227+0.180

Total PC

73.240+0.461

75.900+3.329

72.340+0.775

69.400+1.239

Total SM / DSM

5.113+0.454

4.232+0.313

3.240+0.442

5.215+0.360**

Total ePC

2.389+0.053

2.335+0.140

2.550+0.082

2.350+0.079

Total LysoPE

0.330+0.034

0.295+0.044

0.427+0.022

0.437+0.037

Total PE

12.400+0.691

10.930+3.064

14.370+0.507

13.620+0.532

Total ePE

0.216+0.019

0.197+0.069

0.365+0.017

0.364+0.016

Total PI

4.210+0.188

3.652+0.672

4.653+0.341

6.278+0.267**

Total PS

0.828+0.035

1.489+0.447

0.638+0.037

0.981+0.098*

Total ePS

0.003+0.002

0.007+0.003

0.005+0.002

0.011+0.002

Total PA

0.038+0.006

0.114+0.060

0.034+0.005

0.063+0.006

Total PG

0.012+0.003

0.031+0.009

0.036+0.007

0.068+0.003

Data represented as mean percentage of total signal +/- SEM (n = 5).
Statistical significance determined by Student’s T-test.
*Indicates a p-value < 0.05 and ** Indicates a p-value <0.01.
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Appendix B-7: Compensatory changes in hepatic CYP gene expression after eight
weeks of HFD treatment in Cyp3a-null mice. Immunoblots were performed and
quantified as described previously with β-actin as the reference protein (Hernandez et al.,
2009)
FEMALES

MALES

Genes

WT

Cyp3a-null

WT

Cyp3a-null

Cyp3a11

1.00 +0.240

0.015+0.014**

1.00 +0.171

0.147+0.147**

Cyp3a13

1.00 +0.081

1.188+0.207

1.00 +0.147

0.587+0.103*

Cyp3a25

1.00 +0.173

0.017+0.016****

1.00 +0.174

0.022+0.022***

Cyp3a41

1.00 +0.282

0.010+0.010**

1.00 +0.355

0.000+0.000*

Cyp2a4

1.00 +0.264

2.826+0.603*

1.00 +0.179

0.998+0.173

Cyp2b9

1.00 +0.137

1.495+0.154*

1.00 +0.340

4.250+3.585

Cyp2b10

1.00 +0.210

1.283+0.176

1.00 +0.202

1.819+0.331

Cyp2c29

1.00 +0.135

1.315 +0.170

1.00 +0.071

0.572 +0.101**

Cyp2c40

1.00 +0.176

1.046+0.108

1.00 +0.178

0.494+0.154

Data represented as relative mean +/- SEM (n = 7 or 8). Statistical significance determined
by Student’s t-test. * Indicates a p-value < 0.05, ** Indicates a p-value <0.01, *** Indicates
a p-value <0.001 and **** Indicates a p-value <0.0001.
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Cyp3a-null F

WT M
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Cyp3a-null M

Appendix B-8: Changes in serum leptin levels in Cyp3a-null mice. Serum leptin
concentration was determined using EIA kit from Bertin pharma (Montigny le Bretonneux,
FR). Data are presented as mean blood plasma + SEM. Statistical significance was

Serum Leptin
level (pg/ml)

determined by Student’s t-tests (n=4-5).
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Appendix C
Supplementary figures for Chapter four

Appendix C-1: Timeline of the different procedures performed during a 10-week
treatment of 9-10 week old WT and Cyp2b-null mice with either a normal diet (ND;
6.2%) or a high-fat diet (HFD; 60% fat).
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Appendix C-2: Feed consumption determined in WT and Cyp2b9/10/13-null mice
during the 10-weeks of dietary treatment. Data are presented as mean + SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher’s LSD as post-hoc
test (n= 8-9).‘a’ indicates WT ND are different than Cyp2b9/10/13-null ND, ‘b’ indicates
WT ND are different than WT HFD, ‘c’ indicates Cyp2b9/10/13-null ND are different than
Cyp2b9/10/13-null HFD, ‘d’ indicates WT HFD different than Cyp2b9/10/13-null HFD.

A

B
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Appendix C-3: Fasting blood glucose levels determined during weeks 5 and 8. Mice
were fasted 4-5hr and fasting plasma glucose levels were determined using a glucometer
after tail bleeding. Data are presented as mean blood plasma + SEM. Statistical significance
was determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test (n=
8-9). *Indicates a p-value < 0.05.‘a’ indicates WT-ND are different than Cyp2b9/10/13null-ND, ‘b’ indicates WT-ND are different than WT-HFD, ‘c’ indicates Cyp2b9/10/13null-ND are different than Cyp2b9/10/13-null-HFD ‘d’ indicates WT HFD are different
than Cyp2b9/10/13-null-HFD.
Week 5

Fasting blood glucose (mg/dl)

A

B

Male

Female
Week 8

Female

Male
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Appendix C-4: Insulin Tolerance Test done on week 9. (A & B) Insulin tolerance test
was performed as described in materials and methods and (C & D) results are represented
as area under the curve. Data are presented as mean blood glucose level + SEM. Statistical
significance was determined by Student’s t-test (n = 8 or 9).‘a’ indicates WT ND are
different than Cyp2b9/10/13-null ND, ‘b’ indicates WT ND are different than WT HFD,
‘c’ indicates Cyp2b9/10/13-null ND are different than Cyp2b9/10/13-null HFD, ‘d’
indicates WT HFD are different than Cyp2b9/10/13-null HFD.
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Appendix C-5: Immunoblots show protein expression changes in WT and
Cyp2b9/10/13-null mice. Immunoblot was done using microsome samples as described in
materials and methods. Density of the blots was quantified and shown above the
immunoblots. Data represents relative mean of WT compared to Cyp2b9/10/13-null mice
of the same gender and dietary treatment. Statistical differences were determined by
Student’s t-tests (n = 3) (* p < 0.05 ** p < 0.01).
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